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INTRODUCTION 
Stein and Leventhal described in 1935 a disorder associated with poly-
cystic ovaries and consisting of: "menstrual irregularity featuring 
amenorrhea, a history of sterility, masculine type hirsutism, and less 
consistently, retarded breast development and obesity". Nowadays this 
disease is known as the Stein-Leventhal syndrome or the polycystic 
ovary syndrome (PCO-syndrome). 
Although this syndrome is a rather ill-defined disorder, general 
agreement does exist concerning several aspects. The major characteris-
tic of this disease is chronic anovulation and most women have clinical 
signs of androgen excess. Obesity is also often encountered. Laboratory 
findings reveal inappropriate gonadotrophin secretion and excess 
androgen production. The pathophysiology of the PCO-syndrome is as 
yet not clear; however, evidence exists for both ovarian and adrenal 
disorders. 
In an attempt to elucidate both pathophysiological and therapeutical 
aspects of this disease, it was decided to study women with clinical 
features of the PCO-syndrome. The functional characteristics of 
the hypothalamic-pituitary-ovarian axis and the hypothalamic-pituitary-
adrenal axis were tested and the results were compared with findings in 
normal ovulatory women. Also the process of spontaneous follicular 
maturation was carefully evaluated after a period of ovarian suppression. 
Preceding the presentation of this investigation the literature con-
cerning the PCO-syndrome will be reviewed. 
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1. SURVEY OF THE LITERATURE 
1 1 THE HUMAN MENSTRUAL CYCLE 
1 1 1 Introduction 
The diagnosis and management of a disturbed menstrual cycle must 
be based on an understanding of the physiological mechanisms involved 
in the regulation of female reproductive functions In this survey of the 
literature therefore first briefly some aspects of the normal menstrual 
cycle are dealt with The cyclic release of reproductive hormones is 
described and the complex and delicately balanced feedback system of 
the hypothalamic-pituitary-ovanan axis will be discussed, as well as 
several aspects of follicular development and maturation Finally some 
general information concerning androgen production will be presented 
1 1 2 Cyclic Release of Reproductive Hormones 
The changes of reproductive hormones during the normal ovulatory 
cycle have been studied extensively (for reviews see e g BAIRD, 1974, 
YEN, 1978a, VAN LOOK and BAIRD, 1980) There exists a dynamic 
relationship amongst the hypothalamus, pituitary and ovaries The 
cyclical hormonal changes are correlated with morphological changes in 
the ovary The menstrual cycle is divided into three phases the folli-
cular phase, the ovulatory phase and the luteal phase 
In the late luteal phase, a few days before the onset of menstruation 
and when the corpus luteum regresses, ovarian secretion of 17ß-estra-
diol, progesterone and other ovarian steroids (estrone, androstene-
dione, testosterone) reaches a relatively low level Consequently when 
negative feedback is minimal, FSH and, to a lesser extent, LH are 
released from the pituitary A new crop of antral follicles matures under 
the influence of the rising FSH level As the follicles develop, the ovar-
ian secretion of 17ß-estradiol increases progressively There is a parallel 
rise in the serum estrone, androstenedione and testosterone levels 
(JUDD and YEN, 1973, ABRAHAM, 1974, KIM et al , 1974, VER-
MEULEN and VERDONCK, 1976) However, the ovarian production 
of these latter hormones does not result in distinctive midcycle eleva-
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lions as seen with 17ß-estradiol This is due to a significant contribution 
of extra-ovarian sources in the production of these hormones (BAIRD, 
1974, BAIRD and FRASER, 1974) As the serum 17ß-estradiol level 
rises, the serum level of FSH declines, whereas the serum LH level 
increases Progesterone levels do not show significant changes prior to 
the midcycle LH surge 
The immediate preovulatory period is characterized by an increasing 
ovarian secretion rate of 17ß-estradiol This 17ß-estradiol rise is correla-
ted with rapid follicular maturation of the selected and, by now, domi-
nant follicle When the secretion of 17ß-estradiol reaches a certain 
critical level for a minimum period of time a midcycle surge of LH is 
induced (KARSCH et al , 1973) A simultaneous increase in the FSH 
level is also often noted The rapid rise m the serum LH level leads to 
the final maturation of the Graafian follicle Ovulation can then be seen 
12 to 36 hours after the LH peak (WU, 1978, MOGHISSI, 1980, 
QUEENAN et al , 1980, WHO, 1980) The serum 17ß-estradiol levels 
drop after the onset of the midcycle LH surge Concomitant with the 
LH surge is the rise in progesterone concentrations This increase is likely 
to be a reflection of luteimzation of the granulosa cells 
The luteal phase is characterized by an increase in serum progesterone 
levels secreted by the corpus luteum Parallel rises of 17ß-estradiol and 
17a-OH-progesterone levels are seen, as well as increases, albeit less 
marked, in the serum concentrations of estrone and androstenedione 
Maximum serum concentrations of steroids secreted by the corpus lu-
teum are seen 8 days after ovulation Serum LH and FSH levels decline 
throughout the luteal phase Regression of the corpus luteum starts 
about 10 days after its formation, at which time a decrease in serum 
levels of all gonadal steroids is seen Concomitant with this decrease, 
FSH levels rise and a new ovarian cycle commences 
1 1 3 Feedback Mechanisms 
The delicately balanced feedback mechanism of the hypothalamic-pi-
tuitary-ovanan axis has been the subject of considerable research in 
recent years (for reviews see e g YEN et al , 1976a, YEN, 1978a, VAN 
LOOK and BAIRD, 1980) When modulating influences from the ova-
ries are absent, the hypothalamic-pituitary unit will release FSH and LH 
in an acyclical manner The ovarian unit is "inherently" cyclical by 
virtue of its follicular compartment The non-cyclical tonic secretion of 
gonadotrophins has to be reduced and transformed into a cyclical 
pattern by the influences of secretion products (steroids and possibly 
inhibin) from the ovaries The modulating influence, which is exerted at 
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the level of the hypothalamic-pituitary unit, involves positive and nega-
tive feedback effects. The most important hormones with respect to 
feedback are 17ß-estradiol and progesterone. 
YEN and LEIN (1976) introduced a hypothetical model for the 
hormonal regulation of the menstrual cycle. The main features of this 
model are: 
1. The hypothalamus produces and releases LH-RH which stimulates 
both the pituitary production and the release of LH. 
2. LH is stored within the pituitary in an easily releasible pool (pool 1) 
and in a storage pool (pool 2). 
3. LH-RH stimulates pituitary LH production in both pools and also 
the "transfer" of LH from the second pool to the first; LH release 
occurs from the latter. 
4. 17ß-estradiol has both negative and positive feedback effects on the 
hypothalamic production of LH-RH: as 17ß-estradiol increases 
during the pre-ovulatory period, the positive feedback mechanism 
predominates and an LH-RH discharge occurs. 
5. 17ß-estradiol enhances the sensitivity of the gonadotrophs in pool 2 
to LH-RH, as well as the transport from the second pool into the 
first, but it also inhibits the release of LH from pool 1. 
Hypothalamic dopamine secretion may provide a stabilizing function in 
this system for LH release (HOFF et al., 1977; JUDD et al., 1978, 
1979). 
The synthesis, storage and release of FSH probably follow the same 
regulatory mechanisms as depicted for LH. However, in contrast to LH, 
the sensitivity for the negative feedback effects of 17ß-estradiol is more 
pronounced. This implies that higher 17ß-estradiol concentrations are 
necessary to exert a positive feedback effect (VEMER and ROL-
LAND, 1982). 
Progesterone has little, if any, negative feedback effect itself; 
however, this steroid blocks the positive feedback effect and enhances 
the negative feedback effect of 17ß-estradiol. Thus in the presence of 
elevated levels of progesterone, gonadotrophin secretion is principally 
controlled by the negative feedback effect of 17ß-estradiol. Progeste-
rone seems to have an amplifying effect on LH-RH activity (HOFF et 
al., 1977; CHANG and JAFFE, 1978). This steroid most likely has a 
modulating function in the regulation of the midcycle gonadotrophin 
surge (HELMOND et al., 1980). 
Little is known about possible feedback effects of other gonadal or 
adrenal steroids. Androstenedione may play an important role in hypo-
thalamic feedback mechanisms (BAIRD, 1974). Immunization against 
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androstenedione increases the frequency of pulsatile LH release and 
elevates the basal LH levels and also abolishes the positive feedback 
response of LH secretion to a moderate dose of estradiol benzoate 
(MARTENSZ et al., 1975). Chronic exposure to elevated concen-
trations of androstenedione facilitates estrogen-induced LH-release 
(VAN LOOK and BAIRD, 1980). Immunization against 17ß-estradiol, 
testosterone, or estrone also resulted in increased basal levels of gona-
dotrophins (MARTENSZ et al., 1979). The significance of these 
findings pertaining the regulation of gonadotrophin release remains to 
be determined. 
In recent years several investigators have presented evidence for the 
presence of inhibin, a substance which is capable of selectively inhibiting 
the secretion of FSH (DE JONG and SHARPE, 1976). Inhibin has 
been demonstrated in human follicular fluid (CHARI et al., 1979). 
Changes in follicular fluid inhibin levels throughout the human 
menstrual cycle have been reported by CHAPPEL et al. (1980) and 
CHANNING et al. (1981). It has also been demonstrated that inhibin 
activity of human follicular fluid is a reflection of the general viability of 
a follicle (CHANNING et al., 1981). 
1.1.4 Follicular Maturation 
Follicular development and maturation have been the subjects of 
many studies in both animal and human models (for reviews see e.g. 
ROSS and SCHREIBER, 1978; PETERS and McNATTY, 1980; 
RYAN, 1980; McNATTY, 1981a, 1982). Follicular growth commences 
when the oocyte of a small resting follicle begins to enlarge and when 
the surrounding granulosa cells start to proliferate. The growth of folli-
cles is regulated by intra-ovarian and intra-follicular events as well as by 
extra-ovarian events. The initial steps of follicular development appar-
ently occur autonomously, but maturation beyond the preantral stage 
requires the presence of FSH and LH. A model of the relationship 
between pituitary hormones and ovarian steroids in growing preantral 
follicles was presented by PETERS and McNATTY (1980). According 
to this model preantral follicular growth depends mainly on the 
presence of FSH and high local concentrations of estrogen. The action 
of LH on the preantral follicle is indirect; LH stimulates the interstitial 
tissue to secrete androgens. In this way, LH determines the amount of 
androstenedione and testosterone to which the follicle will be exposed. 
Estrogens enhance granulosa cell proliferation, whereas androgens have 
an inhibitory effect. 
The hormonal control of follicular growth and maturation, as well as 
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ovulation and atresia has been summarized by ROSS and HILLIER 
(1979) in the following way: 
1. The normal progression of follicular maturation to the point of 
ovulation requires stimulation with adequate quantities of FSH and 
LH in appropriate proportions. 
2. Gonadotrophins stimulate the production of estrogens, androgens 
and progestogens. 
3. The sex steroid hormones act locally to modulate follicular growth 
and atresia. 
4. Certain mechanisms exist for regulating the hormonal composition of 
antral fluid in individual follicles. 
5. The hormonal composition of antral fluid either indicates or deter-
mines the fate of individual follicles. 
A healthy follicle has been shown to be one which contains high con-
centrations of estrogens in its follicular fluid and/or aromatizing enzymes 
necessary to synthesize large amounts of these steroids. However, in the 
follicular fluid, an atretic or dying follicle will have very low levels of 
estrogen and the capacity of aromatizing enzymes to synthesize estrogens 
will be low (McNATTY et al., 1979). In humans almost all follicles die 
during their early antral growth phase. Most follicles apparently never 
develop the capacity to aromatize androgens to estrogens (McNATTY, 
1981a). The hormonal environment of atretic follicles is characterized 
by hyperandrogenicity and hypoestrogenicity. 
Little is known about the selection mechanisms that determine which 
follicle will proceed to ovulation. In several respects this selection 
process may be an active procedure. The ability to develop a functional 
estrogensynthetase enzyme system in granulosa cells is of great impor-
tance as well as the extent of blood supply to the follicular tissues. The 
optimal condition for follicular maturation also depends on the FSH/LH 
ratio. The final choice of one follicle seems to be a matter of chance; the 
follicle in the most favorable state of development at the most appro-
priate time of the ovarian cycle will most likely proceed to ovulation 
(McNATTY, 1981b). 
1.1.5 Androgen Production 
Androgens are produced by the ovaries (Scheme 1) and the adrenal 
glands (Scheme 2). The contribution of these glands to the total andro-
gen pool is summarized in Table 1.1. 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-
sulphate (DHEAS) represent the major androgens secreted by the 
adrenal glands, with small amounts derived from the ovary. DHEA 
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TABLE ι ι Contribution of the ovaries and adrenal glands to the total androgen pool. 
Ovaries Adrenals 
Dehydroepiandrosterone 
Dehydroepiandrosterone-sulfate 
Androstenedione 
Testosterone 
20% 
10% 
50% 
5-20% 
80% 
90% 
50% 
0-30% 
(Modified from FARBER et al., 1977). 
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secretion by the adrenal glands appears to be ACTH dependent. The 
diurnal Cortisol rhythm is closely followed by DHEA (YEN, 1978b; 
LACHELINetal.,1979). 
Androstenedione is secreted in equal amounts by the adrenal glands and 
the ovaries. Periovulatory, however, the ovarian contribution increases 
(ABRAHAM, 1974). The adrenal output of androstenedione is respon-
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sive to ACTH stimulation. In concordance with Cortisol, serum androste-
nedione has a circadian rhythm (YEN, 1978b; LACHELIN et al., 1979). 
About 50% of testosterone is produced in nonglandular peripheral 
tissues from the reduction of androstenedione. The remaining 50% origi­
nates from both the adrenal glands and ovaries in equal quantities. 
A diurnal rhythm for testosterone seems to be present (YEN, 1978b; 
LACHELIN et al., 1979). Dihydrotestosterone is probably derived 
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entirely from the peripheral conversion of testosterone and andro-
stenedione (MAHOUDEAU et al , 1971) 
Specific binding globulines exist for several hormones, 99% of testo-
sterone is bound to the carrier protein sex-hormone-binding-globuhn 
(SHBG), whereas androstenedione circulates either as a free steroid or 
in loose association with albumin The synthesis of SHBG is stimulated 
by estrogens and is depressed by androgens The level of SHBG is 
viewed as a major determinant in controlling the balance between 
androgens and estrogens (ANDERSON, 1974) Quantitation of testo-
sterone must be considered in relation to the important binding to 
SHBG Where total testosterone levels in serum show an overlap 
between normal women and those with clinical signs of hyperandro-
genism, free serum testosterone correlates well with the clinical state of 
hirsute women (STRICKLER and WARREN, 1979) 
1 2 THE POLYCYSTIC OVARY SYNDROME 
1 2 1 Introduction 
The polycystic ovary syndrome (PCO-syndrome) is a disorder of ill-
defimtion The great clinical and biochemical variability forms a major 
problem in appropriately denning this disease (for reviews see e g 
GOLDZIEHER and AXELROD 1963, JEFFCOATE, 1964, 
MAHESH and GREENBLATT, 1964, SHEARMAN and COX, 1966, 
ROLLAND, 1980, YEN, 1980, GOLDZIEHER, 1981) Without any 
doubt, the basic symptom of the syndrome is chronic anovulation The 
clinical picture is characterized by signs of androgen excess and 
increased anabohsm The presence of bilateral polycystic ovaries and 
pathological changes in the gonads have also been reported 
The combination of ovulatory failure, hirsutism, obesity and the 
presence of bilateral polycystic ovaries may be associated with several 
endocrine disorders of diverse etiology (YEN, 1980) In the present 
investigation the PCO-syndrome is deñned as a clinical entity with 
exclusion of other well defined endocnnopathies 
Preceding the introduction of this prospective study, some historical 
aspects of the PCO-syndrome will be reviewed Morphological, clinical 
and laboratory findings, as well as aspects of pathophysiology, patho-
genesis and therapy will also be discussed 
12 2 Historical Background 
In the nineteenth century the existence of bilateral polycystic ovarian 
disease was already well known GOLDZIEHER (1981) reported that 
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gross sclerocystic changes in the human ovary were described as early as 
1844 by CHEREAU, and that partial resection of these ovaries was 
practiced by several clinicians in Europe before 1897 WALDO (1895) 
reported on a young patient with severe pain in the lower abdomen 
Cystic degeneration of the ovaries was found and small cysts were 
removed According to the author the treatment was not successful, 
within a year the patient returned and at laparotomy cystic changes of 
the ovaries were diagnosed again GOLDSPOHN (1914) discussed the 
resection of ovaries extensively He stated that "multicystic follicular 
degeneration of ovaries and persistent cystic corpora lutea" were 
without any doubt pathological The changes were said to be caused by 
"chronic inflammation of infectious origin with or without active hyper-
emia as from excessive venery, incomplete coitus, masturbation, 
suppression of menstruation from a cold or from mental trauma, etc , or 
connective-tissue hyperplasia from persistent passive hyperemia which 
is induced in these parts by constipation, vicious dress, sedentary 
employment, etc , but above all things, by descensus or prolapse of the 
ovary caused by uterine displacement" The mode of treatment 
employed by GOLDSPOHN seemed to be simple "Relieve the ovary 
of its tension by enucleating or dissecting out the growing cystic follicles 
by a most careful technic, and then secure it in an elevated position with 
and upon the broad ligament" "The principal cause—venous engorge-
ment—now having been removed, follicular degeneration will usually 
not recur" Accompanied with this, the patient should also correct "evil 
habits of living" McGLINN (1916) brought forward that "the micro-
cystic ovary should not be treated, in the majority of cases, by resec-
tion" He maintained that retrodisplacement of the uterus is the cause of 
the changes seen m such ovaries The therapeutic approach McGLINN 
adviced was "to restore the uterus in its place" 
Further interest in this disorder, to a broad extent, developed after 
1935 when STEIN and LEVENTHAL described a syndrome associated 
with polycystic ovaries This consisted mainly of ' menstrual irregularity 
featuring amenorrhea, a history of sterility, masculine type hirsutism, 
and less consistently, retarded breast development and obesity" The 
delineation of this syndrome and the excellent results which occurred 
after wedge resection led to many speculations on the pathophysiology 
and pathogenesis of this disease (STEIN and LEVENTHAL, 1935, 
STEIN and COHEN, 1939, STEIN, 1945, 1958, 1959, STEIN et al , 
1949, PLATE, 1951, LEVENTHAL, 1958) 
In the original publication of STEIN and LEVENTAL, it was stated 
that "mechanical crowding of the cortex by cysts interferes with the 
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progress of the normal Graafian follicles to the surface of the ovary. 
This mechanical factor may account for the symptoms of amenorrhea 
and sterility". In the later publications an endocrine disturbance was 
thought to be responsible for the development of this condition. 
At the 25th anniversary of the "Stein-Leventhal syndrome", PLATE 
(1960) reviewed some of the 200 reports that were published on this 
subject. At that time it was possible to reflect upon the more pathophysio-
logical aspects of the syndrome. Anovulation was thought to cause 
excessive LH release and it was found that this inappropriate gonado-
trophin release brought about hyperthecosis and consequently hyperan-
drogenism. It was thought that hyperandrogenism could disturb follicle 
maturation and cause fibrosis of the ovaries. Although bilateral wedge 
resection of the ovaries was still the first choice of treatment, other 
therapeutical modalities were introduced e.g. corticosteroids. 
1.2.3 Morphological Findings 
In the first publication concerning the PCO-syndrome the gross 
pathological findings were quite clear; patients with this syndrome had 
bilateral, enlarged, pearly white, sclerosed and polycystic gonads 
(STEIN and LEVENTHAL, 1935). Ovaries of patients with the classi-
cal "Stein-Leventhal" syndrome are subjected to cystic changes. The 
surface of these ovaries is often of a white gray and smooth and glossy 
appearance, without scars caused by ovulation. A thickening of the 
tunica albugínea is also seen. Many follicles of variable sizes show a 
cystic degeneration. Luteinization of the theca interna and sometimes of 
the theca externa is demonstrated. This "hyperthecosis" can be 
expected to be present in both ovaries (PLATE, 1957, 1958). 
GOLDZIEHER and GREEN (1962) reviewed a large series of surgi-
cally proven cases of the PCO-syndrome collected from the literature. 
According to these authors histologic study failed to define a consistent 
entity. In their own series of 39 patients the most striking features of 
polycystic ovaries were a thickened capsule, an increased number of 
Graafian follicles and a scarcity of corpora lutea. Excessive luteinization 
and hyperplasia of the theca interna could not be found. SMITH et al. 
(1965) also reported on a considerable series of patients with surgically 
proven polycystic ovaries. In their study group, 40 % had normal-sized 
ovaries and 46% had thickening of the tunica albugínea. In patients 
with clinical features of the PCO-syndrome and ovarian hyperandro-
genism, both normal and abnormal histologic findings may be noticed in 
the ovaries (KIM et al., 1979). The pronounced luteinization of cells 
surrounding follicles has been questioned by GREEN and GOLD-
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ZIEHER (1965) A light and electron microscopic study of both normal 
and abnormal polycystic ovaries revealed no specific abnormalities of 
the follicular architecture The development and atresia of follicles in 
these ovaries were found to be normal Also in the tunica albugínea 
normal microarchitectonal characteristics were found It seems that a 
consistent and characteristic histopathological picture of polycystic 
ovaries cannot be given 
In spite of the inconsistency of histologic findings, many authors 
recognized an overlap in both clinical and histologic features of "ovarian 
hyperthecosis" and the PCO-syndrome (FARBER et al , 1974, ABRA-
HAM and BUSTER, 1976, AIMAN et al , 1978, WILSON and 
GREENE, 1978, KARAM and HAJJ, 1979, NAGAMANI et al , 1981, 
HUGHESDON, 1982) Some investigators speculated that both disor-
ders show different aspects of the same pathophysiological entity 
(GIVENS et al , 1971, JUDO et al , 1973) 
Coelomic mesothelium-hke cells in the ovarian stroma of patients 
with the PCO-syndrome have been described The possibility that these 
cells may originate from the common pnmordium of the adrenal-genital 
epithelium persisting in the ovary has been discussed (NEBEL et al , 
1971) The presence of a "mini-adrenal" embedded in ovarian stroma 
has been reported (SYMONDS and DRISCOLL, 1973, GOLD-
ZIEHER, 1981) Ovarian secretion of Cortisol was found in a patient 
with clinical features of hyperthecosis (ABRAHAM and BUSTER, 
1976) These findings raise the question as to whether ovaries possess 
the capability of taking on adrenocortical functions 
The various histopathological features of polycystic ovaries have been 
related to functional aspects Since high intra-ovanan androgen levels 
may inhibit follicular maturation and may induce follicular atresia 
(LOUVET et al , 1975), ovarian steroidogenesis is of importance in this 
respect Thecal tissue from hyperandrogenic ovaries produces more 
androgen than similar tissue from normal ovaries Stromal tissue, how-
ever, is responsible for an even more pronounced quantity of androgen 
production (McNATTY et al , 1980) 
The existence of enzymatic defects of ovarian steroidogenesis, similar 
to those observed in congenital adrenal hyperplasia, has been proposed 
as an explanation for the hyperandrogenic state in patients with the 
PCO-syndrome Several studies suggested deficiencies of aromatization, 
17-hydroxylation and 3ß-dehydrogenase activity in polycystic ovarian 
tissue (AXELROD and GOLDZIEHER, 1962, MAHESH and GREEN-
BLATT, 1964) The mechanism of aromatization in normal versus 
polycystic ovarian tissue was expected to be different (AXELROD 
and GOLDZIEHER, 1965) 
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SMUK et al. (1977) reported that enzyme deficiencies in polycystic 
ovaries are not so common. In human polycystic ovaries, in vitro 
steroidogenesis was found to be very similar to that reported from incu-
bations of normal ovarian tissue. WILSON et al. (1979) came to the 
same conclusion; they found that isolated granulosa cells and theca cells 
from mid-antral follicles of normal and polycystic ovaries had a similar 
steroidogenetic capacity, both in the absence and presence of trophic 
agents. It seems that ovarian follicles in polycystic ovaries never develop 
to a size in which the aromatase enzyme system is normally expressed 
(ERICKSON et al., 1979). The ability to respond to FSH is present, as 
are LH-receptor sites (ERICKSON et al., 1979; WILSON et al., 1979; 
RAJANIEMI et al., 1980). It can therefore be concluded that morpho-
logical and steroidogenic abnormalities in ovaries of PCO-patients are 
not due to primary enzymatic defects. They may be secondary to 
inappropriate gonadotrophin stimulation (YEN, 1980). 
1.2.4 Clinical Findings 
1.2.4.1 General Aspects 
According to STEIN and LEVENTHAL (1935) patients with the 
PCO-syndrome had a complex of signs consisting of amenorrhea, 
hirsutism and obesity. Hypoplasia of the mammae was sometimes noted 
as was enlargement of the clitoris. In later years it became clear that the 
"Stein-Leventhal" criteria were inadequate and that the syndrome 
included patients with a heterogeneous array of underlying patho-
physiology. The well known clinical characteristics in combination with 
bilateral polycystic ovaries may be associated with endocrine disorders 
of diverse etiologies (YEN, 1980). The "Stein-Leventhal" criteria 
discern only a small fraction of patients who actually have polycystic 
ovarian disease (GOLDZIEHER, 1981). The frequency of relevant 
signs and symptoms in patients who had been surgically explored for 
polycystic ovarian disease was reexamined by GOLDZIEHER and 
AXELROD (1963). The frequencies of the major clinical features are 
summarized in Table 1.2. It can be seen that in approximately 80% of 
the cases either functional bleeding or amenorrhea were present, 
hirsutism was present in 69% of the cases and obesity in 41 %. It should 
be realized that the frequency of symptoms has a positive bias since 
PCO-syndrome patients with symptoms will be identified with higher 
probability. It is obvious nowadays that the "Stein-Leventhal" syn-
drome is part of a greater entity, that of the polycystic ovary syndrome 
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TABLE ι 2 Signs and symptoms associated with polycystic ovarian disease 
Symptom 
Obesity 
Hirsutism 
Virilization 
Cyclic menses 
Functional bleedi 
Amenorrhea 
Dysmenorrhea 
ng 
Biphasic basal temperature 
Corpus luteum at 
Infertility 
operation 
Usable 
no cases 
600 
819 
431 
395 
547 
640 
75 
238 
391 
596 
Incidence 
Mean 
41 
69 
21 
12 
29 
51 
23 
15 
22 
74 
(%) 
Range 
16-49 
17-83 
0-28 
7-28 
6-65 
15-77 
— 
12-40 
0-71 
35-94 
Data tabulated from 187 references with a total of 1079 cases 
(GOLDZIEHER and AXELROD, 1963) 
or polycystic ovarian disease. This is illustrated once more by the fact 
that throughout 30 years STEIN (1959) collected only 96 patients who 
fulfilled his criteria for justifying surgical treatment. 
Efforts have been made to create two types of the PCO-syndrome. 
Type I, or the typical polycystic ovary syndrome, is characterized by 
ovarian changes as described by STEIN and L E V E N T H A L (1935), 
while type II represents a heterogeneous spectrum of disorders (BER­
G E R et al , 1975, RAJ et al , 1977a). 
In an analysis of 98 documented PCO-syndrome patients YEN et al. 
(1976b) found some common aspects in their case histories. The mean 
age at menarche of this group of women was not different from the 
mean age found in the normal population Although rare, primary 
amenorrhea did occur. The postmenarcheal menstrual irregularity 
continued beyond adolescence Before or around the menarche clini­
cally discernible, excessive hair growth became evident A certain 
amount of overweight was present prior to menarche These findings 
need further evaluation in a prospective clinical trial 
From the referred literature it is evident that the PCO-syndrome 
should be kept in mind when assessing cases of anovulation, with or 
without signs of androgen excess or obesity 
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1.2.4.2 Hirsutism 
1.2.4.2.1 Definition 
The most important expression of androgen excess is hirsutism. 
Hirsutism is defined as a male hair pattern which implicates an excessive 
growth of hair in areas where females would normally have considerably 
less hair than males. Hirsutism may also be associated with acne. Virili-
zation or masculinization is characterized by temporal balding, clitoris 
enlargement, sometimes a lower pitched voice and development of the 
male muscular pattern (STRICKLER and WARREN, 1979; HATCH et 
al., 1981). Scoring systems showing the spectrum from minimal hir-
sutism to frank virilization in several body regions were developed by 
FERRIMAN and GALLWEY (1961) and by LORENZO (1970). Other 
classifications of hirsutism have been described by BARDIN and 
LIPSETT (1967) and ABRAHAM et al. (1976). 
1.2.4.2.2 Hirsutism and Steroidogenesis 
Androgen metabolism in hirsute patients has been the subject of 
extensive investigations (for reviews see e.g. FARBER et al., 1977; 
STRICKLER and WARREN, 1979; GIVENS, 1980; HATCH et al., 
1981; MAROULIS, 1981). The testosterone production rate in hirsute 
women is increased, however, the total testosterone concentration in 
peripheral blood of hirsute women is not always elevated (BARDIN 
and LIPSETT, 1967). According to ABRAHAM et al. (1975) the mean 
levels of all androgenic hormones and prehormones, measured under 
basal conditions, in a group of hirsute women are significantly elevated 
when compared to non-hirsute premenopausal control women. In 
patients with hirsutism, but without signs of virilization, serum levels of 
testosterone, dihydrotestosterone and androstenedione were elevated, 
whereas dehydroepiandrosterone (DHEA) levels were within the 
normal range. However, in hirsute patients with clitoromegaly, as a sign 
of virilization, elevated DHEA levels have been found (MATHUR et 
al., 1981b). 
When androgen levels are measured in individual patients, there is a 
considerable overlap of values between hirsute and non-hirsute women 
(ANDERSON, 1974; ABRAHAM et al., 1975; PAULSON et al., 
1977; WU, 1979). The most consistent endocrinologie finding in the 
individual hirsute patient is an elevation of free (unbound) testosterone 
in serum (PAULSON et al., 1977; HATCH et al., 1981), and a reduc-
tion of sex-hormone-binding-globulin in plasma (SHBG) (ANDER-
SON, 1974; WU, 1979; MATHUR et al., 1981a, 1981b). Free-testo-
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sterone levels correlate well with the clinical severity of the hyperandro-
gemc state (STRICKLER and WARREN. 1979, WU, 1979) A 
decreased estradiol testosterone ratio of both total and free steroid 
concentrations in hirsute females has been reported (TULCHINSKY 
and CHOPRA, 1974, WU, 1979) Hirsute and non-hirsute women can 
almost be completely distinguished from each other by the ratio of 
molar concentrations of 17ß-OH-androgens> to SHBG (ANDERSON, 
1974) or by the testosterone SHBG ratio (MATHUR et al , 1981a) 
If the analysis of the clinically hyperandrogenic female is performed 
with these parameters it is anticipated that the incidence of end-organ 
hypersensitivity as suspected cause for hirsutism will be quite low 
(MATHUR et al , 1981a, 1981b) 
A single plasma androgen level measurement may not be d represen-
tative sample for the average measurements throughout the day because 
androgen levels are pulsatile and reflect episodic ovarian and adrenal 
secretion (see 115) Even by frequent sampling hyperandrogenic states 
will be missed in some hirsute women unless free androgens and 
SHBG are measured simultaneously 
12 4 3 Obesity 
12 4 11 Definition 
Obesity is not a very well defined clinical characteristic of the PCO-
syndrome Various indices of obesity, many of which are derivatives of 
height and weight, have been proposed One possibility is to express 
obesity as the body mass index or Quetelet-mdex This index may vary 
with age, sex, or population under study (KHOSLA and LOWE, 1967, 
KEYS et al , 1972) The amount of adipose tissue as percentage of total 
body weight may be assessed from skin fold measurements (DURNIN 
and WOMERSLEY, 1974) In studies concerning obesity and steroid-
ogenesis, normal weight is often determined from the Metropolitan Life 
Insurance Company Tables (METROPOLITAN LIFE INSURANCE 
COMPANY, 1959) The amount of excessive weight may be considered 
to be that amount of body weight which exceeds the upper limit of ideal 
weight for the woman's height and medium body frame as determined 
from these tables (EDMAN and MacDONALD, 1978) Sometimes 
obesity is determined as weight over 75 kg and in excess of 20% over 
ideal weight (HOSSEINIAN et al , 1976), alternately, patients are con-
sidered to be obese when their weight exceeds 145% of their ideal body 
weight (PLYMATE et al , 1981) 
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12 4 3 2 Obesity and Steroidogenesis 
It is well known that extraglandular formation of estrogens from 
plasma prehormones constitutes a significant proportion of total estro-
gen production in women (SIITERI and MacDONALD, 1973, 
EDMAN and MacDONALD, 1976) The extent of conversion of 
plasma androstenedione to estrone is correlated significantly with total 
body weight and excessive body weight in both ovulatory and anovula-
tory young women The mean conversion rate in anovulatory women is 
not different from that in ovulatory women (EDMAN and Mac-
DONALD, 1978) 
An association of obesity with infertility and menstrual abnormalities 
has been suggested by HARTZ et al (1979) The time of menarche is 
reported earlier m obese adolescents, the moment of menopauze, how-
ever, occurs later in obese women (SHERMAN et dl , 1981) Obesity 
and oligomenorrhea are, even in the absence of hirsutism, associated 
with elevated levels of total and free androgens and depressed levels of 
SHBG (HOSSEINIAN et al , 1976) It has been suggested that obesity 
has an influence on SHBG levels independant of the hormonal status 
(PLYMATE el al , 1981) Increased plasma testosterone and andro-
stenedione concentrations, an increased estrone estradiol ratio and 
decreased SHBG levels have been reported in extremely obese women 
In spite of this, the pituitary release of LH and FSH, after the adminis-
tration of LH-RH, was found to be comparable to that in normal ovula-
tory non-obese women These findings indicate that a disturbance may 
exist in the hypothalamic-pituitary function (KOPELMAN et al , 1980) 
Plasma hormone concentrations returned to normal after substantial 
weight reduction These changes were also associated with normaliza-
tion of the menstrual cycle (KOPELMAN et al , 1981) 
It seems justified to conclude that the actual body weight and the fat 
mass are factors influencing the secretion rate of steroids, the extra-
glandular conversion of these hormones and the concentration of 
SHBG All these effects may have a disturbing influence on the regula-
tory mechanisms of the menstrual cycle 
1 2 5 Laboratory Findings 
12 5 1 Androgens 
Many studies involving patients with the PCO-syndrome have indi-
cated a modest elevation of all circulating androgenic hormones and 
their precursors (for reviews see e g YEN, 1980, GOLDZIEHER, 
1981) Testosterone, dihydrotestosterone, dehydroepiandrosterone 
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(DHEA) and androstenedione have been found to be elevated in such 
patients (BARDIN et al , 1968; ABRAHAM et al , 1975, DeVANE et 
al., 1975, DUIGNAN et al., 1975, DUIGNAN, 1976; RAJ et al , 1978) 
However, an overlap with values in normal individuals does exist. The 
results of dehydroepiandrosterone-sulfate (DHEAS) measurements are 
not consistent; ABRAHAM et al (1975) and DeVANE et al (1975) 
reported elevated levels, while DUIGNAN (1976) found values in 
PCO-syndrome patients not different from control women Increased 
levels of 17a-OH-progesterone have also been found (ABRAHAM et 
al., 1975, SOJO-ARANDA et al , 1979) In PCO-syndrome patients low 
SHBG levels have been reported (ANDERSON, 1974, DUIGNAN, 
1976) Even when testosterone and androstenedione levels were within 
the normal range, the blood production rates of these steroids were high 
in virtually all PCO-syndrome patients (BARDIN and LIPSETT, 1967; 
BARDIN et al , 1968) The existing paradox of elevated production 
rates with normal plasma levels is, according to BARDIN and 
coworkers, due to the increased metabolic clearance rate in women with 
increased androgen production 
The source of this excess androgen production has been a subject of 
controversy Ovarian vein levels of androstenedione, testosterone and 
DHEA were reported as being markedly elevated in PCO-syndrome 
patients compared with normal ovulatory women, whereas polycystic 
ovaries did not secrete DHEAS in significant amounts (LAATIKAI-
NEN et al , 1980) Comparable results were also reported by KASUGA 
(1980): significantly elevated ovarian vein steroid hormone levels in 
PCO-syndrome patients were found for 17a-OH-pregnenolone, proges-
terone, l7a-OH-progesterone, androstenedione and testosterone, but 
not for DHEAS. The ovarian DHEA level was slightly elevated in this 
group of PCO-syndrome patients Administration of HMG resulted in a 
small increase of all ovarian vein steroid hormone levels. During dexa-
methasone suppression ovarian DHEAS levels decreased, whereas 
DHEA levels remained elevated. 
Changes in androgen concentrations following stimulation and sup-
pression of the adrenal glands and/or the ovaries have been studied 
extensively The most direct approach is catheterization of the ovarian 
and adrenal veins (KIRSCHNER and JACOBS, 1971; STAHL et al , 
1973, PARKER et al , 1975, WENTZ et al , 1976; FARBER et al , 
1977). Although several investigators have found this diagnostic proce-
dure clinically applicable in the routine evaluation of hirsutism 
(KIRSCHNER and JACOBS, 1971 ; STAHL et al , 1973, FARBER et 
al , 1977), others advised against differential ovarian and adrenal vein 
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catheterization for this purpose (WENTZ et al , 1976). Conclusions 
drawn from catheterization studies may be biased by several factors. 
Adrenal secretion is both episodic and parallel, necessitating both 
simultaneous catheterization and serial sampling for adequate diag-
nosis Stress of the procedure may provoke increased adrenal output 
The degree of follicular development in the gonad at the moment of 
testing is of importance in the interpretation of data but cannot be 
assessed (WENTZ et al , 1976). Notwithstanding these methodological 
problems, combined ovarian and adrenal vein catheterization have been 
of great value in the determination of sites of androgen overproduction 
in patients with hyperandrogenism Still the results are controversial 
since some suggested the ovaries to be the major source of androgen 
production (KIRSCHNER and JACOBS, 1971), whereas results from 
others suggested combined adrenal and ovarian androgen hypersecreti-
on in PCO-syndrome patients (STAHL et al , 1973) In contrast with the 
findings of KIRSCHNER and JACOBS (1971), STAHL and coworkers 
(1973) reported no patients with excessive androgen production of exclu-
sively ovarian origin ACTH stimulation revealed a dramatic increase in 
adrenal vein steroid concentrations, whereas ovarian vein concentra-
tions were unaffected by the administration of this agent. HCG infusion 
brought about increases in ovarian vein steroid concentrations; HCG 
was ineffective in the stimulation of adrenal steroid secretion (PAR-
KER et al , 1975) Dcxamethasone suppressed adrenal androgen secre-
tion, m a few patients a decrease of ovarian androgen hypersecretion 
was noted as well (JANATA and STARKA, 1964, KIRSCHNER and 
JACOBS, 1971) The mechanism by which this effect of dcxamethasone 
is brought about is as yet unknown 
Because of the drawbacks of catheterization studies, a dcxametha-
sone suppression test, with sampling of peripheral blood, is the method 
of choice for daily practice to distinguish adrenal from ovarian hyperan-
drogenism. ABRAHAM (1974) and KIM et al (1976) stated that dcxa-
methasone (2 mg/day) does not interfere with ovarian function and 
that the observed effects are solely due to suppression of adrenal steroid 
production Dcxamethasone medication for a few days should suppress 
plasma androgens to normal levels in patients with signs of androgen 
excess if ovarian androgen production is normal An excessive ovarian 
contribution is diagnosed if androgen levels remain elevated on this 
regimen ABRAHAM et al (1975) stated that in order to locate the 
source of excess androgens in patients with signs of hyperandrogenism, 
the additional HCG stimulation test during dcxamethasone administra-
tion was of no value and did not add new information to that obtained 
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from the dexamethasone suppression test. Furthermore it became 
apparent that adequate suppression of adrenal androgen production 
needs more than 2 days of dexamethasone treatment. 
The elevated serum levels of DHEA and DHEAS in PCO-syndrome 
patients were readily suppressed by the administration of dexametha-
sone. In contrast, the levels of testosterone, androstenedione and 
17a-OH-progesterone were not depressed significantly (JUDD et al., 
1977; JUDD, 1978). During dexamethasone administration the serum 
levels of free androgens remained significantly higher in hirsute women 
with amenorrhea then in hirsute and non-hirsute women with intact 
cycles. The absolute increments in androgen levels during HCG admin-
istration in this experimental group exceeded those of normal women 
(ROSENFIELD et al., 1972). These results suggest that the ovary is an 
important source of androgen production in the clinical entity under 
discussion. 
Results from several other dexamethasone suppression test studies, 
however, indicate that the adrenal glands may be of primary importance 
in the excess androgen production encountered in patients with clinical 
signs of hyperandrogenism (ABRAHAM et al., 1976, 1981). Data from 
ACTH stimulation tests suggest abnormalities in adrenal steroid biosyn-
thesis in patients with hyperandrogenism (GIVENS et al., 1975a; 
LACHELIN et al., 1979; GIBSON et al., 1980; KANDEEL et al., 
1980). An abnormal adrenal function in women with the PCO-syn-
drome was also delineated by JUDD et al. (1976a); however, an ovarian 
overproduction of certain androgens was recognized as well. 
The heterogeneity of the patient population and the episodic nature 
of androgen secretion as well as the variety in test techniques may 
explain the inconsistencies of data derived from these investigations. 
Considering these factors, a combined adrenal and ovarian source of 
androgen excess in patients with the PCO-syndrome is most likely. 
1.2.5.2 Estrogens 
During the normal menstrual cycle circulating estrogens fluctuate 
substantially, reflecting maturation and involution of ovarian follicles 
and of the corpus luteum (BAIRD, 1974; BAIRD and FRASER, 1974; 
YEN, 1978a; VAN LOOK and BAIRD, 1980). In women with ovulato-
ry cycles the principal circulating estrogen is 17ß-estradiol. The concen-
tration of estrone is nearly always lower than the serum estradiol level. 
Several investigators have measured estrogen levels in PCO-patients. 
Since these women have anovulatory cycles, their estrogen levels do not 
fluctuate in a precise rhythmic fashion. Significantly elevated estradiol 
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levels in PCO-syndrome patients have been reported (BAIRD et al , 
1977) as well as estradiol levels equivalent to those found in normal 
ovulatory women during the early follicular phase (DeVANE et al , 
1975, JUDO. 1978) Although total-estradiol levels in PCO-syndrome 
patients were within the normal range, the percentage of unbound estra-
diol, as well as the total amount of unbound estradiol, were found to be 
elevated (LOBO et al , 1981a) Increased estrone levels have been 
reported in PCO-syndrome patients Estrone concentrations exceeded 
estradiol concentrations in these women (DeVANE et al , 1975, 
BAIRD et al , 1977, JUDD, 1978, LOBO et al , 1981a) 
According to LAATIKAINEN et al (1980) ovarian venous estradiol 
levels in PCO-syndrome patients were within the normal range These 
results are in disagreement with those reported by KASUGA (1980), 
who found significantly elevated estradiol levels in both peripheral and 
ovarian vein blood In addition KASUGA found elevated ovarian vein 
estrone levels, despite normal peripheral plasma levels of this steroid 
This indicates a minor to moderate excess in ovarian estrone produc-
tion 
The peripheral conversion of androstenedione to estrone is consider-
able and may account for more than 50% of the production of this 
steroid (SIITERI and MacDONALD, 1973) In a group of PCO-
syndrome patients extraglandular aromatization of androstenedione 
accounted for almost all of the estrone production The hormonal estro-
gen milieu of the PCO-syndrome group of women is therefore deter-
mined by the extraglandular production of estrone, rather than the folli-
cular production of estradiol (EDMAN and MacDONALD, 1976) As a 
consequence of excessive amounts of androgens and their subsequent 
peripheral conversion to estrogens, the total estrogen pool in patients 
with the PCO-syndrome is increased 
12 5 3 Gonadotrophms 
The most consistent finding in women with the PCO-syndrome is an 
elevated LH level This high LH concentration appears to be the result 
of a greater amplitude of LH pulses and/or an increased frequency of 
the pulsatile LH release In contrast with the considerable fluctuations 
in LH levels, the mean FSH concentrations were remarkably constant 
and were either comparable with or significantly lower than the mean 
FSH concentrations observed during the early follicular phase in normal 
ovulatory women The high LH levels and relatively or absolutely 
reduced levels of FSH resulted in an elevated LH/FSH ratio (YEN et 
al , 1970a, DeVANE et al , 1975. REBAR et al , 1976, BAIRD et al , 
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1977, LOBO et al , 1981a) A few investigators failed to demonstrate 
any significant difference in FSH and LH levels in PCO-patients versus 
normal ovulatory women (ZARATE et al , 1973, DUIGNAN et al , 
1975, DUIGNAN. 1976) Several investigators classified PCO-syn-
drome patients into groups with normal and elevated LH levels The 
mean FSH levels were essentially identical and within the normal early 
or mid-follicular range in these two subgroups (BERGER et al , 1975, 
PATTON et al , 1975, GIVENS et al , 1976a, KATZ and CARR, 1976) 
The disproportionately high LH secretion with constant low FSH 
secretion encountered in patients with the PCO-syndrome suggests a 
disturbance in the hypothalamic regulation of gonadotrophin secretion 
YEN et al , (1970d) speculated that this might be related to chronic 
anovulation and abnormal steroidogenesis Both negative and positive 
feedback effects of estrogen on gonadotrophin release are present in 
PCO-syndrome patients (SHAW et al , 1975, 1976, REBAR et al , 
1976, BAIRD et al , 1977) An appropriate acute decrease in serum LH 
levels, induced by the infusion of 17ß-cstradiol, was demonstrated 
(negative feedback) A rise ot both serum LH and FSH levels has been 
reported to occur after the administration of the antiestrogen clomi-
phene, with the subsequent development of an appropriate LH surge in 
synchrony with the preovulatory rise of 17ß-estradiol followed by ovula-
tion (positive feedback) (YEN et al, 197()a, 197()b, REBAR et al , 1976) 
Many investigators reported results indicating an increased respon-
siveness of the pituitary to LH-RH stimulation in patients with the 
PCO-syndrome (DUIGNAN et al , 1975, DUIGNAN, 1976, KATZ 
and CARR. 1976, REBAR et al , 1976, BAIRD et al , 1977. MORTI-
MER et al , 1978) One study reported less consistent findings in this 
respect (ZARATE et al , 1973) Patients with type I PCO-syndrome 
—defined by the presence ot markedly enlarged ovaries with subcor-
tical cystic follicles, thickened capsule, and usually luteinized follicle 
cells—demonstrated consistently elevated serum LH levels with mean 
LH responses to LH-RH greater than those seen in type II PCO-
patients with smaller sized ovaries and normal serum LH levels (BER-
GER et al , 1975, PATTON et al , 1975) It seems that the chronically 
elevated and acyclic estrogen levels found in patients with the PCO-
syndrome may at least be partly responsible for the exaggerated pulsa-
tile release of LH The pituitary sensitivity for LH-RH is augmented by 
chronically elevated estrogen levels (YEN and LEIN, 1976) A positive 
correlation has been demonstrated to exist between estrogen levels and 
both basal LH levels and LH-RH induced LH release (DeVANE et al , 
1975, REBAR et al , 1976) 
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Data on the precise relationship between gonadotrophms and andro-
gens found in the PCO-syndrome are conflicting In some studies the 
serum LH level correlates positively with plasma testosterone levels 
(MORTIMER et al , 1978), however, a negative correlation between 
these two hormones has been reported as well (DUIGNAN et al , 1975, 
DUIGNAN, 1976) No correlation was found between androgen levels 
and gonadotrophms in PCO-patients studied by KANDEEL et al 
(1978) Several authors reported a positive correlation between serum 
LH levels and estrone and/or estradiol levels (DeVANE et al , 1975, 
KATZ and CARR, 1976, KANDEEL et al , 1978) According to 
LOBO et al (1981a), LH/FSH ratios in PCO-syndrome patients had a 
positive correlation with the relative and absolute concentrations of 
unbound estradiol 
Dopamine is one of the neurotransmitters involved in the inhibitory 
control of LH and FSH (JUDO et al , 1978, 1979) An enhanced LH 
sensitivity to dopamine inhibition in PCO-syndrome patients with 
chronically elevated estrogen levels has likewise been demonstrated 
The inappropriately increased LH release and exaggerated LH pulses 
may be causally related to a reduction of endogenous dopamine inhibi-
tion of LH secretory activity (QUIGLEY et al , 1981) Notwithstanding 
a possible importance of dopamine regulation in pituitary LH and FSH 
release, the major cause for inappropriate gonadotrophin release in 
PCO-syndrome patients, is found in chronically elevated estrone levels 
(CHANG et al , 1982a) Elevated levels of unbound estradiol may play 
an important role as well (LOBO et al , 1981a) 
1 2 6 Pathophysiology 
Chronic anovulation is the most characteristic feature of the PCO-
syndrome The disturbance of follicular maturation is not caused by a 
deficiency in the steroidogenic potential of the numerous midantral folli-
cles of polycystic ovaries, nor by the absence of gonadotrophin recep-
tors on the polycystic ovary follicular cells (WILSON et al , 1979) Data 
from ERICKSON et al (1979) indicate that the absence of aromatase in 
polycystic ovaries and the arrested follicular growth may be caused by a 
reduced local FSH concentration A decreased bioactivity of FSH is 
suggested as well Inappropriate gonadotrophin secretion as seen in the 
PCO-syndrome, resulting in an elevated LH/FSH ratio causes excessive 
androstenedione production by the theca cells In spite of this excess 
aromatase substrate granulosa cells are not capable to form estrogens 
because of the FSH dependent aromatase deficiency Steroids produced 
within the ovary have an important influence on follicular development 
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PROPOSED MECHANSM FOR PERSISTENT ANOVULATION 
IN POLYCYSTIC OVARY SYNDROME 
PITUITARY PULSATILE 
k
 LH RELEASE 
+ PITUITARY SENSITIVITY TO LR F 
\ 
4 CIRCULATING LH LEVELS 
( JFSH ) 
+ OVARIAN STROMA STIMULATION / 
ADRENAL 
ANDROGEN 
/ 
FOLLICULAR 
MATURATION 
/ 
• 
OVARIAN ANDROGEN 
PRODUCTION 
t / ACYCLIC ESTROGEN PRODUCTION (EXTRAGLANDULAR CONVERSION 
OF ANDROGEN) 
FIGURE 1 1 Sequence of events in the maintenance of chronic anovulation m the 
PCO syndrome (YEN 1978b) (with permission) 
(LOUVET et dl , 1975, McNATTY et al , 1979) The resulting hormone 
imbalance (high androgen levels with relatively low estrogen levels) 
causes follicular maturation arrest 
Although disturbed follicular maturation in patients with the PCO-
syndrome is not related to an inherent defect in ovarian steroidogenesis 
or folliculogenesis, the disturbance results in chronic anovulation The 
self-perpetuating cycle of chronic anovulation in the PCO-syndrome is 
summarized in Figure 1 1 Inappropriate gonadotrophin secretion with 
a high LH/FSH ratio may be caused by several mechanisms of which the 
most important is the more or less constant estrogen feedback on the 
hypothalamic-pituitary system Excessive LH release results in hyper-
secretion of ovarian androgens, the elevated androgen production 
provides excessive amounts of substrate for conversion of androgens to 
estrogens by extra-glandular tissues (adipose tissue) The high levels of 
estrogens, in turn, augment pituitary sensitivity to LH-RH with secre-
tion favoring LH over FSH, resulting in inadequate acychcal follicular 
maturation with chronic anovulation (BAIRD, 1976, YEN et al , 
1976b) Very little is known about possible feedback effects of other 
steroid hormones secreted by the ovaries, the adrenal glands or both 
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(see 1.1.3). The possible role of inhibin in the pathophysiology of the 
PCO-syndrome also remains to be elucidated (TANABE et al., 1982). 
1.2.7 Etiology and Pathogenesis 
The etiology of the PCO-syndrome is unclear. Several investigators, 
however, have directed attention to possible genetic causes. It has been 
reported that this syndrome may occur as an inherited disorder 
(COOPER et al., 1968; GIVENS et al., 1971; FERRIMAN and PUR-
DIE, 1979). It was postulated that X chromosomal factors might cause 
an abnormal follicular apparatus (GIVENS et al., 1975b). A typical 
chromosomal abnormality has not been found in the PCO-syndrome by 
COOPER and coworkers (1968). However, banding techniques were 
not employed in this study. Recently, PARKER and coworkers (1980) 
presented results of cytogenetic studies with the use of the trypsin-
Giemsa banding technique in 15 PCO-syndrome patients. Trisomy 14 in 
2 % - 4 % of the cells of 5 patients was diagnosed. The implication of this 
rare cytogenetic finding is unclear and remains to be clarified. 
The fact that both negative and positive feedback responses to estro-
gens can be demonstrated in women with the PCO-syndrome makes it 
unlikely that the failure to ovulate is due to an intrinsic abnormality in 
hypothalamic activity such as occurs in testosterone sterilized rats 
(BARRACLOUGH, 1961; GORSKI and BARRACLOUGH, 1963). 
It has been suggested that a deficiency of some ovarian enzymes, simi-
lar to those found in congenital adrenal hyperplasia, was responsible for 
high androgen production by polycystic ovaries. Recent investigations, 
however, have demonstrated a normal steroidogenic potential in gonadal 
tissues of women with the PCO-syndrome (see 1.2.3). 
The possibility that the PCO-syndrome originates as an adrenal disor-
der during the early years of sexual maturation has been proposed by 
YEN and coworkers (1976b). According to YEN c.s. it is now generally 
established that during adrenarche a progressive increase in adrenal 
androgen secretion takes place. If this adrenal androgen secretion is 
excessive, elevated plasma androgen levels will result with increased 
extraglandular estrogen production as a consequence. This will in turn 
induce inappropriate gonadotrophin release. The primary adrenal 
androgen source shifts in this way to the ovary, and the self-perpetu-
ating cycle of chronic anovulation in the PCO-syndrome is established 
(Figure 1.1). An exaggerated adrenarche may result from a primary 
adrenal enzymatic defect or some adrenal stimulating factor other than 
ACTH may be involved. Further investigations have to clarify the role 
of the adrenal glands in the pathogenesis of the PCO-syndrome. 
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12 8 Therapy 
12 8 1 Introduction 
Many clinical entities can simulate the PCO-syndrome In an excel-
lent review by YEN (1980) these "PCO-like syndromes" have been 
discussed The diagnosis—polycystic ovary syndrome—has to be estab-
lished before starting any treatment In general "PCO-like syndromes" 
need different and specific therapeutical approaches directed more to 
the underlying disease "PCO-like syndromes" include hypercorti-
sohsm, congenital adrenal hyperplasia, hyper- and hypothyroidism, 
ovarian hyperthecosis and androgen producing tumors of the ovary 
A "PCO-like syndrome" is sometimes encountered in patients with 
hyperprolactinemid and/or hypersecretion of LH 
The therapeutic management of the PCO-syndrome is either directed 
to the establishment of ovulatory cycles and consequently improvement 
of fertility, or to the reversal of obesity and hirsutism, acne and other 
clinical signs of androgen excess Induction of ovulation in the PCO-syn-
drome by means of anti-estrogens, gonadotrophins, wedge resection of 
the ovaries or adrenal suppression will be discussed in the following 
sections The possibility to suppress ovarian steroidogenesis with a 
combination of synthetic steroids will also be discussed 
12 8 2 Clomiphene 
The effectiveness of clomiphene-citrate for induction of ovulation in 
patients with the PCO-syndrome is well established In most instances 
clomiphene induces a transient rise in serum FSH and LH levels The 
FSH secretion is critical for the initiation of follicular maturation, resul-
ting in an increase of the circulating estradiol level, which triggers, by 
virtue of an intact positive feedback effect, an ovulatory surge of LH 
and FSH (YEN et al , 1970b, REBAR et al , 1976, BAIRD et al , 
1977) 
The ovulation rate in clomiphene treated PCO-syndrome patients is 
high and reaches 90% in some reports, the conception rate reaches 
about 50% (YEN et al , 1970b, RUST et al , 1974, RAJ et al , 1977b) 
The discrepancy between ovulation rates and conception rates in clomi-
phene-treated cycles has been the subject of considerable research (for 
review see R O U M E N , 1980) An inadequate luteal phase was reported 
in PCO-syndrome patients treated with clomiphene, inappropriate 
timing between gonadotrophin stimulation and follicular maturation has 
been suggested to be the causative factor (YEN et al , 1970b) Notwith-
standing the discrepancy of ovulation rates and conception rates in this 
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group of patients, clomiphene is the treatment of first choice when 
anovulation and subsequent infertility is the major problem (YEN, 
1980; GOLDZIEHER, 1981). 
1.2.8.3 Gonadotrophins 
YEN (1980) stated that human menopausal gonadotrophin (hMG) and 
human chorionic gonadotrophin (hCG) were no longer to be used for in-
ducing ovulation in the PCO-syndrome patients, primarily because of the 
serious side effects. However, WANG and GEMZELL (1980) concluded 
that this treatment modality was safe and effective for women with poly-
cystic ovarian disease who failed to ovulate on clomiphene medication. 
The treatment with hMG and hCG is expensive and complicated. 
Hyperstimulation can be avoided when patients are closely monitored. 
However, in spite of daily measurements of urinary or plasma estrogen 
levels, a high incidence of multiple pregnancies has been reported. 
Multiple pregnancies must be regarded as a complication because of the 
frequent association with maternal complications and fetal wastage 
(INSLER and LUNENFELD, 1977; LAPPÖHN, 1979a, 1979b; 
SCHENKER et al., 1981; SCHWARTZ and JEWELEWICZ, 1981; 
THALER et al., 1981). In a group of clomiphene non-responsive PCO-
patients treated with hMG/hCG, a conception rate of 65.9%, an abor-
tion rate of 24.1% and a multiple pregnancy rate of 36,3% were 
reported. In this group mild and severe hyperstimulation occurred in 
about 10% of the treatment cycles (WANG and GEMZELL, 1980). 
Comparable results were recently reported by KEMMANN et al. 
(1981). These results stress the hypersensitivity of polycystic ovaries to 
exogenously administered gonadotrophins. At present ultrasonographic 
monitoring of follicular development in combination with daily estrogen 
determinations seem to be the best and most efficient procedures for 
the detection of hyperstimulation and polyovulation (WU, 1978; 
MASTROIANNI, 1980; QUEENAN et al., 1980; O'HERLIHY et al., 
1981a, 1981b). 
To evaluate a potential increase in ovarian androgen production due 
to hMG stimulation, plasma androgen levels were determined at the 
beginning and end of hMG-stimulated cycles in women with the PCO-
syndrome. It was demonstrated that androgen levels became signifi-
cantly increased in these women during hMG stimulation (LAWREN-
CE et al., 1976; SKAF et al., 1981). LAWRENCE and coworkers 
(1976) postulated that the increase in androgen levels might be respon-
sible for a reduced conception rate in PCO-patients in whom ovulation 
is apparently succesfully induced. 
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Follicular maturation in the PCO-syndrome is primarily disturbed 
because of the chronically low FSH levels; therefore, purified human 
pituitary FSH should be preferably used instead of hMG/hCG. How-
ever, experience with this treatment modality in patients with the PCO-
syndrome is still limited (RAJ et al., 1977b; SCHOEMAKERet al., 1978; 
ERICKSONetal.,1979;KAMRAVAetal.,1982;SEIBELetal.,1982). 
1.2.8.4 Wedge Resection 
According to the studies of STEIN and LEVENTHAL bilateral 
wedge resection of the ovaries was followed by the initiation of ovula-
tory cycles in almost all women with the PCO-syndrome (STEIN and 
LEVENTHAL, 1935; STEIN, 1958; LEVENTHAL, 1958). An exten-
sive evaluation of the world literature, however, demonstrated highly 
variable results of this surgical approach: a (temporarily) regular cycle 
was re-established in an average of 80% of women with a range of 
6%-95%; a mean pregnancy rate of 63% (range 13%-89%) was 
recorded (GOLDZIEHER and AXELROD, 1963). Recently 
ADASHI et al. (1981) evaluated fertility following bilateral ovarian 
wedge resection in women with the PCO-syndrome. This procedure 
resulted in the resumption of menstrual cyclicity in 91.1%, however, 
regular ovulatory cycles were reported in only 60.3%. The overall 
conception rate was 47.8%. A minimum of 7.8% was documented for 
acquired post-wedge resection pelvic disease. 
STEIN (1959) stated that post-wedge resection periovarian adhesions 
occurred in only a few instances, and these adhesions were not extensive 
enough to prevent conception. However, several recent studies stress 
the high risk of infertility, due to multiple pelvic adhesions, following 
wedge resection of the ovaries (BUTTRAM and VAQUERO, 1975; 
TOAFF et al., 1976). It has been demonstrated that microsurgical 
operating techniques may prevent the adhesion formation encountered 
after wedge resection (EDDY et al., 1980). 
The mechanism by which bilateral wedge resection induces or 
initiates ovulatory and regular cycles is not well understood. The effec-
tiveness of the procedure was first thought to result from the removal of 
the thickened ovarian cortex, which might interfere with extrusion of 
the ovum. When it was demonstrated that clomiphene could induce 
ovulation through the intact cortex, this hypothesis was abandoned. 
Recently, several studies have demonstrated a transient, but significant, 
reduction of ovarian androstenedione production as well as a persistent 
decrease of testosterone secretion after bilateral wedge resection of 
polycystic ovaries. Estrone and estradiol levels also declined (JUDD 
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étal , 1976b, VALKOV and DOKUMOV, 1977, KATZetal ,1978,MA-
HESH et al , 1978) A reduction of LH and a normalization of the LH/FSH 
ratio following the fall in estradiol and testosterone have been reported 
as well as a normalization ot the pituitary response after LH-RH 
administration (VALKOV and DOKUMOV, 1977, KATZ et al , 1978) 
These observations indicate that the mechanisms responsible for the 
initiation of ovulation, following wedge resection of the ovaries, appear 
to be located in the ovaries The following local intra-ovanan factors 
may be responsible for the postoperative resumption of ovulatory cy-
cles (1) the increased intra-ovanan blood flow permitting an increased 
delivery of FSH and LH to the follicles, (2) the reduction of ovarian an-
drogen production resulting in a decrease of the local inhibitory effects 
of androgens on follicular maturation, and (3) a reduction in inhibin 
may also be of importance in establishing the appropriate LH/FSH ratio 
required for follicular development (McNATTY et al , 1980, YEN, 1980) 
Bilateral wedge resection of polycystic ovaries may be useful in selec-
ted circumstances, in general, this procedure will only be performed 
rarely because of the risks of surgery and adhesion formation and 
because of the case and success of ovulation induction with clomiphene, 
with or without additional medication 
12 8 5 Adrenal Suppression 
A combined adrenal and ovarian source of androgen excess seems to 
be present in patients with the PCO-syndrome (see 1 2 5 1) Suppres-
sion of the adrenal capacity to produce androgens may therefore be a 
rational approach to reduce the total androgen pool and, consequently, 
the extraglandular estrogen production It is generally recognized that 
correction of the hyperandrogemc state has substantial benefits for 
menstrual regularity (for review see HOLLANDERS, 1981) The use of 
corticosteroids has been advocated by many investigators A thera-
peutic trial of 6 to 12 months of prednisone therapy for every woman 
with the polycystic ovary disease, before resorting to wedge resection, 
was recommended as early as 1965 (PERLOFF et al , 1965, SMITH et 
al , 1965) An improvement of the menstrual status during dexametha-
sone therapy has been reported in 59% of patients with adrenal or 
mixed hyperandrogenism (ABRAHAM et al , 1981) Several studies 
demonstrated that a regimen of clomiphene and dexamethasone may be 
successful in the treatment of clomiphene non-responsive patients 
(DIAMANT and EVRON, 1981, LOBO et al , 1981b) It is of impor-
tance to note that in patients with even apparently normal ovulatory 
cycles, hyperandrogenism may interfere with conception Corticosteroid 
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administration has been demonstrated to be effective as an additional 
treatment in these patients (LAWRENCE et al., 1976; SMITH et al., 
1979; STEINBERGER et al., 1979; RADWANSKA and SLOAN, 1979). 
In spite of the positive results of adrenal suppression treatment in 
patients with clinical signs of hyperandrogenism, a further evaluation is 
required to establish its usefulness and mode of action (YEN, 1980). 
1.2.8.6 Ovarian Suppression 
Ovarian suppression with synthetic steroids (estrogens and/or proges-
togens) may, just like adrenal suppression, be a rational approach to 
reduce the total androgen pool in patients with the PCO-syndrome. 
However, suppression of ovarian steroidogenesis implicates an arrest of 
follicular maturation; therefore, this mode of treatment deserves prior-
ity in those patients who do not wish to become pregnant immediately. 
In PCO-patients, the administration of medroxyprogesterone acetate 
resulted in a reduction of plasma concentrations of both LH and testos-
terone (GORDON et al., 1972). Implants of estradiol have also been 
studied in some PCO-patients which resulted in a reduction of ovarian 
size and halted the progression of hirsutism (GAMBRELL, 1976). 
Several investigators have demonstrated a decrease of gonadotro-
phins and androgens during the use of an oral contraceptive. An increase 
of SHBG, paralleling a decrease of total and/or free testosterone was 
also found (EASTERLING et al., 1974; ANDERSEN et al., 1976; 
GIVENS et al., 1976b; FERN et al., 1978; TALBERT and SLOAN, 
1979). The dynamics of suppression and recovery of gonadotrophins and 
ovarian steroids in PCO-patients using an oral contraceptive have been 
studied by GIVENS et al. (1974). After a refractory period both androste-
nedione and testosterone were found to decrease progressively during 
treatment. The recovery rates of LH, androstenedione and testosterone 
after withdrawal of the combined estrogen-progestogen preparation were 
slower than the suppression rates. The changes of androstenedione and 
testosterone levels during suppression and recovery were correlated with 
LH. FSH recovered at a faster rate, resulting in a normalization of the 
originally increased LH/FSH ratio. The changed LH/FSH ratio creates a 
situation which allows normal follicular maturation. This benefits those 
patients who wish to become pregnant. Details concerning this last aspect 
will be discussed extensively in Chapters 7 and 8. 
1.2.9 Concluding Remarks 
The PCO-syndrome still remains a disorder of ill-definition. In spite of 
the great clinical and biochemical variability, a general agreement does 
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exist concerning several aspects of this disease. Hallmark of the syn-
drome is chronic anovulation and most women have clinical signs of 
androgen excess. Often a third characteristic, obesity, is also encoun-
tered. Although the early publications suggested typical morphological 
characteristics of the ovaries, later studies could not confirm these 
findings. Laboratory findings reveal inappropriate gonadotrophin secre-
tion and excess androgen production. The pathophysiology of this 
syndrome is not clear; however, evidence exists for both ovarian and 
adrenal disorders. 
We decided to study women with clinical features of the PCO-syn-
drome in an attempt to elucidate further pathophysiological aspects of 
the disease. The functional characteristics of both the hypothalamic-
pituitary-ovarian axis and the hypothalamic-pituitary-adrenal axis were 
tested and the results were compared with findings in normal ovulatory 
women. Finally the process of spontaneous follicular maturation was 
carefully evaluated after a period of ovarian suppression. 
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2. MATERIALS AND METHODS 
2.1 INTRODUCTION 
The patients selected for the present study attended the out-patient 
clinic of the Division of Gynaecological Endocrinology and Infertility, 
Department of Obstetrics and Gynaecology, Sint Radboud University 
Hospital, Nijmegen, The Netherlands. 
The study group consisted of 22 women with clinical features of the 
polycystic ovary syndrome (PCO-group). All patients gave their informed 
consent prior to the study. These women underwent a dexamethasone 
suppression test. Under standardized conditions a luteinizing hormone-
releasing hormone stimulation test (LH-RH test) and an adrenocortico-
tropic hormone stimulation test (ACTH test) were performed as well. To 
induce suppression of ovarian steroidogenesis, an estrogen-progestogen 
combination preparation was prescribed for 12 weeks. Following this 
period, the process of spontaneous follicular maturation was studied in 
those 17 women who wished to conceive. 
During each test or test period blood samples were taken at frequent 
intervals for gonadotrophin and/or steroid hormone determinations. 
The methodology of each test or test period, as well as the methods of 
statistical analysis, will be presented in the appropriate chapter in 
connection with results of the test or test period under discussion. 
For comparative purposes, 31 healthy women with regular menstrual 
cycles served as control group; all gave their informed consent prior to 
the study. These women were divided into three groups: 11 women who 
underwent a dexamethasone suppression test, 10 who underwent an 
LH-RH test, and 10 who underwent an ACTH test. 
This chapter describes the selection criteria for the PCO- and control 
group of women, the test schedules used and the applied radioimmuno-
assay techniques. 
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2 2 SUBJECTS 
2 2 1 Selection Criteria for the PCO-group 
The following criteria were used for qualifying the PCO-patients for 
this study they should either have oligomenorrhea, secondary ame-
norrhea or evidence of chronic anovulation, as well as hirsutism, and/or 
obesity 
In order to standardize the selection procedure the following defini-
tions were used 
— Oligomenorrhea the existence of menstrual intervals exceeding the 
95,h percentile for the age related frequency distribution of menstrual 
intervals according to TRELOAR et al (1967) 
— Amenorrhea the absence of menstruation for 6 months or more 
— Hirsutism the occurrence of a male hair pattern, which implicates 
excessive hair-growth in areas where females would normally have 
considerably less hair than males 
— Obesity the existence of a Quetelet-index exceeding the age related 
mean plus 2 standard deviations 
Applying these criteria 22 women could be selected to serve as the PCO-
group 
2 2 2 Selection Criteria for the Control Group 
In order to be considered a participant in the control group, the 
following criteria had to be met a woman should have regular menstru-
al cycles and should not be obese 
Similar to the PCO-cntena, the following standardized definitions 
were used 
— Regular menstrual cycles the occurrence of menstrual intervals 
within the range of the 5lh and 95th percentiles for the age related 
frequency distribution of menstrual intervals according to TRE-
LOAR et al (1967) 
— Non obesity a Quetelet-index not exceeding the age related mean 
plus 2 standard deviations 
Applying these criteria, 31 women could be included in the control group 
2 3 TEST SCHEDULE 
Table 2 1 summarizes the hormonal, haematological and biochemical 
measurements performed at the time of selection of the PCO-patients as 
well as the studies carried out in this group 
The PCO-patients were examined for their general health Blood 
hemoglobin levels were measured Various renal function parameters 
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TABLE 2 ι Schedule of initial hormonal and biochemical measurements and tests 
performed during this study in the PCO-patients 
Parameters 
Hemoglobin 
Liver function 
Renal function 
Prolactin 
T4 
LH 
FSH 
Cortisol 
17a-OH-Prog 
Progesterone 
Estrone 
Estradiol 
Select 
of pat 
X 
X 
X 
X 
X 
Androstenedione 
Testosterone 
Dex suppr 
test 
X 
X 
X 
X 
X 
LH-RH 
test 
X 
X 
X 
X 
X 
X 
X 
X 
ACTH 
test 
X 
X 
X 
X 
X 
X 
X 
Ovarian 
suppr 
X 
X 
X 
X 
X 
X 
X 
Follicular 
maturation 
X 
X 
X 
X 
X 
X 
were determined m serum including creatinine, uric acid and urea Liver 
function parameters were also determined in serum GOT, GPT and 
LDH To exclude hyperprolactinemia in PCO-patients, serum prolactin 
was measured and the thyroid function was evaluated by the 
determination of T4 All PCO-patients had the stimulation and the 
suppression tests performed in the same order as indicated in Table 2 1 
2 4 RADIOIMMUNOASSAY PROCEDURES 
2 4 1 Luteinizing Hormone (LH) 
Serum concentrations of LH were measured by specific, homologous, 
double-antibody solid-phase radioimmunoassay (DASP, Organon 
Tekmka В V , Oss, The Netherlands) (VAN GEELEN et al , 1981) 
LH was assayed with the use of rabbit antisera against highly purified 
human chorionic gonadotrophin (hCG) Within the range of the 
standard dose-response line for LH (2 to 400 IU First International 
Reference Preparation [IRP] of human pituitary LH [MRC 68/40] per 
liter of serum), the highest purified FSH (6000 IU/mg) and thyroid-
stimulating hormone (TSH) (4 IU/mg) preparations currently available 
showed some apparent cross-reaction, for which the LH contamination 
of these preparations is responsible Radiolabeling with I (The 
Radiochemical Centre, Amersham, U K ) was applied to pure human 
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LH (hLH-NM14, immunopotency 6440 IU/mg) After lodination, 
according to GREENWOOD et al (1963), purification was achieved by 
gel filtration on Sephadex G-25 and Sephadex G-100 (Pharmacia Fine 
Chemicals AB, Uppsala, Sweden) The lower detection limit was fixed 
at B/Bo = 0 9 and revealed 2 IU/1 for the LH assay The intra-assay and 
inter-assay variabilities for means of duplicate measurements were 
calculated from several pools of serum (RODBARD, 1971) and were 
8 6% and 16 3% respectively 
2 4 2 Follicle-Stimulating Hormone (FSH) 
Serum concentrations of FSH were measured by specific, homo­
logous, DASP radioimmunoassay (VAN GEELEN et al , 1981) Rabbit 
antisera were raised against highly purified FSH preparations The anti­
serum used failed to show any significant cross-reaction with the IRP's 
for LH, hCG, TSH, and their subumts within the range of the standard 
dose-response line for the FSH system (1 to 100 IU second IRP of 
human pituitary gonadotrophins LH and FSH for bioassay [MRC 
78/549] per liter of serum) after absorption of FSH antiserum with 
purified hCG (HUNTER and BENNIE, 1971) Radiolabehng with , 2 5I 
was applied to pure human FSH preparations (IRE, Fleuris, Belgium, 
immunopotency 6000 IU/mg) (GREENWOOD et al , 1963) After lodi-
nation, purification was similarly achieved as previously described for 
radiolabeled LH The lower detection limit for the FSH assay at B/B() = 
0 9 revealed 0 7 IU/1 whereas the intra-assay and inter-assay variabilities 
were 8 1% and 15 5% respectively 
2 4 3 Prolactin (PRL) 
Serum concentrations ot PRL were measured by specific, homolo­
gous, DASP radioimmunoassay The rabbit antiserum (AB Kabi, 
Stockholm, Sweden) did not cross-react with appreciable amounts of 
the IRP's for LH, FSH, TSH, hCG, and ACTH within the range of the 
standard dose-response (50 to 7500 mlU First IRP of human PRL for 
immunoassay [MRC 75/504] per liter of serum, equivalent to 1 to 
150 μg PRL VLS#1 per liter of serum) In addition, no cross-reac-
tivities were observed with dosages as high as 4400 mIU/1 of the hCG 
standard MRC 66/217 and with 8 mg/1 of the PRL standard MRC 
73/545 Radiolabehng with '^I and subsequent purification were 
similarly performed with human PRL (AB Kabi, Stockholm, Sweden) 
as for LH and FSH preparations The minimum detectable dose (B/B0 
= 0 9) revealed 50 mIU/1 (approximately 1 μg/l), whereas the intra-
assay and inter-assay variabilities were 6 3% and 14 6% respectively 
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2 4 4 Estrone (E,) 
Serum concentrations of Eì were measured by estrogen-specific 
dextran-coated charcoal (DCC) radioimmunoassay The rabbit anti-
serum used was directed against estnol (E3)-16,17-disuccinyl-BSA and 
showed significant cross-reactivities with standard preparations of Ε,, E 2 
and Ej, irrespective of which particular tntiated estrogen was used as 
the labeled steroid (Table 2 2) All other relevant related steroids cross-
reacted less than 0 02% in the system which applied [2,4,6,9-3Н]Ез (The 
Radiochemical Centre, Amersham, U К , specific activity 109 
Ci/mmol) as the radioactive component in order to maximize the sensi­
tivity of the assay system (Table 2 2) The standard dose-response line 
used ranged from 3 to 400 pg E,, equivalent to 0 01 and 1 47 pmol E, 
standard per assay tube The specific determination of E, in serum 
samples could be achieved by extraction of the samples with diethyl 
ether and subsequent chromatographic isolation of the E, containing 
fraction This was readily done on columns containing 0 5 g Sephadex 
LH-20 (Pharmacia Fine Chemicals AB, Uppsala, Sweden) and devel­
opment of the column with toluene-methanol (9 1, v/v) The recovery of 
TABLE 2 2 Sensitivities and cross-reactions of E,, E2 and E-, in estrogen-specific 
radioimmunoassay 
Labeled Steroid Sensitivity Cross-Reaction 
^H-estrogen (pgE/tube) (%) 
at B/B0 = 0 9 at B/B„ = 0 5 at В/Вц = 0 5 
I 2 3 
E, 4 34 100 45 16 
E 2 5 34 100 85 28 
E, 3 11 100 65 32 
p A ó J ^ H J E , (The Radiochemical Centre, Amersham, U К , specific 
activity 102 Ci/mmol) added to serum samples before extraction was 76 
± 7 (SD)% (n = 35) in the Ε,-containing fraction after chromato­
graphic isolation Parallelism between serial dilutions of this fraction 
and the E, standard dose-response line was present, whereas no other 
estrogens could be demonstrated in the E, fraction Substantial amounts 
of exogenously added E2 to serum samples before extraction failed to 
show any significant increase of E, levels in this fraction as compared to 
the endogenous E, concentrations of the same sera Similarly, when E 2 
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was added to water samples, E, values were obtained which were within 
the variability of the initial binding (B
n
) Method blanks were always 
much lower than the minimum detectable dose (3 pg E, standard per 
assay tube at В/Вц = 0 9) and were neglected The intra-assay and inter-
assay variabilities for duplicate measurements as calculated from several 
pools of serum (cf description of LH assay) were 5 3 % and 13 7 % 
respectively 
2 4 5 Estradiol·! 7ß (E2) 
Serum concentrations of E2 were measured by specific, DCC radioim-
munoassay (THOMAS et al , 1977) Rabbit antiserum was raised 
against E2-6-(o-carboxymethyl)-oxime-BSA Within the range of the 
standard dose-response line (3 to 400 pg, 1 e 0 01 to 1 47 pmol E2 
standard per tube), a variety of relevant, related steroids showed cross-
reactivities of less than 1% at 50% inhibition Radiochemical purity of 
tntiated steroid ([ZAó^-^HJEi, The Radiochemical Centre, Amers-
ham, U К , specific activity 112 Ci/mmol) was checked by chromatogra­
phy on Sephadex LH-20 columns The recovery of tntiated E 2 added to 
serum was 91 ± 7 ( S D ) % (n = 36) following extraction with diethyl 
ether Method blanks were always much lower than the minimum detec­
table dose (4 pg E, per assay tube at B/B() = 0 9) and were, therefore, 
neglected The intra-assay and inter-assay variabilities as calculated 
from several pools of serum (cf description of LH assay) were 6 2% 
and 9 0 % respectively 
2 4 6 Progesterone (P) 
Serum concentrations of Ρ were measured by specific, DCC radio­
immunoassay (THOMAS et al , 1977) The rabbit antiserum used was 
raised against 1 Ια-ΟΗ-progesterone-hemisuccinate-BSA Within the 
range of the standard dose-response line (8 to 1000 pg, equivalent to 
0 03 to 3 18 pmol Ρ standard per tube), all the relevant, related steroids 
showed cross-reactions of less than 0 1 % at B/B
n
 = 0 5 Radiochemical 
purity of the tntiated Ρ used ([1,2,6,7-^]?, The Radiochemical Centre, 
Amersham U К , specific activity 100 Ci/mmol) was checked by chro­
matography on Sephadex LH-20 columns The recovery of tntiated Ρ 
added to serum samples was 97 ± 3 ( S D ) % (n = 37) following extrac­
tion with diethyl ether Method blanks were always much lower than the 
minimum detectable dose (10 pg Ρ standard per assay tube at B/B0 = 
0 9) and were, therefore, neglected The intra-assay and inter-assay 
variabilities as calculated from several pools of serum (cf description of 
LH assay) were 7 2 % and 1 1 % respectively 
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2.4.7 17a-OH-Progesterone (17-OH-P) 
Serum concentrations of 17a-OH-progesterone (17-OH-P), testos-
terone (T) and androstenedione (A) were measured by DCC radio-
immunoassay (WELLEN et al., 1982). The specific determination of 
17-OH-P, T, and A in serum could be achieved by extraction of the 
samples with diethylether and subsequent chromatographic isolation of 
the steroids on Whatman paper no. 1 using a modified Bush A system 
(petroleumether [80:110]-methanol-water, 9:7:4, v/v). The recoveries of 
tritiated steroids ([1.2-3H]17-OH-P, [lß,2ß-3H]T, and [ 1 , 2 , 6 , 7 - ^ ^ , 
New England Nuclear, Boston, U.S.A. , specific activities 50.0 Ci/mmol, 
50.4 Ci/mmol, and 90.0 Ci/mmol, respectively) added to serum samples 
before extraction were 58 ± 4 (SD)% (n = 30) in the 17-OH-P contain-
ing fraction (Rf = 0.21), 45 ± 7 (SD)% (n = 30) in the Τ containing 
fraction (Rf = 0.30), and 36 ± 5 ( S D ) % (n = 30) in the A containing 
fraction (Rf = 0.67). 
Sheep antiserum was raised against ll-desoxycortisol-21-hemi-
succinate-BSA and showed 100% cross-reactivities with both 11-des-
oxycortisol and 17-OH-P. Within the range of the standard dose-re­
sponse line (0-320 pg) other cross-reactivities at 50% inhibition were 
shown by Cortisol (1.5%), Τ (3.6%) and Ρ (5.1%). The inter-assay 
variability was 8.3% at a mean concentration of 114 ng/100 ml (n = 6) 
of the control sample. 
2.4.8 Testosterone (T) 
Serum concentrations of Τ were measured by DCC radioimmuno­
assay (SMALS et al., 1976; WELLEN et al., 1982) after extraction and 
chromatographic purification as described for 17-OH-P (cf. 2.4.7). 
The rabbit antiserum (kindly provided by Dr. Pratt, State University, 
Groningen) was raised against testosterone-7a-carboxyethylether-BSA. 
The assay sensitivity was 5 ng/100 ml. The mean inter-assay coefficient 
of variation in this study was 9 .3% at a mean Τ level of 258 ng/10() ml 
(n = 32). 
2.4.9 Androstenedione (A) 
Serum concentrations of A were measured by DCC radioimmuno­
assay (WELLEN et al., 1982) after extraction and chromatographic 
purification as described for 17-OH-P (cf. 2.4.7). 
The antiserum was raised against androstenedione-19-carboxy-
methylether-BSA (Radioassay Systems Laboratories Inc., California). 
Within the range of the dose-response line (0-320 pg) this antiserum 
cross-reacts at 50% inhibition for 4.2% with dchydroepiandrosterone, 
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1.5% with androsterone, 0.34% with Τ and 0.02% with 17-OH-P. The 
mean inter-assay coefficient of variation in this study was calculated to 
be 8.6% at a mean androstenedione level of 260 ng/100 ml (n = 31). 
2.4.10 Cortisol (F) 
Serum concentrations of F were measured by direct double antibody 
1 2 5I radioimmunoassay in an automated system (Centria System, Union 
Carbide Clinical Diagnostics, Rye, NY 10580). The rabbit antibody 
used was raised against cortisol-21-hemisuccinate-BSA and the second 
antibody was raised in sheep against rabbit γ-globulin (MERIADEC et 
al., 1979). With this technique a good correlation coefficient was 
observed with the technique previously described by SMALS et al. 
(1978a). Replicate analysis of a plasma pool with a Cortisol level of 
0.51 цтоі/і disclosed an intra-assay coefficient of variation of 5.9% 
(n = 21). The inter-assay coefficient of variation in this study was calcu­
lated to be 6.8% (mean level of the control Cortisol samples 0.41 μπιοΐ/ΐ 
[π = 28]). 
2.4.11 Thyroxine (T4) 
Serum concentrations of X, were measured by specific radioimmuno­
assay. The method used is a modification of the original assay as de­
scribed by MURPHY and JACHAN (1965). This technique has been 
described by BEEX et al. (1977). 
2.4.12 Units 
The use in medicine of the "Système International d'Unités" (SI) 
developed by the "Conférence Général des Poids et Mesures" was 
TABLE 2 3 Conversion factors for "old" and SI units 
Hormone "old" units factor SI units 
LH 
FSH 
Prolactin 
Thyroxine 
Cortisol 
Testosterone 
Androstenedione 
Estrone 
Estradiol 
Progesterone 
17a-OH-Progesterone 
mIU/ml 
mIU/ml 
ng/ml 
μβ/dl 
цтоі/і 
ng/dl 
ng/dl 
pg/ml 
pg/ml 
ng/ml 
ng/dl 
1 
1 
¡0 
2.87 
1 
0.0347 
0.0349 
3.699 
3.671 
3.180 
0.0303 
IU/1 
IU/1 
mIU/1 
nmol/1 
цтоі/і 
nmol/1 
nmol/1 
pmol/1 
pmol/1 
nmol/1 
nmol/1 
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supported by the Thirtieth World Health Assembly in May 1977. The 
adoption of the SI by the entire scientific community and particularly 
the medical community was recommended. Since our laboratories have 
as yet not adopted SI units for each hormone, the conversion factors are 
summarized in Table 2.3. 
The figures which illustrate the results of the present study show SI 
units on the left y-axis whereas the right y-axis shows the units as used in 
this Institute. 
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3. CLINICAL AND BASAL ENDOCRINOLOGICAL 
CHARACTERISTICS OF THE PCO-GROUP AND 
THE CONTROL GROUP 
3.1 CLINICAL CHARACTERISTICS 
3.1.1 Introduction 
Details concerning the age, height and weight of women in the study 
group and women in the control group are presented in Table 3.1. The 
mean age in the control women is higher than that in the PCO-patients. 
All women have an age compatible with normal ovulatory function and 
normal reproductive capacity. 
TABLE 3.1 Age, height and weight of women in the PCO-group (n = 22) and the 
control group (n = 31). 
Age (years): 
PCO-group 
Control group 
Height (cm): 
PCO-group 
Control group 
Weight (kg): 
PCO-group 
Control group 
Mean 
27.1 
31.9 
165 
167 
85 
60 
SD 
4.7 
4.5 
7 
6 
15 
8 
Median 
27 
32 
164 
168 
84 
60 
Range 
1 9 - 36 
21 - 39 
1 5 5 - 180 
153 - 180 
5 4 - 112 
4 8 - 80 
All volunteering participants (both PCO-patients and control women) 
were in good health. Two women in the control group, however, used 
some medication; one (no. 4) because of slight hypertension (meto-
prololtartrate and chloortalidon) and the other (no. 31) because of 
stationary ulcerative colitis (salicylazosulfapyridine and indometha-
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cine) Women taking oral contraceptives discontinued at least three 
months prior to their participation in this study. After the LH-RH test 
PCO-patients received iron supplementation (ferrofumarate, 3 x 200 
mg/day) for one month to prevent anemia due to iron deficiency as a 
consequence of frequent blood sampling. 
Some biochemical characteristics of the PCO-patients are presented 
in Table 3.2. Details of clinical features are presented below 
TABLE 3 2 Non-hormonal laboratory findings in the PCO-group of women 
Parameter 
Hemoglobin 
Serum creatinine 
Serum uric acid 
Serum urea 
Serum GOT ( + ) 
Serum GPT ( x ) 
Serum LDH ( + ) 
Unit 
mmol/1 
μτηοΐ/ΐ 
mmol/1 
mmol/1 
U/l 
U/l 
U/l 
Median 
8 9 
72 
0 37 
4 2 
15 
13 
201 
Range 
7 7 - 9 9 
49 -113 
0 26 - 0 46 
2 4 - 6 7 
5 - 34 
6 - 88 
127 - 306 
(+) π = 20 (x)· η = 19 
3.1.2 Signs of Chronic Anovulation 
Participants in both groups reported the length and variation of their 
menstrual cycles during one year prior to the study The results for both 
groups are presented in Figure 3.1. 
Twenty-one women had an interval between menstrual onsets 
exceeding the 95th percentile of TRELOAR et al. (1967), 5 of whom had 
no spontaneous menstruation in the year prior to the study; 1 woman 
had, in spite of menstrual onsets within the normal range, evidence of 
chronic anovulation (monophasic basal body temperature [BBT], 
absence of midcycle pain, and absence of premenstrual sensations) and 
could therefore be included in this study. 
Additional evidence, for the existence of predominantly anovulatory 
cycles in the PCO-patients, was obtained from anamnestic data; no 
PCO-patient ever experienced mid-cycle pain (ovulation pain) and only 
5 women (23%) experienced certain premenstrual sensations The 
majority of PCO-patients (21) measured their BBT for a varying period 
of time. In 15 of them (71%) the BBT charts always showed a mono-
phasic pattern, whereas in 6 women (29%) the BBT charts were inter-
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mittently monophasic and biphasic. These findings demonstrate that 
patients with the PCO-syndrome may occasionally have spontaneous 
ovulatory cycles as also seen by BAIRD et al. (1977). 
Midcycle pain was reported by 15 control women (48%); most 
control women had certain premenstrual sensations (28/31, 90%). 
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FIGURE з ι Longest interval in days between spontaneous menstrual onsets in the 
year prior to this study for each PCO-patient (o) and control woman ( ·) . 
The 5,h, 50,h, and 95lh percentiles for the distribution of menstrual intervals are 
according to TRELOAR et al. (1967). 
The shortest interval in days between spontaneous menstrual onsets was within the 
normal range for some PCO-patients. These women, however, always had clinical 
evidence of anovulation and were therefore included in the study. 
For practical reasons one PCO-patient (no. 116, age 19 years) is plotted as 20 years old. 
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3.1.3 Signs of Androgen Excess 
The most important expression of androgen excess in women is hirsu-
tism. In the present study the degree of hirsutism was classified accor-
ding to BARDIN and L1PSETT (1967). In this classification only facial 
hirsutism, which could be graded in both PCO-patients and control 
women, is involved. Details concerning the degree of hirsutism of 
women of both study groups are presented in Table 3.3. Facial hirsutism 
was present in 19 women of the PCO-group (86%) and only 3 (10%) 
from the control group. 
Additional anamnestic data concerning the growth of hair in other 
body regions are summarized in Table 3.4. Although these anamnestic 
TABLE 3.3 Degree of hirsutism of women in the PCO-group (n = 22) and the con-
trol group (n = 31). 
PCO 
Subject 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
-group 
Degree of 
hirsutism 
+ + 
+ + 
+ 
+ + + 
-
-
+ + 
+ 
-
+ 
+ 
+ + + 
+ + + 
+ 
+ + 
+ + 
+ + + 
+ + 
+ + 
+ + + 
+ + + 
+ + 
Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
011 
012 
013 
014 
015 
016 
017 
018 
019 
020 
021 
022 
Control 
Degree of 
hirsutism 
_ 
-
+ 
-
-
-
-
-
-
+ 
-
-
-
-
-
-
-
+ + 
-
-
-
-
group 
Subject 
023 
024 
025 
026 
027 
028 
029 
030 
031 
Degree of 
hirsutism 
_ 
-
-
-
-
-
-
-
-
LEGEND: Facial hirsutism was graded + for each portion of the face involved (side-
burns, upper lip, chin) and + + + + if the entire beard was involved (BARDIN and 
LIPSETT, 1967). 
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TABLE 3.4 Anamnestic data concerning the presence of growth of hair in several 
body regions in women in the PCO-group and the control group. 
14/22 
2/22 
21/22 
7/22 
21/22 
20/22 
22/22 
21/22 
20/22 
(64%) 
(10%) 
(96%) 
(32%) 
(96%) 
(91%) 
(100%) 
(96%) 
(91%) 
0/31 
0/31 
0/31 
0/31 
12/31 
3/31 
19/31 
7/31 
1/31 
(0%) 
(0%) 
(0%) 
(0%) 
(39%) 
(10%) 
(61%) 
(23%) 
(3%) 
Site PCO-group Control group 
Thorax: 
Periareolar 
Presternal 
Abdomen: 
Male escutcheon 
Lower back: 
Sacral tuft of hair 
Extremities: 
Fore-arm 
Upper-leg 
Lower-leg 
Perivulvar 
Perianal 
data have limited value, it is clearly demonstrated that PCO-patients 
tend to have a male hair pattern in other body regions as well. Viriliza­
tion was not present in either group. Eleven PCO-patients (50%) had 
acne, and 14 (64%) complained of seborrhea, whereas in the control 
group, 4 women (13%) had acne, and 8 (26%) reported seborrhea. 
3.1.4 Signs of Increased Anabolism 
Details concerning height and weight of women from both groups are 
presented in Table 3.1. There were no differences between the two 
groups of women in mean height; however the mean weight was higher 
in the PCO-patients. 
In this study the Quetelet-index was used to express the degree of 
obesity. This index was calculated with the formula: 
Quetelet-index = ^ Щ χ iti* (height)2 
The range of expected normal values of the Quetelet-index was calcu­
lated from an epidemiological preventive investigation, performed in 
two Dutch districts, concerning cardiovascular risk factors (VALKEN­
BURG et al., 1980). Because of the changing Quetelet-index with age, 
two age groups were created. In Figure 3.2 the Quetelet-indices of 
PCO-patients and control women are presented. Fifteen PCO-patients 
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(68%) had an excessive Quetelet-index, indicating the presence of 
obesity in these women. Women in the control group did not have a 
Quetelet-index exceeding the upper limit of the normal range (X + 
2SD), indicating the absence of obesity. 
Quetelet- index 
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FIGURE 3 2 Age related Quetelet-index for each PCO-patient (o) and control 
woman (·). _ 
The shaded area represents the expected normal range (X ± 2SD) for the popula­
tion of two Dutch districts (VALKENBURG et al. 1980). 
For practical reasons one PCO-patient (no. 116, age 19 years) is plotted as 20 
years old. 
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3.2 BASAL ENDOCRINOLOGICAL CHARACTERISTICS 
3.2.1 Introduction 
In the present investigation blood samples for the determination of 
gonadotrophin, androgen and estrogen levels were collected in both 
groups of women. Since androgen and estrogen production in women 
depends on the stage of follicular development, an effort was made to 
obtain the basal endocrinological data under standardized conditions. 
Hence, in the PCO-patients blood samples were taken during a pro-
gestogen withdrawal bleeding, following a progestogen challenge 
(medroxyprogesterone-acetate, 3 x 5 mg/day for 5 days). The proges-
togen challenge mimics the second half of the menstrual cycle. There-
fore the basal data were obtained at a time when the hypothalamus and 
pituitary gland remain in a situation comparable to the early follicular 
phase. 
In control women, blood samples were collected during the early folli-
cular phase of the menstrual cycle. 
After the collection of three reference samples, an LH-RH test was 
performed in both groups of women. The results of this LH-RH test will 
be discussed in Chapter 5. The serum levels of gonadotrophins, andro-
gens and estrogens determined from the LH-RH test reference samples 
will be the subject of discussion in this chapter. 
3.2.2 Materials and Methods 
3.2.2.1 Subjects 
There were 22 PCO-patients who underwent the standardized 
LH-RH test. At the time of the testing 2 PCO-women, however, 
happened to have serum progesterone levels which were compatible 
with mid-luteal phase concentrations; therefore, results from these 2 
patients were not included in this presentation (no. 106 and no. 114). 
There were 10 control women who also underwent the LH-RH test. 
3.2.2.2 Sampling Procedure 
All blood samples were collected and all tests were performed in the 
out-patient department. All testing was done by the principal inves-
tigator assisted by sufficiently instructed nurses. Blood samples were 
obtained from each patient between 9 and 10 a.m. An indwelling cannu-
la was placed in a convenient vein and a slow running physiological saline 
solution was connected. Sampling from this cannula was performed at 30 
and 15 minutes and immediately before the administration of LH-RH. 
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Determinations of FSH, LH, estrone, estradiol, Cortisol, androstene-
dione and testosterone were performed in all three samples of each 
PCO-patient and control woman, while progesterone was determined in 
the sample obtained 30 minutes prior to the LH-RH injection. The 
blood was allowed to clot at room temperature, centrifuged and the 
supernatant was stored at —20°C until assayed. All samples from one 
patient were determined in the same assay-run. 
3.2.2.3 Statistical Analysis 
The Wilcoxon two-sample test was used to evaluate differences 
between the distribution of values found in the PCO-patients and the 
control women. 
For both groups of women, the Kendall-test was used for the evalua­
tion of correlations between several pairs of parameters. 
3.2.3 Results 
For both groups of women, the serum levels of LH, FSH, estrone, 
estradiol, androstenedione and testosterone, as well as the LH/FSH 
ratio, in each reference sample, are presented in Figures 3.3 - 3.5. The 
results are summarized in Table 3.5. 
The PCO-patients had significantly higher LH levels and significantly 
lower FSH levels as compared to the control women. As a consequence 
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TABLE 3 5 Basal endocrinological characteristics of women in the PCO-group and 
the control group. 
Parameter 
LH 
FSH 
LH/FSH ratio 
Estrone 
Estradiol 
Cortisol 
Androstenedione 
Testosterone 
PCO-group 
(n = 20) 
X SD 
19 6 
4.6 1.2 
4.3 1.6 
97 50 
67 13 
0.52 0.17 
382 136 
66 31 
Control 
(n = 
X 
14 
6 1 
2.3 
58 
54 
0.54 
165 
30 
group 
10) 
SD 
4 
0.9 
0.6 
14 
17 
0.13 
65 
14 
Ρ 
0.04* 
0.006* 
0.0002* 
0.006* 
0.03* 
0.51 
0.0001* 
0.0008* 
* Significant difference 
Within a woman the averaged value of the three samples on t = 
was here taken as basal value. 
-30, - 1 5 and 0 
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FIGURE ι ч Serum androstenedione and testosterone concentration at t = 0 in 20 
PCO-patients and 10 control women (X ± SD) 
of these differences the LH/FSH ratio was significantly elevated in the 
PCO-patients Serum estrone and estradiol concentrations were also 
significantly elevated in the PCO-patients, as were the serum levels of 
androstenedione and testosterone Despite these significant differences 
a marked degree of overlap existed in PCO-patients and control women 
for gonadotrophins, estrogens and androgens In both groups serum 
Cortisol levels were comparable 
In Table 3 6 results are presented in relation to the sampling time 
The forementioned findings were established at each of the three 
moments of blood sampling before LH-RH injection 
To assess the possibility of significant correlations amongst the 
variables studied, Kendall correlation coefficients were calculated for 
pairs of hormonal parameters measured at time 0 This was done for 
both groups separately No significant correlation coefficient between 
basal estrogen or androgen levels and serum LH or FSH concentrations 
in either group of subjects was found 
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TABLE з 6 Basal endocrinological characteristics of women in the PCO-group and 
the control group 
PCO-group Control group 
Parameter (" = 2 0> (" = 1 0 ) 
X SD X SD 
LH 
-30 
-15 
0 
FSH 
-30 
-15 
0 
Estrone 
-30 
-15 
0 
Estradiol 
-30 
-15 
0 
Androstenedione 
-30 
-15 
0 
Testosterone 
-30 
-15 
0 
Cortisol 
-30 
-15 
0 
210 
18 3 
17 3 
4 9 
4 4 
4 5 
104 
94 
95 
71 
64 
67 
416 
386 
344 
75 
62 
60 
0 59 
0 51 
0 45 
7 2 
6 3 
5 8 
1 4 
1 3 
1 1 
46 
47 
60 
14 
14 
15 
152 
132 
140 
33 
30 
30 
0 23 
0 17 
0 17 
13 3 
14 6 
14 1 
6 0 
6 0 
6 2 
61 
60 
54 
56 
53 
53 
178 
165 
152 
34 
29 
26 
0 57 
0 55 
0 50 
4 2 
5 6 
4 4 
0 8 
0 8 
1 5 
16 
17 
14 
19 
19 
17 
77 
59 
62 
15 
15 
13 
0 17 
0 15 
0 11 
0 003* 
0 07(·) 
0 06(*) 
0 01* 
0 001* 
0 002* 
0 001* 
0 0 1 * 
0 002* 
0 01* 
0 05* 
0 02* 
0 0001* 
00001* 
0 0001* 
0 0002* 
0 001* 
0 002* 
0 74 
0 34 
0 23 
* significant difference (ρ =£ 0 05) 
(*) tendency for a significant difference (0 05 < ρ ^ 0 10) 
3 2 4 Discussion 
Of the 22 PCO-patients, 20 responded to the progestogen challenge 
with the expected withdrawal bleeding The two non-responders had 
progesterone levels compatible with mid-luteal phase concentrations, 
indicating the presence of an ovulatory cycle These two women demon­
strate that, although classically the PCO-syndrome is associated with 
oligomenorrhea or amenorrhea, occasional ovulatory cycles may occur 
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spontaneously as also reported by GOLDZIEHER and AXELROD 
(1963) and BAIRD et al (1977) 
The basal concentrations of gonadotrophins observed in the PCO-
patients were significantly different from those found in normal ovula-
tory women during the early follicular phase The mean basal LH level 
was elevated in the PCO-patients However, the LH concentration 
was variable from patient to patient and in the same patient remarkable 
fluctuations of the LH level could also be observed Although there 
have been conflicting reports on basal gonadotrophin levels found in 
PCO-patients, the results of the present study arc in agreement with 
most studies reported in literature YEN et al (1970a) found that the 
mean LH level was constantly and significantly higher in PCO-patients 
Similarly elevated LH levels were subsequently reported by DeVANE 
et al (1975),REBARetal (1976) and BAIRD et al (1977) Mean LH 
values within the normal range were reported by ZARATE et al 
(1973) DUIGNAN et al (1975) and DUIGNAN (1976) 
The concentration of FSH was significantly lower in PCO-patients 
FSH levels m PCO-patients have been reported to be either comparable 
with or lower than the mean FSH concentration observed during the 
early follicular phase m normal ovulatory women (YEN et al , 1970a, 
DeVANE et al , 1975, REBAR et al , 1976, BAIRD et al , 1977) 
The elevated LH levels and reduced levels of FSH resulted in an 
elevated LH/FSH ratio in PCO-patients The optimal condition for 
follicular maturation depends on the LH/FSH ratio, it appears that the 
successful maturation of small antral follicles during the early follicular 
phase is enhanced when there is a relatively high FSH concentration, 
thus a low LH/FSH ratio (McNATTY, 1981a) The increased LH/FSH 
ratio encountered in PCO-patients may therefore be expected to cause 
disturbances in follicular growth and maturation 
In the PCO-group of women the mean estrone and estradiol concen-
trations were significantly elevated This confirms the previous observa-
tion of BAIRD et al (1977) Estradiol levels equal to those found in 
normal women during the early follicular phase have also been reported 
(DeVANE et al , 1975, JUDD, 1978) Although total estradiol levels 
were within the normal range in a group of PCO-patients studied by 
LOBO et al (1981a), the percentage of unbound estradiol, as well as 
the amount of unbound estradiol, were significantly elevated General 
agreement exists on the finding of increased estrone levels in PCO-pa-
tients (DeVANE et al , 1975, BAIRD et al , 1977, JUDD, 1978) Most 
circulating estrogens in patients with the PCO-syndrome do not orig-
inate from direct ovarian secretion, but from peripheral conversion of 
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androgens (SIITERI and MacDONALD, 1973, EDMAN and Mac-
DONALD, 1976) In the present study, a significant elevation of 
androstenedione and testosterone was seen in PCO-patients This 
increased androgen pool probably accounted for the elevated estrone 
and estradiol levels 
Many studies performed on women with the PCO-syndrome have 
indicated a modest elevation of all circulating androgenic hormones and 
their precursors, however, an overlap with normal values was reported 
as well (BARDIN et al , 1968, ABRAHAM et al , 1975, DeVANE et 
al , 1975, DUIGNAN et al , 1975, RAJ et al , 1978) The androgen 
excess found in PCO-patients in the present study is in agreement with 
these investigations 
The PCO-patients had Cortisol levels similar to the values found in the 
control women, indicating the absence of hypercortisolism The 
existence of Cushing's syndrome was further excluded by means of a 
dexamethasone suppression test (see Chapter 4) 
In the present investigation no consistent correlation could be demon­
strated between basal estrogen or androgen levels and serum LH and 
FSH concentrations in either group of women The absence of any cor­
relation between basal LH and testosterone levels, as well as both 
positive and negative correlations between these two hormones have 
been reported in other groups of PCO-patients (DUIGNAN et al , 
1975, MORTIMER et al , 1978, KANDEEL et al , 1978) Several 
investigators reported a significant, positive correlation between LH 
and estradiol and estrone levels (DeVANE et al , 1975, К ATZ and 
CARR, 1976, KANDEEL et al , 1978) Since the statistical analysis of 
data in these studies seemed to be influenced by extreme data points of 
highest and lowest levels of the investigated parameters, the real impor­
tance of these findings cannot be established 
Although the presence of polycystic ovaries in the investigated PCO-
group of women was not confirmed by laparoscopy, laparotomy or 
histological examination of ovarian tissue, these women had basal endo­
crinological characteristics comparable with those found in well-proven 
PCO-patients reported in the literature A group of women selected on 
the basis of clinical features of the PCO-syndrome may therefore be 
considered to have the polycystic ovarian disease 
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4. THE DEXAMETHASONE SUPPRESSION TEST 
4.1 INTRODUCTION 
In Chapter 3 it was demonstrated that serum testosterone and andro-
stenedione levels are elevated in patients with the PCO-syndrome. The 
predominant glandular source of excess androgen production in women 
with clinical signs of hyperandrogenism can be evaluated by means of 
stimulatory and inhibitory tests of either the adrenal glands or the ova-
ries. In order to evaluate the role of the adrenal glands in the hyperan-
drogenic state encountered in the PCO-patients, a dexamethasone sup-
pression test and an ACTH test were performed. The circadian rhythm 
of several adrenal and/or ovarian steroids was also evaluated. The 
results were compared with data obtained in normal ovulatory women. 
The circadian rhythm study and the dexamethasone suppression test will 
be the subjects of discussion in this chapter; results of the ACTH test 
will be presented in Chapter 6. 
4.2 MATERIALS AND METHODS 
4.2.1 Subjects 
The study group consisted of 22 PCO-patients who underwent the 
circadian rhythm evaluation and the dexamethasone suppression test. 
However, in one PCO-patient (no. 105) blood samples were not 
collected according to the time-schedule and this patient also failed to 
take the prescribed dose of dexamethasone at the appropriate time. The 
results from this patient were therefore not included in this presen-
tation, leaving a total of 21 PCO-patients. The blood samples were 
collected irrespectively of any possible menstrual cycle phase. 
A total of 11 control women underwent the circadian rhythm evalua-
tion, 10 of whom also underwent the dexamethasone suppression test. 
In these control women the blood samples were collected during the 
early follicular phase of their menstrual cycles. 
All women in both groups had normal schedules of daytime activity 
and sleep. 
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4 2 2 Sampling Procedure 
All blood samples were collected in the out-patient department. Blood 
samples were obtained on two consecutive days. On day one a first 
specimen was collected between 8.30 and 9.30 a.m (sample 1), and a 
second specimen was collected between 3 30 and 4.30 p.m (sample 2) 
Dexamethasone (Oradexon®, Organon Nederland B.V , 4 x 0 5 mg) 
was administered orally at 11.00 p.m On day two a third blood sample 
was obtained between 8 30 and 9.30 a.m (sample 3). 
Determinations of serum Cortisol, estrone, estradiol, androstene-
dione and testosterone levels were performed in all samples of each 
patient and control woman. The blood was allowed to clot at room tem­
perature, then centnfuged and the supernatant was stored at — 20°C 
until assayed All samples from one patient were determined in the 
TABLE 4 1 Results of Cortisol measurements in the PCO-patients and the control 
women during the dexamethasone suppression test 
CORTISOL (μιηοΐ/ΐ) 
PCO-group 
Control group 
DIURNAL RHYTHM 
PCO-group 
Control group 
DEXAMETHASONE 
PCO-group 
Control group 
SAMPLE 1 
(9 00a m ) 
X SD 
0 49 0 15 
0 46 0 16 
(mean difference 
X 
0 18 
0 11 
SUPPRESSION ( 
X 
0 48 
0 45 
SAMPLE 2 
(4 00 ρ m ) 
Χ 
0 31 
0 35 
samples 1 
mean diffe 
SD 
0 17 
0 17 
and 2) 
SEM 
0 03 
0 05 
:rence samples 
SEM 
0 03 
0 05 
SAMPLE 3 
(9 0 0 a m ) 
X 
0 02 
0 02 
1 and 
SD 
0 01 
0 02 
Ρ 
0 001* 
0 03* 
3) 
Ρ 
0 001* 
0 003* 
* significant difference 
PCO-group samples 1, 2 and 3 η = 21 
Control group samples 1 and 2 η = 11, sample 3 π = 10 
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same assay-run. Unfortunately a few estrone values are missing since 
the amount of serum was to small in these cases. 
4.2.3 Statistical Analysis 
The Wilcoxon one-sample test (normal approximation) was used to 
determine the presence of a circadian rhythm of the measured steroids 
and to determine the effect of dexamethasone administration on serum 
levels of these steroids in both the PCO- and control groups of women. 
One-sided ρ values are given for Cortisol, androstenedione and testo­
sterone as one may expect these hormones to be at least partly derived 
from the adrenals; such a presupposition could not be made for estrone 
and estradiol and therefore two-sided ρ values are given for these two 
hormones. 
Cortisol ( m e a n i S E M ) 
( / j m o l / l ) £-~]
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S a m p l i n g t i m e 
FIGURE 4 ι Serum Cortisol concentrations in the PCO-group and the control group 
during the dexamethasone suppression test (X ± SEM). 
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4.3 RESULTS 
4.3.1 Cortisol 
The results of Cortisol measurements in the PCO-group and the 
control group are presented in Table 4.1 and Figure 4.1. Seventeen 
PCO-patients and 8 control women had high Cortisol levels in the mor­
ning in comparison with Cortisol levels measured in the afternoon. A 
significant difference between samples 1 and 2 was found in both the 
PCO-group and the control group. 
All PCO-patients and control women had depressed Cortisol levels 
after the administration of dexamethasone. The difference of samples 1 
and 3 was, as might be expected, highly significant in both groups. 
TABLE 4 2 Results of estrone measurements in the PCO-patients and the control 
women during the dexamethasone suppression test 
ESTRONE (pg/ml) 
SAMPLE 1 
(9 00 a m ) 
X SD 
PCO-group 108 55 
Control group 51 13 
DIURNAL RHYTHM (mean difference 
X 
PCO-group -14 5 
Control group - 5 3 
DEXAMETHASONE SUPPRESSION (ι 
X 
PCO-group -1 9 
Control group 1 2 
SAMPLE 2 
(4 00 ρ m ) 
X SD 
125 
57 
samples 
67 
13 
1 and 2) 
SEM 
9 2 
3 6 
mean difference samples 
SEM 
12 2 
4 8 
SAI 
(9 С 
Χ 
114 
54 
1 and 
W L E 3 
Юа m ) 
SD 
68 
19 
Ρ 
0 0 9 Π 
0 07(*) 
3) 
Ρ 
0 55 
0 6 4 
(*) tendency for a significant difference 
PCO-group samples 1 and 3 η = 20, sample 2 π = 19 
Control group samples 1 and 3 η = 10, sample 2 η = 11 
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4.3.2 Estrone 
The results of estrone measurements in the PCO-patients and the 
control women are presented in Table 4.2 and Figure 4.2. Fourteen 
PCO-patients and 9 control women had low estrone levels in the mor­
ning in comparison with estrone levels measured in the afternoon. 
A tendency for a significant difference of samples 1 and 2 was present 
in both groups. 
Both increases and decreases of estrone levels were found in PCO-
patients and control women after the administration of dexamethasone. 
The difference of samples 1 and 3 was not significant in either group. 
E s t r o n e (mean ± S Ε M ) 1 
( р г т ю і / I) (рд / m l ) 
6 0 0
~ ι [ZU control g r o u p (η =10)(-n=11) r 1 6 0 
500-
AOO-
3 0 0 -
200-
100 
H P C O - g r o u p ( n = 20)(»»n=19) 
è * à 
-IAO 
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FIGURE 4 2 Serum estrone concentrations in the PCO-group and the control group 
during the dexamethasone suppression test (X ± SEM). 
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4.3.3 Estradiol 
The results of estradiol measurements in the PCO-patients and the 
control women are presented in Table 4.3 and Figure 4.3. Sixteen PCO-
patients had high estradiol levels in the morning in comparison with 
estradiol levels measured in the afternoon. A significant difference of 
samples 1 and 2 was found in this group. In the control group such a 
difference was not present. 
Both increases and decreases of estradiol levels were found in PCO-
patients and control women after the administration of dexamethasone. 
The difference of samples 1 and 3 was not significant in either group. 
TABLE 4 ι Results of estradiol measurements in the PCO-patients and the control 
women during the dexamethasone suppression test. 
ESTRADIOL (pg/ml) 
SAMPLE 1 
(9.00 a.m.) 
X SD 
PCO-group 116 83 
Control group 65 24 
DIURNAL RHYTHM (mean difference 
X 
PCO-group 14 
Control group - 1 
DEXAMETHASONE SUPPRESSION ( 
X 
PCO-group 7 
Control group -17 
SAMPLE 2 
(4.00 p.m.) 
X 
101 
66 
SD 
76 
23 
samples 1 and 2) 
mean diffe 
SEM 
6 
7 
rence samples 
SEM 
12 
11 
SAMPLE 3 
(9.00 a.m.) 
X 
109 
79 
1 and 
SD 
114 
33 
Ρ 
0.04* 
0.96 
3) 
Ρ 
0.30 
0.21 
* significant difference 
PCO-group samples 1, 2 and 3: η = 21 
Control group samples 1 and 2: η = 11; sample 3: η = 10 
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4.3.4 Androstenedione 
The results of androstenedione measurements in the PCO-patients 
and the control women are presented in Table 4.4 and Figure 4.4. Six­
teen PCO-patients had high androstenedione levels in the morning in 
comparison with androstenedione levels measured in the afternoon. A 
significant difference of samples 1 and 2 was found in this group. In the 
control group this difference was not present. 
Twenty PCO-patients and 9 control women had depressed andro­
stenedione levels after the administration of dexamethasone. The differ­
ence of samples 1 and 3 was significant in both groups and the decrease 
of the androstenedione level was approximately 35%. 
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FIGURE 4 3 Serum estradiol concentrations in thePCO-group and the control 
group during the dexamethasone suppression test (X ± SEM). 
77 
4.3.5 Testosterone 
The results of testosterone measurements in the PCO-patients and 
the control women are presented in Table 4.5 and Figure 4.5. Seventeen 
PCO-patients had high testosterone levels in the morning in comparison 
with testosterone levels measured in the afternoon. A significant 
difference of samples 1 and 2 was found in this group. In the control 
group this difference was not present. 
Nineteen PCO-patients and 8 control women had depressed testo­
sterone levels after the administration of dexamethasone. The difference 
of samples 1 and 3 was significant in both groups. In the PCO-group of 
women the decrease of the testosterone level was approximately 20%, 
whereas in the control group of women a decrease of about 30% was 
calculated. 
TABLE 4 4 Results of androstenedione measurements in the PCO-patients and the 
control women during the dexamethasone suppression test. 
ANDROSTENEDIONE (ng/dl) 
SAMPLE 1 
(9.00 a.m.) 
X 
PCO-group 411 
Control group 151 
SD 
156 
62 
DIURNAL RHYTHM (mean difference sampl 
X 
PCO-group 43 
Control group - 2 
DEXAMETHASONE SUPPRESSION 
X 
PCO-group 145 
Control group 52 
(mean 
SAMPLE 2 
(4.00p.m.) 
X 
367 
153 
es 1 and 2) 
SEM 
13 
7 
difference : 
SEM 
25 
17 
SD 
134 
56 
samples 
SAMPLE 3 
(9.00a.m.) 
X SD 
265 108 
103 27 
Ρ 
0.003* 
0.30 
1 and 3) 
Ρ 
0.001* 
0.005* 
* significant difference 
PCO-group samples 1, 2 and 3: η = 21 
Control group samples 1 and 2: η = 11; sample 3: η = 10 
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4.4 DISCUSSION 
The fluctuations of steroid levels in blood during the course of a 
24-hour period have been studied extensively. Under normal conditions, 
Cortisol concentrations rise rapidly, beginning shortly after midnight, to 
reach maximum levels between 6.00 and 8.00 a.m. Thereafter, levels 
drop rapidly between 8.00 and 12.00 a.m. and then more slowly until 
after midnight (KRIEGER et al., 1971). In normal women circadian 
rhythms for pregnenolone, 17a-OH-pregnenolone, 17a-OH-progeste-
rone, DHEA, androstenediol, androstenedione and testosterone have 
been demonstrated. These circadian rhythms were significantly correla­
ted with the diurnal variation of plasma Cortisol (GIVENS et al., 1975a; 
LACHELIN et al., 1979). Both the presence of a circadian variation as 
well as the absence of daily fluctuations of plasma free testosterone 
levels have been reported (ROSENFIELD and HELKE, 1974; STRICK­
LER et al., 1981). 
In PCO-patients the ACTH-dependent circadian rhythms of Cortisol, 
Androstenedione (mean i S E M ) 
( n m o l / l ) 
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FIGURE 4 4 Serum androstenedione concentrations in the_PCO-group and the 
control group during the dexamethasone suppression test (X ± SEM). 
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DHEA, androstenediol, pregnenolone, and 17a-OH-pregnenolone 
were both quantitatively and qualitatively similar to those found in 
normal women, however, differences were reported for androstene-
dione, testosterone and 17a-OH-progesterone. A significant morning 
rise of these steroids was found; the night time nadirs, however, were 
blunted, probably reflecting increased ovarian secretion of androstene-
dione, testosterone and 17a-OH-progesterone (LACHELIN et al., 1979). 
In the present investigation involving 21 PCO-patients and 11 control 
women the diurnal variation of Cortisol, estrone, estradiol, andro-
stenedione and testosterone was studied. 
The majority of PCO-patients and control women had high Cortisol 
levels in the morning in comparison with Cortisol levels measured in the 
afternoon. A significant diurnal Cortisol rhythm could be demonstrated 
TABLE 4 5 Results of testosterone measurements in the PCO-patients and the 
control women during the dexamethasone suppression test. 
TESTOSTERONE (ng/dl) 
SAMPLE 1 SAMPLE 2 SAMPLE 3 
(9.00a.m.) (4.00p.m.) (9.00a.m.) 
X SD X SD X SD 
PCO-group 86 32 75 30 
Control group 25 11 24 9 
69 33 
18 9 
DIURNAL RHYTHM (mean difference samples 1 and 2) 
X SEM 
PCO-group 11.0 3.0 
Control group 1.4 2.2 
DEXAMETHASONE SUPPRESSION (mean difference samples 
X SEM 
PCO-group 17.0 3.3 
Control group 7.4 2.3 
Ρ 
0.001* 
0.29 
1 and 3) 
Ρ 
0.001* 
0.006* 
* significant difference 
PCO-group samples 1, 2 and 3: η = 21 
Control group samples 1 and 2: η = 11; sample 3: η = 10 
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in both groups. This finding is in agreement with results from various 
other studies (KRIEGER et al., 1971; GIVENS et al., 1975a; LACHE-
LIN et al., 1979). 
Although the majority of PCO-patients and control women had 
low estrone levels in the morning in comparison with estrone levels 
measured in the afternoon, only slight evidence for a diurnal rhythm 
could be demonstrated in either group. The origin of circulating estrone 
is complex. The ovary secretes estrone from both the preovulatory 
follicle and the corpus luteum. During the early follicular phase of the 
menstrual cycle significant amounts of estrone are derived from direct 
adrenal secretion (BAIRD, 1974). However, a circadian rhythm has not 
been described. In women with the PCO-syndrome peripheral conver­
sion of androstenedione to estrone accounts for almost all of the estrone 
production (EDMAN and MacDONALD, 1976). A circadian rhythm 
of androstenedione has been demonstrated in both normal women and 
in women with the PCO-syndrome (LACHELIN et al., 1979). Conse­
quently, fluctuations of estrone may reflect variations in androstene-
Testosterone ( m e a n i S E M ) 
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FIGURE 4 ч Serum testosterone concentrations in the PCO-group and the control 
group during the dexamethasone suppression test (X ± SEM). 
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dione production. In the present investigation, however, the andro-
stenedione rhythm encountered in PCO-patients is inversely related 
with the possible daily variation of estrone. Therefore a sufficient 
explanation for the tendency of estrone to fluctuate is not given. 
The majority of PCO-patients had high estradiol levels in the morning 
in comparison with estradiol levels measured in the afternoon. A small 
but significant diurnal rhythm could be demonstrated in this group. In 
the control group of women this difference between morning and after-
noon samples was not found. The presence of significant daily variations 
of estradiol levels in women with the PCO-syndrome is an unexpected 
finding. The estradiol rhythm is synchronous with the diurnal variation 
of plasma Cortisol which suggests an ACTH-dependent estradiol 
production. However, in women of the reproductive age group 17ß-
estradiol is almost exclusively derived by direct ovarian secretion. 
Dynamic studies have demonstrated that less than 5% of estradiol is 
produced by extraglandular conversion of estrone and no estradiol is 
secreted by the adrenal glands (BAIRD, 1974). In the present investiga-
tion a diurnal rhythm of testosterone was found in the PCO-group; the 
biotransformation of this steroid may therefore account for the daily 
fluctuations of estradiol levels. 
The majority of PCO-patients had high androstenedione levels in the 
morning in comparison with androstenedione levels measured in the 
afternoon. A significant diurnal rhythm could also be demonstrated in 
this group. In the control group of women, this difference between 
morning and afternoon samples was not found. In PCO-patients the 
presence of significant daily variations of androstenedione, synchronous 
with the diurnal rhythm of Cortisol, suggests an ACTH-dependent 
androstenedione production in this group. This finding is in agreement 
with results from other studies (GIVENS et al., 1975a; LACHELIN et 
al., 1979; LISSE et al., 1980). The absence, in our control women, of an 
ACTH-mediated circadian rhythm of androstenedione, contrasts with 
other results reported in the literature. Both GIVENS et al. (1975a) and 
LACHELIN et al. (1979) demonstrated diurnal variations of andro-
stenedione concentrations in normal women. The discrepancy between 
findings in our control women and those reported elsewhere may be 
explained by methodological differences, especially with regard to the 
frequency of sampling. This frequency has varied from sampling every 
hour (LACHELIN et al., 1979) or every 4 hours (GIVENS et al., 
1975a) over a 24 hour period, to only one morning sample and one after-
noon sample in the present study. The afternoon sample does not 
necessarily represent the lowest androstenedione level; the presence of 
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a diurnal androstenedione rhythm in our control group may have been 
missed because of infrequent sampling. Although the frequency of 
sampling was limited in the present study, the PCO-patients demon-
strated a diurnal rhythm of androstenedione whereas the control women 
did not have such a variation. These findings indicate an excess of 
androstenedione production from adrenal origin in women with the 
PCO-syndrome. A blunting effect of excess ovarian androstenedione 
secretion on the daily variation of ACTH-mediated androstenedione 
production, as mentioned by LACHELIN et al. (1979), was not present 
in our PCO-patients. 
The majority of PCO-patients had high testosterone levels in the 
morning in comparison with testosterone levels measured in the after-
noon. A significant diurnal rhythm could also be demonstrated in this 
group. In the control group of women this difference between morning 
and afternoon samples was not found. In PCO-patients the presence of 
significant daily variations of testosterone, synchronous with the diurnal 
rhythm of Cortisol, suggests an ACTH-dependent testosterone produc-
tion in this group. This finding is in agreement with results from other 
studies (GIVENS et al., 1975a; LACHELIN et al., 1979; LISSE et al., 
1980). In control women, the absence of an ACTH-mediated circadian 
rhythm contrasts with results of most other studies. ROSENFIELD and 
HELKE (1974), GIVENS et al. (1975a) and LACHELIN et al. (1979) 
demonstrated diurnal variations of total and/or free testosterone 
concentrations; STRICKLER et al. (1981), however, did not find a cir-
cadian pattern of total and free testosterone. The discrepancy between 
findings in our control women and those of most other studies may be 
explained by the same methodological differences as mentioned for 
androstenedione. Although the frequency of sampling was limited in the 
present study, PCO-patients demonstrated a diurnal rhythm of testoster-
one whereas the control women did not have this variation. These 
findings indicate an excess of testosterone production from adrenal 
origin in women with the PCO-syndrome. A blunting effect of excess 
ovarian testosterone secretion on the daily variation of ACTH-mediated 
testosterone production, as mentioned by LACHELIN et al. (1979), 
was not present in our PCO-group of women. 
The dexamethasone suppression test is used in the evaluation of 
women with signs of hyperandrogenism to rule out serious disorders as 
Cushing's syndrome or adrenal or ovarian tumors and to designate the 
major source of excess androgen production. Adrenal suppression may 
be obtained with dexamethasone; the specificity of dexamethasone as an 
adrenal suppressive agent, however, has been questioned. Dexametha-
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soné may act directly at the level of the anterior pituitary and also by 
direct inhibition of LH-RH release (SAKAKURA et al., 1975; SO-
WERS and FAYEZ, 1979). A direct suppressive action of dexametha-
sone on ovarian steroidogenesis has also been suggested (KIRCHNER 
and JACOBS, 1971). Most investigators, however, are convinced that 
dexamethasone has no significant effect on ovarian steroidogenesis 
(ABRAHAM et al., 1981; HATCH et al., 1981; MAROULIS, 1981). 
Data from several studies demonstrated normal ovarian function during 
adequate adrenal suppression with dexamethasone. During dexametha-
sone-treated cycles no effect on plasma concentrations of LH, estrone, 
estradiol, progesterone and 17a-OH-progesterone were found and 
dexamethasone treatment did not affect ovulation (ABRAHAM, 1974; 
KIM et al., 1974). 
In the present study all PCO-patients and control women had, as 
expected, very low Cortisol levels after administering 2 mg of dexa-
methasone similar to that found in other reports thus indicating that the 
PCO-patients were not suffering from early developing hypercortisolism 
(ABRAHAM, 1974; JUDD et al., 1977; LACHELIN et al., 1979). 
Concentrations of estrone and estradiol did not change after the 
administration of dexamethasone in either group of women; the same 
finding has been reported by ABRAHAM (1974) and KIM et al. (1974). 
Estrone and estradiol production is primarily non-adrenal and the 
results of the present study illustrate that short term effects of 
dexamethasone on the levels of these steroids are not significant. 
In both groups of women the androstenedione and testosterone levels 
were significantly reduced after the administration of dexamethasone. 
In the PCO-patients the circulating levels of androstenedione and 
testosterone still remained higher than in the control women. The 
results of this test are in agreement with results from other investigators 
(ABRAHAM et al., 1975; KIM et al., 1976; JUDD et al., 1976a, 1977; 
LACHELIN et al., 1979). The decrease of androstenedione levels was 
approximately 35% in both groups of women; the decrease of testoster-
one was approximately 20% in the PCO-patients, whereas a decrease of 
30% was calculated in the control women. Due to methodological 
differences comparison of these data with results reported in the litera-
ture is difficult. However, our findings are within the range calculated 
from data reported by JUDD et al. (1977) and LACHELIN et al. 
(1979). The elevated basal levels of androstenedione and testosterone 
and the failure to decrease to the normal range after dexamethasone 
suppression may reflect an increased ovarian secretion of these 
androgens. According to ABRAHAM et al. (1975, 1976), however, 
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prolonged adrenal suppression of at least two weeks duration is neces-
sary for an adequate evaluation of adrenal and/or ovarian hyperandro-
genism. In contrast, JUDD et al. (1977) found no further suppression 
of either urinary or serum androgens after the first two days of dexa-
methasone administration. 
The interpretation of data derived from the short dexamethasone sup-
pression test may be difficult. This test does identify, however, glucocor-
ticoid suppressible hyperandrogenism. Therefore the test is considered 
to be useful in determining proper endocrine treatment. In the present 
investigation results from the circadian rhythm study have suggested an 
excess androgen production by the adrenal glands; data from the dexa-
methasone suppression test, however, suggested the ovaries as being a 
possible source of hyperandrogenism. Considering these different 
findings, a combined adrenal and ovarian source of androgen excess in 
women with the PCO-syndrome seems to be most likely. 
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5. THE LH-RH TEST 
5.1 INTRODUCTION 
In Chapter 3 an increased concentration of LH and a decreased con-
centration of FSH were found in patients with the PCO-syndrome, 
thereby resulting in an elevation of the LH/FSH ratio. This inappro-
priate gonadotrophin secretion may be caused by or associated with a 
hypothalamic and/or pituitary disturbance. Since the availability of 
purified synthetic LH-RH (AMOSS et al., 1971; MATSUO et al., 
1971), the pituitary function in women with the PCO-syndrome has 
been evaluated in several studies in order to test whether the hyper-
secretion of LH is associated with an exaggerated pituitary responsive-
ness to LH-RH (ZARATE et al., 1973; DUIGNAN et al., 1975; 
PATTON et al., 1975; DUIGNAN, 1976; KATZ and CARR, 1976; 
SHAW et al., 1976; REBAR et al., 1976; KANDEEL et al., 1978; 
MORTIMER et al., 1978; MOLTZ et al., 1979). 
In the present study an LH-RH test was performed to determine the 
pattern of LH and FSH secretion in women with clinical features of the 
PCO-syndrome. The response of ovarian and/or adrenal steroidogenesis 
to the small endogenous LH and FSH surges, following the administra-
tion of LH-RH, was evaluated by the determination of serum Cortisol, 
estrone, estradiol, androstenedione and testosterone levels. As the 
release of LH and FSH in response to LH-RH varies during the 
different phases of the menstrual cycle (NILLIUS and WIDE, 1972; 
YEN et al., 1972; SHAW et al., 1974), the LH-RH test was performed 
under the standardized conditions previously discussed (see 3.2.1). 
The results were compared with data obtained in normal ovulatory 
women during the early follicular phase of the menstrual cycle. 
5.2 MATERIALS AND METHODS 
5.2.1 Subjects 
There were 22 PCO-patients who underwent the standardized 
LH-RH test. However, while being tested, 2 of these women happened 
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to have serum progesterone levels compatible with midluteal phase 
concentrations Therefore, their results are not included in this 
presentation (no 106 and no 114), leaving a total of 20 PCO-patients 
The control group consisted of 10 normal women who also underwent 
the LH-RH test 
5 2 2 Sampling Procedure 
The LH-RH tests were performed in the out-patient department 
during morning hours All testing was performed by the principal 
investigator assisted by sufficiently instructed nurses An indwelling 
cannula was placed in a convenient vein and a slow running physio­
logical saline solution was connected Sampling from this cannula was 
performed at 30 minutes, 15 minutes and immediately before, and at 10, 
20, 30, 45, 60 and 90 minutes after the rapid intravenous administration 
of 25 μg LH-RH (Hoechst Nederland Ν V ) 
Determinations of LH, FSH, Cortisol, estrone, estradiol, androstene-
dione and testosterone were performed in all samples, while proges­
terone determinations were done in the samples obtained 30 minutes 
prior to and 90 minutes after the administration of LH-RH The blood 
was allowed to clot at room temperature, then centnfuged and the 
supernatant was stored at -20°C until assayed All samples from one 
patient were determined in the same assay-run Unfortunately a few 
estrone and estradiol values are missing since the amount of serum was 
too small in these cases 
5 2 3 Statistical Analysis 
As previously described, serum levels of LH, FSH, Cortisol, estrone, 
estradiol, androstenedione and testosterone were measured at 30 min­
utes (t_ i0), 15 minutes (t_ l s), immediately before (tn) and 10 minutes 
(tU)), 20 minutes (too), 30 minutes (Іж), 45 minutes (t4 5), 60 minutes (t^,), 
and 90 minutes (ty,,) after the rapid intravenous administration of 25 μg 
of LH-RH As a result of the LH-RH administration the serum levels 
of hormones may change The effect of the LH-RH administration was 
evaluated in the following way a certain serum level is noted X, the 
serum level at t0 is noted X() Х0 was taken as basal value and not the 
average of the values at t
 V), 1_и and t(), in order to eradicate the stress of 
venipuncture, possibly present at t
 1() and t_|S (FRIESEN et al , 1972, 
ROBYN et al , 1973) The mean hormone level during the experimental 
period (t()-t4„) is noted XLXp The effect of LH-RH administration (Xcft) 
is defined as the difference of Χ^
ρ
 and X() (Xet) = Xexp - X,,) 
The Wilcoxon one-sample test was used to test for the presence of a 
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systematic effect of LH-RH administration on hormone levels in the 
PCO- and the control groups of women. The Wilcoxon two-sample test 
was used to evaluate differences between the hormone responses found 
in the PCO-group and the control group after LH-RH administration. 
One-sided ρ values are given for LH and FSH as one may expect an 
increase of these hormones after the administration of LH-RH; for the 
other hormones such a presupposition could not be made. Consequently 
two-sided ρ values are given for Cortisol, estrone, estradiol, androstene-
dione and testosterone. Separately for the PCO-group and the control 
group the Kendall-test was used for the detection of correlations 
between several pairs of parameters. 
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FIGURE 5 ι Serum LH concentrations in the PCO-group and the control group 
during the LH-RH test (X ± SEM). 
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5.3 RESULTS 
5 3.1 Introduction 
In Figures 5.1-5.7 and Tables 5.1 and 5.2 the results of the LH-RH 
test are presented. 
5.3.2 LH 
There were 20 PCO-patients and 9 control women who had elevated 
serum LH levels after the administration of LH-RH. In both groups 
of women a significant, positive effect of LH-RH administration on LH 
levels was found. 
The LH response in the PCO-patients was significantly more pro­
nounced than in the control women (Figure 5.1; Tables 5.1-5.2). 
TABLE 5 ι Basal hormone levels (X0) and mean hormone levels during the experi­
mental period of the LH-RH test (X
eXp) in the PCO-patients and the control women 
LH 
FSH 
Cortisol 
Estrone 
Estradiol 
Androstenedione 
Testosterone 
LH 
FSH 
Cortisol 
Estrone 
Estradiol 
Androstenedione 
Testosterone 
Xo 
17 3 
4 5 
0 45 
95 
67 
344 
60 
Xo 
14 1 
6 2 
0 50 
54 
53 
152 
26 
PCO-group ( 
SD 
5 8 
1 1 
0 17 
60 
15 
140 
30 
Control group 
SD 
4 4 
1 5 
0 11 
14 
17 
62 
13 
η = 20) 
Xexp 
37 9 
6 2 
0 33 
92 
67 
363 
65 
(η = 10) 
Xexp 
22 5 
7 7 
0 37 
53 
57 
138 
25 
SD 
17 4 
1 7 
0 12 
45 
16 
125 
31 
SD 
5 1 
1 6 
0 13 
13 
17 
62 
13 
90 
TABLE 5 2 Evaluation of the effects of LH-RH administration on hormone levels 
in the PCO-patients and the control women 
LH 
FSH 
F 
E, 
E, 
A 
Τ 
Xeff 
20 6 
1 7 
- 0 13 
- 2 5 
0 0 
19 
5 3 
PCO-group 
(n = 20) 
SD 
13 2 
0 9 
0 10 
22 1 
10 8 
55 
8 4 
Ρ 
0 001* 
0 001* 
0 002* 
0 85 
0 85 
0 07(*) 
0 02* 
Control group 
Xeff 
8 5 
1 6 
- 0 12 
- 1 6 
3 8 
- 1 3 
- 0 . 9 
(n = 10) 
SD 
5 0 
1 1 
0 15 
7 3 
8 7 
26 
4 3 
Ρ 
0 004* 
0 005* 
0 03* 
0 45 
0 14 
0 14 
0 39 
PCO-
versus 
control 
group 
Ρ 
0 03* 
0 93 
0 96 
0 6 4 
0 6 0 
0 03* 
0 09(*) 
* significant difference 
(*) tendency for a significant difference 
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FIGURE 5 2 Serum FSH concentrations in the PCO-group and the control group 
during the LH-RH test (X ± SEM) 
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5.3.3 FSH 
Similar to the LH results, there were 20 PCO-patients and 9 control 
women who had elevated FSH levels after the administration of 
LH-RH. In both groups of women a significant, positive effect of 
LH-RH administration on FSH levels was found. 
The FSH responses in the PCO-patients and the control women were 
not significantly different (Figure 5.2; Tables 5.1-5.2). 
5.3.4 Cortisol 
There were 18 PCO-patients and 8 control women who demonstrated 
a consistent decrease of Cortisol levels after the administration of 
Cortisol ( m e a n ± S E M ) 
(длтюі/ I) 
0 g o - , PCO-group ( n = 2 0 ) 
c o n t r o l g r o u p (n=10) 
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FIGURE 5 3 Serum cortisoU:oncentrations in the PCO-group and the control group 
during the LH-RH test (X ± SEM). 
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LH-RH. In both groups of women a significant, negative effect of 
LH-RH administration on Cortisol levels was found. 
The changes of serum Cortisol concentrations in the PCO-patients and 
the control women were not significantly different (Figure 5.3; Tables 
5.1-5.2). 
5.3.5 Estrone 
PCO-patients and control women showed both increasing and de­
creasing estrone levels after the administration of LH-RH. A systematic 
change of estrone levels was not found in either group (Figure 5.4; 
Tables 5.1-5.2). 
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FIGURE 5 4 Serum estrone concentrations in the PCO-group and the control group 
during the LH-RH test (X ± SEM). 
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5 3 6 Estradiol 
PCO-patients showed both increasing and decreasing estradiol levels 
after the administration of LH-RH A systematic change of estradiol 
levels was not found in this group Most control women (8) demon­
strated slightly higher estradiol levels after the administration of LH-RH, 
a statistically significant positive effect was not found 
The changes of serum estradiol concentrations in the PCO-group and 
the control group were not significantly different (Figure 5 5, Tables 
5 1-5 2) 
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FIGURE 5 5 Serum estradiol concentrations in the PCO-group and the control 
group during the LH-RH test (X ± SEM) 
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5.3.7 Androstenedione 
There were 16 PCO-patients who showed an increase of androstene-
dione levels after the administration of LH-RH; this positive effect of 
LH-RH administration on androstenedione levels was almost statisti-
cally significant. Although eight control women demonstrated a decrease 
of androstenedione levels after the administration of LH-RH, a signifi-
cant, negative effect was not found in this group. 
The changes of serum androstenedione concentrations in the PCO-
patients and the control women were significantly different (Figure 5.6; 
Tables 5.1-5.2). 
Androstenedione (mean t S E M ) 
( n m o l / l ) 
2 5
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FIGURE 5 6 Serum androstenedione concentrations in the PCO-group and the 
control group during the LH-RH test (X ± SEM). 
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5 3 8 Testosterone 
There were 14 PCO-patients who showed an increase of testosterone 
levels after the administration of LH-RH The effect of LH-RH admin­
istration on testosterone levels was statistically significant Control 
women demonstrated both increasing and decreasing testosterone levels 
after the administration of LH-RH So a significant change of testoster­
one levels was not found in this group 
There is some evidence that the distribution of the changes of serum 
testosterone concentrations in the PCO-patients and the control women 
are different (Figure 5 7, Tables 5 1-5 2) 
Testosterone ( m e a n ± S Ε M ) 
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FIGURE ч ι Serum testosterone_concentrations in the PCO-group and control 
group during the LH-RH test (X ± SEM) 
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5 3 9 Progesterone 
Progesterone measurements in the PCO- and the control groups of 
women (see appendix) showed very low levels of this steroid both 30 
minutes prior to and 90 minutes after the administration of LH-RH 
5 4 DISCUSSION 
Luteinizing hormone-releasing hormone (LH-RH) has been widely 
used to investigate the pituitary gonadotrophic function The release of 
LH and FSH in response to LH-RH vanes during the different phases 
of the menstrual cycle, the sensitivity of pituitary gonadotrophins to 
LH-RH increases during the late follicular phase and a maximum pitu­
itary responsiveness occurs at midcycle (NILLIUS and WIDE, 1972, 
YEN et al , 1972, SHAW et al , 1974) The pituitary can detect small 
changes of circulating LH-RH It has also been documented that vari­
ations m the amount of prior exposure to endogenous or exogenous 
estradiol levels represent the most important factors influencing the pitu­
itary response to LH-RH (for review see YEN, 1978a) In women with 
the PCO-syndrome the pituitary release of LH and FSH after the admin­
istration of LH-RH has been extensively studied Varying lesults have 
been reported, ranging from responses similar to those of normal 
women to very exaggerated response patterns (ZARATE et al 1973, 
DUIGNAN et al , 1975, PATTON et al , 1975, DUIGNAN, 1976, KATZ 
and CARR, 1976, SHAW et al , 1976, REBAR et al , 1976, KANDEEL 
et al , 1978, MORTIMER et al , 1978, MOLTZ et al , 1979) 
In the present investigation, m 20 PCO-patients and 10 control 
women, gonadotrophin release and changes in adrenal and/or ovarian 
steroid levels were studied after the ι ν administration of a low dose of 
LH-RH Except for LH and FSH in the control group, in both groups of 
women a gradual decrease in the concentrations of the hormones was 
seen from t
 ад
 towards t,, (Table 3 6) This change of hormone levels 
may be stress-related (FRIESEN et al , 1972, ROBYN et al , 1973) 
The pattern was the same in PCO-patients and control women, there­
fore, the hormone concentration at t(l was defined as the basal level for 
this study 
The FSH release in PCO-patients was similar to that found m normal 
ovulatory women during the early follicular phase of the menstrual 
cycle The LH release, following a single ι ν injection of 25 μg LH-RH, 
was exaggerated in the PCO-patients Furthermore a positive correla­
tion between basal LH and FSH levels and the LH and FSH responses 
were seen (r = 0 44, ρ < 0 05 and r = 0 45, ρ < 0 05 respectively) 
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These results are in agreement with findings from several previous 
reports DUIGNAN and coworkers (DUIGNAN et al , 1975, DUIG-
NAN, 1976) and REBAR et al (1976) demonstrated a significantly 
greater LH release in PCO-patients than in normal women during 
either the early or late follicular phase of the menstrual cycle In these 
studies LH release was induced with high doses of LH-RH (100 μg and 
150 μg respectively) 
Results of the present study differ from those reported by ZARATE 
et al (1973) who were unable to demonstrate an exaggerated LH release 
in 6 PCO-patients KATZ and CARR (1976) reported an excessive, 
exaggerated, delayed and prolonged LH response after a single ι ν 
injection of 100 μg LH-RH in a group of PCO-patients A subdivision 
into two groups was made by these authors, patients in group 1 had high 
basal LH values and an excessive response to LH-RH, whereas patients 
in group 2 had normal basal LH values and a quantitatively normal 
response to LH-RH On the basis of ovarian morphology PATTON et 
al (1975) also divided PCO-patients into two groups In women with 
type I PCO (typical polycystic ovaries) a greater LH response was noted 
than in women with type II PCO (smaller polycystic ovaries) It has 
been suggested that differences between basal LH levels and LH 
responses to LH-RH in both groups of PCO-patients represent observa­
tions at different stages of the same disease (BERGER et al , 1975, 
PATTON et al ,1975, KATZ and CARR, 1976) REBAR et al (1976) 
found no relationship between ovarian size and LH concentrations and 
stated that their PCO-patients with normal LH levels were studied du­
ring a period of reduced pituitary LH secretion and did not form a 
distinct group In the present investigation 10 PCO-patients had an LH 
response exceeding the highest response in the control group, whereas 
the other 10 demonstrated an LH release within the range of the control 
group The morphology of the ovaries in our PCO-patients is not 
known Therefore a possible relationship between morphological 
findings and LH release could not be determined in this study 
In normal women and men investigations with prolonged LH-RH 
infusion have revealed a biphasic pattern of LH release This finding has 
given rise to the concept of two functional pituitary pools of gonadotro-
phms (BREMNER and PAULSEN, 1974, WANG et al , 1976a, 1976b, 
YEN and LEIN, 1976, HOFF et al , 1977) In PCO-patients continuous 
intravenous infusion of small doses of LH-RH has also been associated 
with a biphasic pattern of LH release The first phase of LH secretion, 
however, was significantly pronounced in these patients as compared 
with normal control women It was therefore concluded that in PCO-
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patients the first pool is much larger than that in normal ovulatory 
women in the early and late follicular phases of the menstrual cycle and 
quantitatively resembles the normal periovulatory pattern (MORTI-
MER et al., 1978). Increased endogenous LH-RH secretion may be the 
cause for the relatively large early phase of LH secretion (MORTIMER 
et al., 1978). Recently, however, LH-RH levels in PCO-patients were 
demonstrated to be comparable with basal levels during the normal 
cycle (KAWAMURA et al., 1980). Most probably the large first pool, 
and consequently the exaggerated LH release after LH-RH administra-
tion, is related to the relatively high and constant estrogen level encoun-
tered in PCO-patients. Although a positive correlation between estrogen 
levels and both the basal LH level and LH-RH induced LH release 
has been reported (DeVANE et al., 1975; KATZ and CARR, 1976; 
REBAR et al., 1976), such a correlation could not be demonstrated 
in the present investigation. The disparity between LH and FSH secre-
tion in women with the PCO-syndrome was explained by the preferen-
tial inhibitory effect of estrogen on FSH and the relative insensitivity 
of FSH release to LH-RH stimulation. A possible role of inhibin, 
which selectively inhibits the FSH release, remains to be elucidated 
(YEN, 1978b). 
Although an excessive LH release was demonstrated in the PCO-
patients, the LH-RH test has limited value as a single diagnostic tool 
to categorize individual patients due to the variability in gonadotro-
phin responses encountered in these women. This conclusion confirms 
previous reports (KEYE et al., 1976; CANTOR et al., 1977; MOLTZ 
et al., 1979; SOULES et al., 1979). 
In both study groups a significant decrease of Cortisol levels during the 
LH-RH test was found. The initial decrease from t,,,, towards t,, conti-
nued until 90 minutes after the administration of LH-RH. The changes 
of serum Cortisol concentrations in the PCO-patients and the control 
women were not significantly different. The Cortisol levels at t() (Table 
3.6) were comparable with those found in the first samples of the dexa-
methasone suppression test (Table 4.1). This suggests that a stress 
related increase of Cortisol levels occurs at t_30 and t.,, in the LH-RH 
test. It seems that the installation of an indwelling cannula causes more 
stress than a simple venipuncture. After the administration of LH-RH a 
further decrease of Cortisol concentrations was seen in both groups of 
women. As previously suggested by PIETERS et al. (1979) the physio-
logical diurnal variation of Cortisol may be responsible for this 
decrease. Results from PIETERS (1981, personal communication) indi-
cate an identical decrease of Cortisol levels in women who underwent 
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LH-RH and placebo LH-RH tests. An "anti-ACTH" effect of LH-RH 
is therefore very unlikely. 
Estrone and estradiol levels did not change significantly after the ad­
ministration of LH-RH in either group of women. In normal ovulatory 
women periodic pulses of LH-RH (10 μg i.v. at 2 hour intervals) over 
a 10 hour period resulted in a significant increase in estradiol levels 
(WANG et al., 1976b). In 2 hypoestrogenic women a gradual increase of 
estradiol levels was seen during the LH-RH treatment (10 μg i.v. every 
90 minutes) (LEYENDECKER, 1979). BAIRD et al. (1977) found, in 
a PCO-patient, a significant rise in the concentration of estrone and 
estradiol, 30 and 90 minutes respectively after the injection of 50 μg 
LH-RH. Also, SOULES et al. (1979) demonstrated a significant rise of 
estrogen levels in PCO-patients. This increase was seen 240 minutes 
after the subcutaneous injection of 100 μg of LH-RH. Therefore these 
results from the literature strongly suggest a steroidogenic response of 
the ovary to endogenous gonadotrophin surges elicited with exogenous-
ly administered LH-RH. A statistically significant positive effect of 
LH-RH on estrone and estradiol levels was absent in the present investi­
gation. According to our test protocol the last blood sample was already 
collected 90 minutes after the injection of a relatively low dose of LH-RH 
(25 μg); this may explain the discrepancy of the present findings with 
those reported in literature. 
The majority of our PCO-patients showed an increase of androstene-
dione levels after the administration of LH-RH, whereas most control 
women demonstrated a decrease of androstenedione concentrations. 
The changes of serum androstenedione levels in the PCO-patients and 
the control women were significantly different. In PCO-patients a posi­
tive correlation was found between the LH response and the andro­
stenedione response (r = 0.30; ρ = 0.04). BAIRD et al. (1977) demon­
strated in a PCO-patient a remarkable rise of androstenedione 10 
minutes after an LH surge was induced by 50 μg of LH-RH. Although 
such an excessive response was not found in our PCO-patients, the 
present results also suggest that the production of androstenedione is 
responsive to LH and is therefore, in PCO-patients at least in part, 
derived from ovarian origin. 
The increase of testosterone was statistically significant in the PCO-
patients; such a significant change was not found in the control women. 
The change of serum testosterone levels in the PCO-group was almost 
significantly different from the control group. The effect of a single dose 
of 25 μg LH-RH on testosterone concentrations in women with the 
PCO-syndrome has not been previously studied. Although a positive 
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correlation between the LH response and the testosterone response was 
not found in this study (r = 0.08; ρ = 0.60), the excess production of 
testosterone, at least in part, may come from ovarian origin. 
A hyperandrogenic response of polycystic ovaries to exogenously 
administered gonadotrophins has been reported by LAWRENCE et al. 
(1976) and SKAF et al. (1981). The androstenedione and testosterone 
responses in our PCO-patients demonstrate a hyperandrogenic reaction 
of polycystic ovaries to endogenously released gonadotrophins as well. 
Recently much attention was given to LH-RH as a therapeutic agent for 
the control of ovulation as well as follicular growth and maturation 
(NILLIUS, 1982; SCHOEMAKER et al.. 1982; SKARIN et al., 1982). 
From our results it can be concluded that, as ovulation induction by 
means of pulsatile LH-RH in women with the PCO-syndrome will result 
in the production of excess androgens and consequently inappropriate 
follicular maturation, this mode of treatment is probably not indicated 
in these patients. It has been postulated, however, that appropriate 
exogenous LH-RH administration will overrule the existing inappro­
priate endogenous LH-RH secretion which is present in PCO-patients. 
In a very limited number of women with the PCO-syndrome it was 
demonstrated that, after an initial period, the LH/FSH ratio normalized 
on a strict exogenous LH-RH regimen with finally normal ovulatory 
cycles resulting (BURGER et al., 1982). 
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6. THE ACTH TEST 
6.1 INTRODUCTION 
In Chapter 3 it was demonstrated that serum testosterone and andro-
stenedione levels are elevated in patients with the PCO-syndrome. In 
order to evaluate the role of the adrenal glands in the hyperandrogenic 
state encountered in these women both a dexamethasone suppression 
test and an adrenocorticotropic hormone (ACTH) stimulation test were 
performed. The results of the dexamethasone suppression test have 
been presented in Chapter 4; the ACTH test will be the subject of 
discussion in this chapter. 
Data from several ACTH stimulation test studies have suggested 
abnormalities in adrenal steroid biosynthesis in patients with clinical 
signs of hyperandrogenism (GIVENS et al., 1975a; LACHELIN et al., 
1979; GIBSON et al., 1980; KANDEEL et al., 1980; LOBO and GOE-
BELSMANN, 1981). This test is of importance in the differentiation 
of the PCO-syndrome from adult manifestation of congenital adrenal 
hyperplasia due to incomplete 21-hydroxylase deficiency (LOBO and 
GOEBELSMANN, 1980). Standardization of the ACTH test is of 
importance for the correct interpretation of the data. The use of dexa-
methasone suppression is advised in order to reduce Cortisol levels in all 
women to basal. Since a significant quantity of progesterone and 17a-
OH-progesterone is synthesized by the corpus luteum, the ACTH test 
should be performed in the early follicular phase of the menstrual cycle 
(EDITORIAL COMMENT, 1981; KRUYT and ROLLAND, 1982). 
In the present study the ACTH test was performed after dexametha-
sone suppression; the response of adrenal steroidogenesis following the 
administration of ACTH was evaluated by the determination of Cortisol, 
progesterone, 17a-OH-progesterone, androstenedione, testosterone, 
estradiol and estrone. The clinical data (menstrual history and basal 
body temperature chart), obtained from the PCO-patients, ensured that 
the ACTH test was not performed in the midcycle or luteal phase; 
retrospectively, almost all PCO-women had progesterone and estradiol 
levels at the moment of the test which were compatible with the early or 
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mid-foUicular phase The results were compared with data obtained in 
normal women during the early follicular phase of the menstrual cycle 
6 2 MATERIALS AND METHODS 
6 2 1 Subjects 
The study group consisted of 21 PCO-patients who underwent the 
standardized ACTH test At the time of the testing, however, it was 
discovered that one of these patients had basal serum progesterone 
levels of 2 8 and 2 6 ng/ml These progesterone concentrations were 
compatible with early luteal phase levels and therefore the results from 
this patient (no 115) were not included in the following presentation 
For comparative purposes, there were 1Ü healthy women, acting as 
the control group, who also underwent the ACTH test Data from 5 of 
these women have been previously published (K.RUYT and ROL-
LAND, 1982) Although the ACTH test was performed during the early 
follicular phase of the menstrual cycle, it was discovered that one 
control woman had basal serum progesterone levels, at the moment of 
the test, of 2 2 and 2 1 ng/ml Results from this woman (no 020) were 
likewise not included in this presentation 
6 2 2 Sampling Procedure 
The ACTH tests were performed in the out-patient department during 
morning or afternoon hours Two mg of dexamethasone (Oradexon®, 
Organon Nederland B V ) were given at 11 00 ρ m on the day previous 
to the test, in these cases the ACTH test started at 9 00 a m the follow­
ing morning Whenever the ACTH test started at 2 00 in the afternoon, 
1 mg of dexamethasone was given at 11 00 ρ m on the day previous 
to the test and a second mg of dexamethasone was given at 9 00 a m 
on the day of the test 
In all PCO-patients and in 5 control women an indwelling cannula was 
placed in a convenient vein and a slow running physiological saline solu­
tion was connected Sampling from this cannula was performed 30 min­
utes and immediately before the administration of 25 IU of synthetic 
ACTH (Synacthen®, Ciba Farmaca, 0 25 mg) The ACTH was diluted 
in 100 ml of physiological saline solution and administered intravenously 
in 10 minutes Following the onset of the infusion, blood samples were 
drawn after 30, 60 and 90 minutes In the control women from KRUYT 
and ROLLAND (1982) the procedure was slightly different These 
women did not receive a slow running physiological saline solution, 
instead, sampling was performed from an indwelling cannula with a 
heparin lock 
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Determinations of Cortisol, progesterone, 17a-OH-progesterone, an-
drostenedione, testosterone and estradiol levels were performed in all 
samples from each PCO-patient and control woman, whereas estrone 
levels were determined in samples obtained from all but 4 control 
women, as the quantity of serum taken from these 4 women was insuf­
ficient. Unfortunately 17a-OH-progesterone, androstenedione and tes­
tosterone values from one PCO-patient at t0 are missing, since in this 
woman the amount of serum was also too small. The blood was allowed 
to clot at room temperature, centrifuged and the supernatant was stored 
at -20oC until assayed. All samples from each patient were determined 
in the same assay-run. 
6.2.3 Statistical Analysis 
As described before, during the ACTH test serum levels of Cortisol, 
progesterone, 17a-OH-progesterone, androstenedione, testosterone, 
estradiol and estrone were measured 30 minutes (t з0) and immediately 
before (t0) as well as 30 minutes (ίί(,), 60 minutes (t^) and 90 minutes 
(t9ü) after the initiation of the intravenous infusion of 0.25 mg ACTH. 
The effect of the ACTH administration was evaluated in the same way 
as discussed previously for the LH-RH test. The serum level at t(j is 
noted Xu·, Хц was taken as basal value. The mean hormone level during 
the experimental period (t()-t9ü) is noted XeXp. The effect of ACTH 
administration (Xeir) was defined as the difference between Xexp and 
The Wilcoxon one-sample test was used to determine the presence of 
an effect of ACTH administration on hormone levels in the PCO-group 
and the control group. The 4 women from KRUYT and ROLLAND 
(1982) and the 5 from our own study were joined into one control group. 
It was assumed that performing an ACTH test in each of the two ways 
(see 6.2.2) would give no systematically different results. For compari-
son of differences between basal hormone values in both groups and 
differences between the hormone responses found in the PCO-group 
and the control group after ACTH administration, the Wilcoxon two-
sample test was used. Separately for the PCO-group and the control 
group the Kendall-test was used for the determination of correlations 
between several parameters. One-sided ρ values are given for Cortisol, 
progesterone, 17a-OH-progesterone, androstenedione and testosterone 
as one may expect an increase of these hormones after the administra­
tion of ACTH; for estradiol and estrone such a presupposition could not 
be made and therefore two-sided ρ values are given. 
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6.3 RESULTS 
6.3.1 Introduction 
The results of the ACTH test are shown in Figures 6.1-6.7 and in 
Tables 6.1-6.3. 
6.3.2 Cortisol 
In both groups the adrenal glands were well suppressed during dexa-
methasone medication as illustrated by the low mean basal levels of 
Cortisol. 
Cortisol (mean t S E M ) 
(/umol / I ) 
0.80-1 
0 . 7 0 -
0 . 6 0 -
0 . 5 0 -
0.Д0-
0 . 3 0 -
0 . 2 0 -
0 . 1 0 -
δ ^ ^ 
-30 
№.. 0.25mg Synacthen^ i.v. 
PCO-group (n=20) 
Control group (n = 9) 
ι -
Ο 
— ι 1 1 
3 0 6 0 9 0 
T i m e (min) 
FIGURE 6 ι Serum Cortisol concentrations in the PCO-group and the control group 
during the ACTH test (X ± SEM). 
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All PCO-patients and control women had an increase of Cortisol 
levels after the administration of ACTH; this positive effect of ACTH 
infusion on Cortisol production was statistically significant in both 
groups of women. 
The Cortisol response in the PCO-group was significantly more pro­
nounced (Figure 6.1; Tables 6.1-6.3). 
TABLE 6 ι Comparison of basal hormone levels after dexamethasone suppression 
in the PCO-patients and the control women. 
Data are presented in relation with the sampling time. 
Cortisol 
-30 
0 
Progesterone 
-30 
0 
17a-OH-Progesterone 
-30 
o
2 
Androstenedione 
-30 
02 
Testosterone 
-30 
o
2 
Estradiol 
-30 
0 
Estrone 
-30 3 
o
3 
PCO 
(n = 
X 
0.02 
0.02 
0.3 
0.3 
77 
69 
248 
223 
58 
53 
76 
79 
87 
77 
-group 
=20) 
SD 
0.02 
0.03 
0.2 
0.1 
29 
34 
91 
94 
20 
23 
28 
31 
28 
21 
Control 
(n = 
X 
0.03 
0.02 
0.4 
0.4 
34 
27 
61 
53 
21 
17 
78 
71 
62 
55 
group 
9) 
SD 
0.02 
0.01 
0.3 
0.3 
20 
19 
58 
45 
14 
10 
13 
17 
21 
31 
Ρ 
1 
1 
ι 
1 
0.0008* 
0.0006* 
0.0001* 
0.0001* 
0.0002* 
0.0001* 
0.40 
0.49 
0.06(*) 
0.13 
* significant difference 
(*) tendency for a significant difference 
1
 too many values under threshold of laboratory determination for a meaningful 
comparison 
2
 PCO-group η = 19 
Control group η = 5 
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6.3.3 Progesterone 
In both groups the basal progesterone concentrations were low, 
indicating the absence of an active steroid producing corpus luteum in 
these women. 
All control women and 19 out of 20 PCO-patients had an increase of pro­
gesterone levels after the administration of ACTH; this positive effect of 
ACTH infusion on progesterone production was significant in both groups. 
In the PCO-group the progesterone response was somewhat less 
pronounced than in the control group (Figure 6.2; Tables 6.1-6.3). 
Progesterone ( m e a n t S Ε M ) , 
5 ( n m o l / l ) ( n g / m l ) 
5 -
3 -
2 -
1 -
. 3 0 
(δ) 0.25 mg Synacthen w ¡.ν. 
PCO-group (η =20) 
Control group ( η = 9) 
r i - θ 
- 1 . 6 
1.Д 
- 1 . 2 
•1.0 
0.8 
-0.6 
-0.4 
-0.2 
τ -
Ο 
3 0 6 0 9 0 
T i m e ( m i n ) 
FIGURE 6 2 Serum progesterone concentrations in the PCO-group and the control 
group during the ACTH test (X ± SEM). 
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6.3.4 17 a-O Η-progesterone 
In the PCO-group of women the basal 17a-OH-progesterone levels 
were significantly higher than those found in the control group of women. 
1 7 a - O H - P r o g e s t e r o n e ( m e a n t S E M ) 1 
( n m o l / l ) ( n g / d l ) 
б п 
A -
3 -
0.25mg Synacthen®! 
PCO-group(nz20;· n = 19) 
Control group (n = 9 ) 
г 2 0 0 
-1Θ0 
-160 
- I A O 
120 
-100 
- 8 0 
6 0 
-АО 
- 2 0 
- 3 0 3 0 
— ι 1 
6 0 9 0 
T i m e ( m i n ) 
FIGURE б з Serum 17a-OH-progesterone concentrations in the PCO-group and the 
control group during the ACTH test (X ± SEM). 
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All PCO-patients and control women had an increase of 17a-OH-
progesterone levels after the administration of ACTH; this positive 
effect of ACTH infusion on 17a-OH-progesterone production was signi­
ficant in both groups. 
The changes of serum 17a-OH-progesterone concentrations in the 
PCO-patients and the control women were almost identical (Figure 6.3; 
Tables 6.1-6.3). 
TABLE 6 2 Basal hormone levels after dexamethasone suppression (XQ) and mean 
hormone levels during the experimental period of the ACTH test (Χ„ρ) in the 
PCO-patients and the control women. 
Cortisol 
Progesterone 
17a-OH-Progesterone ' 
Androstenedione' 
Testosterone' 
Estradiol 
Estrone 
Xo 
0.02 
0.3 
69 
223 
53 
79 
77 
PCO-group 
SD 
0.03 
0.1 
34 
94 
23 
31 
21 
(η = 20) 
Xexp 
0.64 
1.0 
166 
348 
60 
83 
91 
SD 
0.09 
0.6 
61 
120 
23 
33 
21 
(' XQ: Π = 19) 
Cortisol 
Progesterone 
17a-OH-Progesterone 
Androstenedione 
Testosterone 
Estradiol 
Estrone2 
Xo 
0.02 
0.4 
27 
53 
17 
71 
55 
Control 
SD 
0.01 
0.3 
19 
45 
10 
17 
31 
group (n = 9) 
Xexp 
0.50 
1.4 
126 
116 
23 
75 
59 
SD 
0.17 
0.3 
57 
96 
12 
20 
18 
(2 Xo and X
e x p: η = 5) 
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6.3.5 Androstenedione 
In the PCO-group of women, the basal androstenedione levels were 
significantly higher than those found in the control group of women. In 
the PCO-group the basal androstenedione concentrations were compar-
able with the androstenedione levels previously determined during the 
dexamethasone suppression test (Chapter 4). 
All PCO-patients and control women had an increase of andro-
stenedione levels after the administration of ACTH; this positive effect 
of ACTH infusion on androstenedione production was significant in 
both groups. 
The androstenedione response in the PCO-patients was significantly 
more pronounced (Figure 6.5; Tables 6.1-6.3). 
A n d r o s t e n e d i o n e ( m e a n ± S E M ) 
( n m o l / I ) 
2 0 
15 
1 0 -
5 -
0 -
0.25mg Synacthen®¡.v. 
• - 1 
( n g / d l ) 
г 6 0 0 
5 0 0 
-Д00 
PCO-group ln=20;·n=19) 
Control group I η = 9 ) 
. 3 0 
- τ -
0 
-300 
- 2 0 0 
- 1 0 0 
3 0 6 0 9 0 
T i m e (min) 
FIGURE 6 4 Serum androstenedione concentrations in the PCO-group and the 
control group during the ACTH test (X ± SEM). 
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6.3.6 Testosterone 
In the PCO-group of women, the basal testosterone levels were 
significantly higher than those found in the control group of women. 
In both groups the basal testosterone concentrations were comparable 
with the testosterone levels previously found during the dexamethasone 
suppression test (Chapter 4). 
All control women and 19 out of 20 PCO-patients had an increase of 
testosterone levels after the administration of ACTH; this positive 
effect of ACTH infusion on testosterone production was statistically 
significant in both groups. 
The changes of serum testosterone concentrations in the PCO-
patients and the control women were almost identical (Figure 6.5; 
Tables 6.1-6.3). 
T e s t o s t e r o n e ( m e a n + S E M ) 1 
( n m o l / l ) ( n g / d l ) 
^ H 0.25 mg Synacthen® i.v. 
PCO-group (n = 2 0 ; · n = 19) 
Control group (n = 9 ) 
ι 1 1 1 1 
-30 0 30 60 9 0 
Time (min) 
FIGURE 6 s Serum testosterone_concentrations in the PCO-group and the control 
group during the ACTH test (X ± SEM). 
-100 
- 0 
- 6 0 
-ДО 
- 2 0 
- 0 
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6.3.7 Estradiol 
The distribution of basal estradiol levels in the PCO-group of 
women was comparable with the one found in the control group of 
women. The control women had basal estradiol levels comparable with 
the estradiol concentrations previously found during the dexamethasone 
suppression test, whereas PCO-patients had lower basal estradiol levels 
in the present test (Chapter 4). 
No significant change of estradiol levels after the administration of 
ACTH was found in either group of women, the groups did not differ in 
their estradiol response (Figure 6.6; Tables 6.1-6.3). 
E s t r a d i o l ( m e a n t S Ε M ) 
( p m o l /1 ) 
6 0 0 - 1 
5 0 0 
4 0 0 
2 0 0 -
1 0 0 
. 3 0 
JO:. 0.25mg Synacthen^-^i.v, 
( p g / m l ) 
г 160 
- IAO 
•120 
- 1 0 0 
PCO-group Ι η = 20) 
Control group (n=9)l· n = 8) 
- 6 0 
-АО 
- 2 0 
30 60 90 
Time (min) 
FIGURE 6.6 Serum estradiol concentrations in the PCO-group and the control group 
during the ACTH test (X ± SEM). 
113 
6.3.8 Estrone 
In the PCO-group of women, the basal estrone levels were slightly ele­
vated in comparison with those found in the control group of women. 
However, this difference was not statistically significant. The control wo­
men had basal estrone levels comparable with the estrone concentrations 
previously found during the dexamethasone suppression test, whereas 
PCO-patients had lower basal estrone levels in the present test (Chapter 4). 
In the PCO-group of women, 18 out of 20 patients had an increase of 
estrone levels after the administration of ACTH; this positive effect of 
ACTH infusion on estrone production was statistically significant. In 
control women no consistent change of estrone levels was found. 
The changes of estrone concentrations in the PCO-patients and con­
trol women were not significantly different (Figure 6.7; Tables 6.1-6.3). 
E s t r o n e ( m e a n + S Ε M ) 1 
(pmol/l) (pg/ml) 6 0 0 
5 0 0 -
4 0 0 -
3 0 0 -
2 0 0 -
100 
0.25mg Synacthen® i.v. 
• PCO-group (η = 20)|·η=19) 
• Control group (η = 5) 
г 160 
1Д0 
- 1 2 0 
-100 
8 0 
•60 
-АО 
2 0 
. 3 0 О 3 0 
Ί 
60 90 
Time (min) 
FIGURE 6 7 Serum estrone concentrations in the PCO-group and the control group 
during the ACTH test (X ± SEM). 
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TABLE 6 3 Evaluation of the effects of ACTH administration on hormone levels in 
the PCO-patients and the control women 
F 
Ρ 
17-OH Ρ 
А 
Τ 
Ег 
E,1 
X Cf f 
0 62 
0 8 
97 
122 
7 
4 
14 
PCO group 
(η = 20) 
SD 
0 09 
0 5 
46 
72 
7 
13 
12 
Ρ 
0001* 
ооог 
0 001* 
0001* 
0 001* 
0 22 
0001* 
Xeff 
0 48 
1 0 
99 
63 
7 
5 
4 
Control group 
(π = 9) 
SD 
0 16 
0 1 
53 
52 
3 
11 
19 
Ρ 
0 004* 
0 004* 
0 004* 
0 004* 
0 004* 
0 4 4 
0 69 
PCO-
versus 
control 
group 
Ρ 
0 02* 
0 06(*) 
0 67 
0 03* 
0 62 
0 96 
0 71 
* significant difference 
(*) tendency for a significant difference 
1
 Control group η = 5 
6 4 DISCUSSION 
In the present study an ACTH test was performed in patients with the 
PCO-syndrome and in normal ovulatory control women during the early 
follicular phase of the menstrual cycle This test was performed under 
standardized conditions All women received 2 mg of dexamethasone in 
order to reduce the adrenal steroid production to basal levels It was 
ascertained that the test would not be performed during the pen-
ovulatory or during the luteal phase of the menstrual cycle This was 
established by the measurement of estradiol and progesterone concen­
trations in serum 
A comparison of basal hormone levels in the PCO-patients and the 
control women was made In both groups of women, an adequate 
suppression of the adrenal glands was present as illustrated by the low 
basal levels of Cortisol The basal concentrations of progesterone in 
several PCO-patients were somewhat lower than those found in control 
women Since the control women underwent the ACTH test during the 
early follicular phase (CD 1-5), the somewhat higher progesterone con­
centrations found in this group are probably due to progesterone 
production by the regressing corpus luteum of the preceding cycle 
(BRIET, 1978) 
The basal serum levels of 17a-OH-progesterone were significantly 
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elevated in the PCO-patients This finding is in agreement with results 
from the literature Both before and after the administration of dexa-
methasone, elevated concentrations of 17a-OH-progesterone have been 
reported in PCO-patients (ABRAHAM et al , 1975, PARKER et al , 
1975, JUDD et al , 1976a, LACHELIN et al , 1979, SOJO-ARANDA 
et al ,1979, GIBSON et al , 1980, LOBO and GOEBELSMANN, 1980) 
Direct blood sampling from ovarian veins revealed significantly elevated 
levels of 17a-OH-progesterone in patients with the PCO-syndrome 
(KASUGA, 1980, LAATIKAINEN et al , 1980) These findings suggest 
that the ovary may be the main source of 17a-OH-progesterone over-
production In spite of this excess production of 17a-OH-progesterone 
from ovarian origin, a circadian rhythm was demonstrated to be present 
in PCO-patients, indicating an adrenal production as well (LACHELIN 
et al , 1979) 
The basal concentrations of androstenedione and testosterone after 
dexamethasone suppression were found to be significantly elevated in 
the PCO-patients The hyperandrogenic state encountered in our PCO-
patients has been previously discussed (Chapter 3) and is in agreement 
with other results reported in the literature In the present study there 
was no statistically significant difference between the basal concentra-
tions of estrogens in either group of women after dexamethasone 
suppression The hyperestrogenic state previously found in our patients 
with the PCO-syndrome was therefore not confirmed This may be due 
to differences in the stage of follicular development as well as to inter-
assay variability 
In most studies concerning the adrenal function of women with the 
PCO-syndrome a single intravenous bolus of 0 25 mg synthetic ACTH 
was used (GIVENS et al , 1975a, GIBSON et al , 1980, LOBO and 
GOEBELSMANN, 1980, 1981) In order to disclose subtle and 
subclinical abnormalities in adrenal steroidogenesis in PCO-patients, 
LACHELIN et al (1979) tested both adrenal sensitivity and capacity by 
sequential pulses and infusion of ACTH KANDEEL et al (1980) 
administered intramuscularly 2 x 0 5 mg of ACTH per day for four 
days, with this maximal stimulation, adrenal steroidogenesis in PCO-
patients was studied Since the clinical and biochemical criteria for the 
diagnosis of the PCO-syndrome were not the same in these studies and 
the ACTH tests were not always performed after adequate suppression 
of adrenal steroidogenesis, it can be understood that results and conclu-
sions concerning the adrenal function in the PCO-syndrome differ 
In the present investigation after ACTH stimulation a significant 
increase of Cortisol, progesterone, 17a-OH-progesterone, androstenedi-
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one and testosterone was found in both study groups. A comparison of 
the absolute effects of ACTH administration on progesterone, 17a-OH-
progesterone and testosterone revealed no differences between both 
groups. However, an excess production of androstenedione and Cortisol 
was found in the PCO-group of women as compared to controls 
(p = 0.03 and ρ = 0.02 respectively). Since ovarian steroidogenesis is 
not significantly affected by ACTH (PARKER et al., 1975; WILSON et 
al., 1979) it is likely that these findings reflect alterations in adrenal 
steroidogenesis itself. 
Our findings of a normal increase of 17a-OH-progesterone and a 
greater increase of androstenedione and Cortisol in the PCO-patients in 
response to ACTH exclude the possibility of the existence of (mild) 
adrenal hyperplasia due to partial 21- or llß-hydroxylase deficiency in 
these women. There was no individual PCO-patient with a 17a-OH-pro-
gesterone response exceeding the upper limit of normal (mean + 2SD 
of the control women). Several investigators have suggested the presence 
of a mild but compensated reduction of 21- or 1 lß-hydroxylase activity in 
women with clinical signs of hyperandrogenism (GIVENS et al., 1975a; 
GIBSON et al., 1980; KANDEEL et al., 1980). The adult manifestation 
of congenital adrenal hyperplasia due to 21-hydroxylase deficiency 
mimicks the polycystic ovary disease; the diagnosis is made upon an 
excessive rise of 17a-OH-progesterone in combination with a significant 
increase of androstenedione levels after ACTH stimulation (LACHE-
LIN et al., 1979; LOBO and GOEBELSMANN, 1980). Such a response 
was not encountered in the present investigation. 
A partial deficiency of 3ß-ol-hydroxysteroid dehydrogenase activity in 
hirsute women has also been suggested as a possible cause for excess 
androgen production (GIBSON et al., 1980; LOBO and GOEBELS-
MANN, 1981). The best screening criterion for mild 3ß-ol-dehydro-
genase deficiency is the elevation of DHEAS levels with normal andro-
stenedione and testosterone concentrations. Elevated Δ5 (pregnenolone, 
17a-OH-pregnenolone, DHEA, DHEAS) to Δ 4 (progesterone, 17a-
OH-progesterone, androstenedione) steroid ratios in response to stimu­
lation with ACTH after previous adrenal suppression with dexametha-
sone will identify this condition with certainty (LOBO and GOEBELS­
MANN, 1981). In the present investigation Δ 5 steroids were not deter­
mined and therefore the existence of a partial 3ß-ol-hydroxysteroid 
dehydrogenase deficiency cannot be excluded. However, since andro-
stenedione and testosterone levels were elevated the presence of this 
enzyme deficiency in our PCO-group of women is very unlikely. 
The common precursor of androstenedione and Cortisol is 17a-OH-
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progesterone. The excessive production of androstenedione and Cortisol 
in the PCO-patients as a response to ACTH may therefore be due to the 
presence of an extra amount of this precursor. The absolute effect of 
ACTH administration on 17a-OH-progesterone production was identi­
cal in both groups of women, but the basal concentration of this steroid 
was significantly elevated in the PCO-group of women. One of the 
effects of ACTH is the stimulation of adrenal enzyme activity 
(LIDDLE, 1974). Presuming that adrenal enzyme activity is stimulated 
identically in PCO-patients and control women, the presence of more 
substrate will result in the formation of an extra amount of product. 
According to this hypothesis, a relative excess amount of 17a-OH-
progesterone resulted in the production of significantly more andro­
stenedione and Cortisol in PCO-patients in our study. 
Further support for this hypothesis is found by the fact that in both 
groups of women a significant correlation is present between the basal 
concentrations of 17a-OH-progesterone and androstenedione (PCO-
group: r = 0.71, ρ = 0.001; control group: г = 0.72, ρ = 0.007). The 
correlation between the basal 17a-OH-progesterone concentration and 
the extra androstenedione production after ACTH administration was 
not significant in the PCO-patients (r = -0.10, ρ = 0.54). In the control 
women this correlation was significant (r = 0.67, ρ = 0.01). Between 
basal 17a-OH-progesterone levels after dexamethasone administration 
and the extra Cortisol production after the administration of ACTH no 
significant correlation was present. 
Since the hormonal milieu of PCO-patients is significantly different 
from the basal endocrinological characteristics of normal women, incon­
sistencies in the presence or absence of correlations between several 
parameters in each group of women may be due to subtle differences in 
adrenal steroidogenesis. Functional changes of the adrenal synthesis of 
steroids, due to elevated androgen levels, have been described (SHAR-
MA et al., 1963; MORROW et al., 1967). Estrogens, however, do not 
directly influence adrenal steroidogenesis (ANDERSON and YEN, 
1976). 
Complete suppression of adrenal steroidogenesis is not realized after 
the administration of one single 2 mg dose of dexamethasone (ABRA­
HAM et al., 1975), therefore, the relative proportion of adrenal and 
ovarian androgen production in each group of women cannot be calcula­
ted. In this study, it is not possible to determine the exact relationship 
between the ovarian production under basal conditions of 17a-OH-
progesterone and the adrenal production of androstenedione and corti-
sol after the administration of ACTH. Notwithstanding these uncertain 
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aspects, it may be concluded that in the present study overt enzymatic 
abnormalities in patients with the PCO-syndrome have not been found, 
which is in agreement with several reports from the literature (LACHE-
LIN et al., 1979; YEN, 1980). 
In conclusion the following mechanism is proposed to exist in women 
with the PCO-syndrome: 17a-OH-progesterone is synthesized by theca 
cells in the ovary (PETERS and McNATTY, 1980). Therefore, it can be 
expected that the LH dependant hyperplasia of theca cells encountered 
in PCO-patients is responsible for the excessive production of 17a-OH-
progesterone. Consequently circulating levels of 17a-OH-progesterone 
increase in PCO-patients and this steroid can act as a precursor for both 
androstenedione and Cortisol production by the adrenals. Assuming that 
adrenal enzyme activity is adequately stimulated by endogenous 
ACTH, a hyperandrogenic response from the adrenal glands as well as 
an excess Cortisol response are expected under these circumstances. Ex-
cess adrenal androgen production, in turn, will help to maintain the 
vicious circle of chronic anovulation in women with the PCO-syndrome 
(see Figure 1.1). 
In the present investigation no systematic change of estradiol levels 
after the administration of ACTH was found in either group of women. 
Estrone concentrations however, increased significantly in the PCO-
group of women after the administration of ACTH. In the control group 
this change of estrone levels was not seen. The estrone response in 
PCO-patients may be due to direct adrenal production (BAIRD, 1974) 
and to the peripheral conversion of androstenedione to estrone, as dis-
cussed previously (see 1.2.5.2). The absence of a significant change of 
estrone levels in control women may be explained by the limited 
number of determinations. 
Although results from the present study indicate a hyperandrogenic 
response of the adrenal glands in women with the PCO-syndrome, the 
adrenal function itself seems to be normal. The pathophysiological 
importance of this finding will be discussed further in Chapter 9. 
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7. OVARIAN SUPPRESSION 
7.1 INTRODUCTION 
Ovarian suppression by means of synthetic steroids (estrogens and/or 
progestogens) may be, just like adrenal suppression by means of dexa-
methasone, a rational approach to reduce the total androgen pool in 
patients with the PCO-syndrome. Several investigators have demon-
strated a decrease of gonadotrophins and androgens during oral contra-
ceptive use. An increase of SHBG, parallelling a decrease of total and/or 
free testosterone, was found (EASTERLING et al., 1974; GIVENS et al., 
1974, 1976b; ANDERSEN et al., 1976; FERN et al., 1978; TALBERT 
and SLOAN, 1979). The following is a recent summary of the therapeuti-
cal benefits of a combination preparation of estrogens and progestogens 
for PCO-patients (GOLDZIEHER, 1981): 
1. The excessive LH production becomes normalized. 
2. Overstimulation of the ovaries ceases with a consequent decrease 
occurring in the rate of follicular atresia and cyst formation, thereby 
lessening stromal hyperplasia and hyperstimulation and lessening 
ovarian androgen production. 
3. The decrease in plasma androgen levels lessens the androgenic 
symptomatology. 
4. The estrogens in the combination preparation may increase the level 
of SHBG, thus decreasing the biological activity of the plasma 
androgens. 
5. Estrogens inhibit 5a-reductase which converts testosterone to the 
more active 5a-dihydrotestosterone in the skin. 
6. The contraceptive steroids have an inhibitory effect on the adrenal 
cortical activity and lessen the androgenic output from this source. 
7. The contraceptive steroids ensure an appropriate stimulus to the 
endometrium and cyclic shedding, thus serving as a prophylaxis 
against endometrial hyperplasia and metaplasia. 
Ovarian suppression may be obtained with several combinations of 
estrogens and progestogens. In the present study a combination prep-
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aration was chosen consisting of cyproterone acetate (CPA) (6-chloro-
la,2a-methylene-4,6-pregnadien-17a-ol-3,10-dione) and ethinyl estra­
diol (ЕЕ); each tablet contained 2 mg of CPA and 0.05 mg of ЕЕ 
(Diane®, Schering Nederland B.V.). Since the estrogenic component in 
oral contraceptives is mainly responsible for the increase of SHBG 
levels (ANDERSON, 1974) a combination preparation with 0.05 mg 
ЕЕ was prefered. CPA is a potent anti-androgen and is regarded as a 
highly effective progestogen. A combination of 100 mg CPA, given 
daily from day 5 until day 14, together with 0.05 mg ЕЕ, administered 
daily from day 5 until day 25 of the cycle, 'reversed sequential' regimen, 
has been proven highly effective in the treatment of clinical signs of 
hyperandrogenism (BROTHERTON, 1975; HAMMERSTEIN et al., 
1975; LACHINSKY et al., 1976; VAN WAYJEN and VAN DEN EN­
DE, 1976; DEWHURSTet al., 1977; EBLING et al., 1977; FRÖLICH 
et al., 1977, 1980; BRECKWOLDT et al., 1978; COELINGH BEN-
NINK, 1979; KUTTENN et al., 1980; YLÖSTALO et al., 1981). The 
combination preparation with a low dose of CPA (2 mg/day), as used in 
the present investigation, has also been reported as effective (HAM-
MERSTEIN et al., 1975; LACHNIT-FIXSON and KAUFMANN, 
1977; SCHMIDT-ELMENDORFF and STEYER, 1977; BRECK-
WOLDT et al., 1978). According to most authors side effects of this 
medication are comparable to those generally observed with oral con-
traceptives, with the exception of tiredness, lassitude and loss of libido 
which are seen more often. 
Conflicting results have been published concerning the influence of 
CPA on the adrenal function. STI VEL et al. (1982) presented evidence 
of adrenal suppression due to CPA, while data from SMALS et al. 
(1978a, 1978b;) indicate no influence of short-term administration of 
CPA (100 mg) on the pituitary-adrenal function in adult women with 
idiopathic hirsutism. 
In the present investigation, the dynamics of suppression and recov-
ery of gonadotrophins and ovarian and adrenal steroids in PCO-
patients using an estrogen-progestogen combination preparation have 
been studied. The data obtained during the period of ovarian suppres-
sion will be presented in this chapter. The process of spontaneous 
follicular maturation after withdrawal of the suppressive agent will be 
discussed in the following chapter. 
Almost all PCO-patients started with their ovarian suppressive medi-
cation one week after the ACTH test in the follicular phase of the cycle. 
The response of pituitary gonadotrophin release and of ovarian and 
adrenal steroidogenesis following the administration of CPA+EE 
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(Diane®) was evaluated by determining the levels of LH, FSH, Cortisol, 
estrone, estradiol, androstenedione and testosterone. All women were 
advised to take additional non-hormonal contraceptive measures during 
the first month of CPA + EE administration. 
7.2 MATERIALS AND METHODS 
7.2.1 Subjects 
The study group consisted of 21 PCO-patients who underwent the 
ovarian suppression evaluation. In one PCO-patient (no. 115) however, 
blood samples were not collected according to the time schedule; results 
from this woman were therefore not included in this presentation. 
7.2.2 Sampling Procedure 
The CPA + EE treatment was administered for 21 days, 1 tablet per 
day, followed by 7 days of no medication. During the 7-day tablet-free 
period, a withdrawal bleeding always occurred. All PCO-patients were 
administered the CPA + EE for a period of 3 months (12 weeks). 
Medication was started on a Monday and the tablets were taken at bed­
time. Blood samples were collected according to a strict time schedule. 
The first blood sample was taken in the morning of the day previous to 
the initiation of CPA + EE therapy. The remaining blood samples were 
obtained after 4, 7, 11, and 14 days. With this time schedule the 
hormonal events during the first two weeks of CPA + ЕЕ administration 
were monitored with high frequency. After this initial period another 5 
samples were obtained at two-week intervals. The majority of PCO-
patients used CPA + EE during the summer season and unfortunately 
several samples are missing due to holidays. 
Determinations of LH, FSH, Cortisol, estrone, estradiol, andro­
stenedione and testosterone levels were performed in all samples. The 
blood was allowed to clot at room temperature, centrifuged and the 
supernatant was stored at -20°C until assayed. All samples from one 
patient were determined in the same assay-run. 
7.2.3 Statistical A nalysis 
The Wilcoxon one-sample test was used to determine the effect of 
CPA + EE administration on the serum levels of the measured steroids 
in the PCO-patients. Two-sided ρ values are given for all parameters. 
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7 3 RESULTS 
7 3 1 Introduction 
In Figures 7 1-7 6 and Table 7 1, the results of the ovarian suppres­
sion period are presented 
7 3 2 LH 
The pretreatment LH level was slightly elevated in comparison with 
the previously found basal LH concentration obtained under standard­
ized conditions in this group of patients (see Table 3 6) 
In most PCO-patients the LH levels increased during the first days of 
CPA + EE treatment This increase was statistically significant 
(p = 0 02) After this initial increase the LH concentration decreased 
progressively Withdrawal of the drug after three weeks caused a slight 
increase of the LH level, however, the pretreatment LH concentration 
was not reached During the next two periods of CPA + ЕЕ administra­
tion a further decrease of LH levels was seen The LH concentration 
after eight and ten weeks was significantly lower than the pretreatment 
level (p = 0 02 and ρ = 0 005 respectively) After the final withdrawal 
of CPA + EE treatment the LH level increased slightly, however, it was 
still lower than the pretreatment LH concentration (Figure 7 1) 
7 3 3 FSH 
The pretreatment FSH level was comparable with the previously 
found FSH concentration obtained under standardized conditions in this 
group of patients (see Table 3 6) 
TABLE 7 ι Changes of the LH/FSH ratio in twenty women with the PCO-syndrome 
during a 12 week period of CPA + EE (Diane®) administration 
Changes of the Periods of CPA + EE 
LH/FSH ratio administration 
Γ ΙΓ Ill-
Increase 7 5 3 
Decrease 10 13 15 
No change 1 1 0 
Missing values 2 1 2 
Ν В Blood samples were obtained 7 days after the end of each three-week medica­
tion period 
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Although in several of the women small spikes of FSH were found, 
the majority of PCO-women demonstrated a decrease of the FSH 
concentration during the first two weeks of CPA + EE treatment. After 
two weeks a significantly lower FSH level was found as compared with 
the pretreatment concentration (p = 0.001). Withdrawal of the drug 
after the first three weeks of medication caused a rapid recovery to 
LH (IU/1) ( m e a n t S E M ) · 
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FIGURE 7 ι Serum LH and FSH concentrations in the PCO-group during ovarian 
suppression (X ± SEM). 
The dotted rectangles indicate the three periods of CPA + EE treatment. 
The dotted line indicates the expected trend of increase and decrease of LH and 
FSH levels in each third week of CPA+EE administration and each period of 
medication withdrawal. 
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pretreatment concentrations. In the following two periods of CPA + EE 
treatment the same pattern was seen. The FSH concentrations after six 
and ten weeks were significantly lower than the pretreatment level 
(p < 0.001 and ρ < 0.001 respectively). A rapid recovery of FSH to a 
somewhat higher mean level than the pretreatment FSH concentration 
was seen after the final withdrawal of CPA + EE (figure 7.1). 
7.3.4 LH/FSH Ratio 
The pretreatment LH/FSH ratio was comparable with the previously 
found basal LH/FSH ratio obtained under standardized conditions in 
this group of patients (see Table 3.5). 
In Figure 7.1 it can be seen that the LH levels decreased progressively 
during the period of ovarian suppression; the FSH levels also decreased 
during this period. However, a rapid recovery of FSH levels was seen 
after withdrawal of the medication. The changes of these two parame­
ters defined the pattern of the LH/FSH ratio. After the first recovery 
period the abnormally elevated LH/FSH ratio was decreased in ten 
PCO-patients, while seven PCO-patients demonstrated an increase 
(Table 7.1). The mean LH/FSH ratio remained comparable with the 
pretreatment value. After the second and third recovery period the 
majority of PCO-patients had a lower value of the LH/FSH ratio. The 
LH/FSH ratio after eight and twelve weeks was significantly lower than 
the pretreatment value (p = 0.04 and ρ = 0.008 respectively). 
However, the LH/FSH ratio in women with the PCO-syndrome re­
mained elevated in comparison with early follicular phase values 
obtained in normal ovulatory women (see Table 3.5). 
7.3.5 Estrone 
The pretreatment estrone level in the investigated group of patients 
was comparable with the previously found basal estrone concentration 
obtained under standardized conditions (see Table 3.6). 
After an initial, small increase of the mean estrone level a gradual 
decrease during the first period of medication was seen. The estrone 
level after two weeks of CPA + EE administration was significantly 
lower than the pretreatment concentration (p = 0.006). Withdrawal of 
the drug after three weeks was not followed by an increase of estrone 
levels, as previously demonstrated for LH and FSH levels. During the 
second period of CPA + EE administration, the estrone concentration 
remained at the level as seen at the end of the first period; during the 
third period, a further decrease of estrone levels was found. After the 
final withdrawal of CPA + EE a small rise of the estrone concentration 
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was seen. However, the estrone level after this period of ovarian 
suppression was still significantly lower than the pretreatment estrone 
concentration (p = 0.03) (Figure 7 2). 
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FIGURE 7 2 Serum estrone concentrations m the PCO-group during ovarian 
suppression (X ± SEM) 
The dotted rectangles indicate the three periods of CPA + EE treatment 
The dotted line indicates the expected trend of increase and decrease of estrone 
levels in each third week of CPA + EE administration and each period of medica­
tion withdrawal 
7.3 6 Estradiol 
The mean pretreatment estradiol level in the present study was higher 
than the previously found basal estradiol concentration obtained under 
standardized conditions m the same group of patients (p = 0.03) (see 
Table 3.6). 
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The estradiol level decreased progressively in the first weeks of 
CPA + E E treatment. The estradiol concentration after two weeks of 
ovarian suppression was significantly lower than the pretreatment con­
centration (p = 0.003). Withdrawal of the drug after three weeks 
caused an increase of the estradiol level to pretreatment concentrations. 
During the next two periods of CPA + E E administration the same 
pattern of changes was seen. A rise in estradiol concentrations was 
demonstrated during the last recovery period (Figure 7.3). 
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FIGURE 7.3 Serum estradiol concentrations in the PCO-group during ovarian 
suppression (X ± SEM). 
The dotted rectangles indicate the three periods of CPA + EE treatment. 
The dotted line indicates the expected trend of increase and decrease of estradiol 
levels in each third week of CPA + EE administration and each period of medica­
tion withdrawal. 
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7.3.7 Androstenedione 
The pretreatment androstenedione level was comparable with the 
previously found androstenedione concentration obtained under 
standardized conditions in this group of patients (see Table 3.6). 
The majority of PCO-patients demonstrated a decrease of the andro­
stenedione concentration during the first and second week of СРАЧ-ЕЕ 
treatment. The androstenedione concentration after two weeks of 
ovarian suppression was significantly lower than the pretreatment level 
(p = 0.004). Withdrawal of the drug after three weeks caused an 
increase of the androstenedione level to pretreatment concentrations. 
During the following two periods of CPA + EE treatment the same 
pattern was seen. The androstenedione concentrations after six, eight 
Androstenedione (meant SEM) 1 
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FIGURE 7 4 Serum androstenedione concentrations in the PCO-group during 
ovarian suppression (X ± SEM) 
The dotted rectangles indicate the three periods of C P A + E E treatment 
The dotted line indicates the expected trend of increase and decrease of andro­
stenedione levels in each third week of CPA + EE administration and each period 
of medication withdrawal 
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and ten weeks of ovarian suppression were significantly lower than the 
pretreatment level (p = 0 004, ρ = 0 02 and ρ < 0.001 respectively) 
At the end of the third recovery period the mean androstenedione 
concentration was slightly lower than the pretreatment level (p = 0 08) 
(Figure 7 4) 
7 3 8 Testosterone 
The pretreatment testosterone level was comparable with the previ­
ously found testosterone concentration obtained under standardized 
conditions in this group of patients (see Table 3 6). 
After an initial small increase of the mean testosterone level a gradual 
decrease during the first period of medication was seen. One and a half 
week after the onset of CPA + EE treatment a significantly lower testo-
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FIGURE 7 5 Serum testosterone concentrations in the PCO-group during ovarian 
suppression (X ± SEM) 
The dotted rectangles indicate the three periods of C P A + E E treatment 
The dotted line indicates the expected trend of increase and decrease of testo­
sterone levels m each third week of C P A + E E administration and each period of 
medication withdrawal 
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sterone level could be demonstrated (p = 0.006). Withdrawal of the 
drug after the first three weeks of medication was followed by an 
increase of the testosterone level to pretreatment concentrations. The 
following two periods of CPA + ЕЕ treatment demonstrated the same 
Cortisol (/umol/l)(mean±SEM) 
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FIGURE 7 6 Serum Cortisol concentrations in the PCO-group during ovarian 
suppression (X ± SEM). 
The dotted rectangles indicate the three periods of CPA+EE treatment. 
The dotted line indicates the expected trend of increase and decrease of Cortisol 
levels in each third week of CPA + EE administration and each period of medica­
tion withdrawal. 
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pattern During the second period of ovarian suppression the testoster­
one concentration decreased to a slightly lower level than the pretreat­
ment concentration (p = 0 08), during the third period of CPA + EE 
administration a significantly reduced testosterone concentration was 
seen (p = 0 01) A rapid recovery of testosterone to a somewhat higher 
mean level than the pretreatment concentration was seen after the final 
withdrawal of CPA + EE (Figure 7 4) 
7 39 Cortisol 
The pretreatment Cortisol level was lower than the previously found 
Cortisol concentration obtained under standardized conditions in this 
group of patients (p = 0 03) (see Table 3 6) 
After the onset of CPA + ЕЕ treatment a rapid and significant in­
crease of the Cortisol concentration was seen (p < 0 001) Withdrawal 
of the drug resulted in a relatively small decrease of the Cortisol concen­
tration During the next two periods of CPA + EE administration a 
further increase of the Cortisol level was demonstrated After the final 
withdrawal of CPA + EE the Cortisol concentration was still significantly 
elevated in comparison with the pretreatment level ( p < 0 001) 
(Figure 7 6) 
7 4 DISCUSSION 
In the present study 20 PCO-patients were administered a combina­
tion preparation containing 0 05 mg ethinyl estradiol and 2 mg cyproter-
one acetate (Diane®), for a period of three months in a discontinuous 
way The dynamics of suppression and recovery of gonadotrophins as 
well as adrenal and ovarian steroids were studied 
As expected (see Chapter 3), the PCO-patients had elevated pretreat­
ment LH levels, which is in agreement with results from other studies 
During the first few days of CPA + EE treatment most women 
responded with an increase in LH levels GIVENS et al (1974) reported 
cither no change or spiking increases of LH during the first days of 
treatment with an estrogen-progestogen combination preparation 
(mestranol [0 1 mg] and norethindrone [2 mg]) in PCO-patients Erratic 
surges of LH were demonstrated in hirsute women after the administra­
tion of either diethylstilbestrol or norethindrone acetate resulting in an 
increase of the LH level as seen in the present study (DAANE et al , 
1973) The failure to suppress LH encountered during the first days of 
CPA + ЕЕ administration may be due to resistance of the negative feed­
back system as well as to a positive feedback of the estrogen component 
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in the presence of a progestogen This initial increase was followed by a 
decrease m the second week As illustrated in Figure 7 1, a further 
decrease of the LH concentration during the third week of CPA + EE 
treatment is to be expected Withdrawal of the drug after the first period 
of three weeks was followed by a slight increase ot LH levels This 
finding is in agreement with results from GIVENS et al (1974) During 
the next two periods of treatment a further decrease of LH was seen In 
other studies women with clinical signs of hyperandrogenism demon­
strated an adequate suppression of gonadotrophin secretion during 
treatment with either estrogen-progestogen or single progestogen 
preparations ( G O R D E N et al , 1972; GIVENS et al , 1976b; WORTS-
MAN et al , 1981) After the final withdrawal of CPA + EE a slow rise 
of LH was seen, the rate of increase was less than the rise of FSH levels, 
resulting in a decrease of the previously elevated LH/FSH ratio 
The pretreatment FSH levels in PCO-patients studied in the present 
investigation were comparable with the previously found basal FSH 
concentrations in the PCO-group and were reduced in comparison with 
the FSH levels of normal ovulatory control women The administration 
of CPA + EE resulted in a rapid decrease of FSH This finding is in 
agreement with data from several other studies. The administration of 
both diethylstilbestrol and norethindrone acetate was effective in 
suppressing FSH levels in most women with the PCO-syndrome 
(DAANE et al , 1973) A rapid decrease of FSH after the administra­
tion of estrogen-progestogen preparations was also demonstrated by 
GIVENS с s (GIVENS et al , 1974, 1976b) After withdrawal of 
CPA + E E FSH levels rose promptly to pretreatment concentrations 
whereas LH levels remained almost unchanged This pattern of FSH 
secretion during the first suppression and recovery phase was also seen 
in the following two periods of CPA + EE administration The rebound 
increase of FSH after the withdrawal of CPA + ЕЕ also occurs in normal 
women following short-term estrogen administration (CARGILLE et 
al , 1973) The same phenomenon is seen in normal cycles during the 
second half ot the luteal phase Relatively or absolutely depressed FSH 
levels represent a major factor in the inadequate follicular maturation 
encountered m PCO-patients Since preantral follicular growth mainly 
depends on the presence ot FSH and high local concentrations of estro­
gen (see 1 1 4), the rebound of FSH after (short-term) ovarian suppres­
sion will probably benefit follicular maturation in these women 
Although both LH and FSH declined during CPA + EE treatment, 
the elevated and unphysiological prctreatment LH/FSH ratio in the 
studied group even increased further as a result of the prompt decline of 
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FSH. Inappropriate gonadotrophin secretion, characteristic of women 
with the PCO-syndrome (see Table 3.5 and Chapter 5), persisted during 
the period of ovarian suppression. However, a reduction of the LH/FSH 
ratio after withdrawal of medication during the recovery phase was 
seen. After the second and third treatment cycle this decrease was most 
obvious (see Table 7.1). The differential responses of FSH and LH 
during the recovery phases were responsible for this 'normalization' of 
the LH/FSH ratio. As previously discussed, normal progression of folli-
cular maturation requires stimulation with adequate quantities of FSH 
and LH in appropriate proportions (see 1.1.4). Although the LH/FSH 
ratio in our PCO-patients was still elevated in comparison with normal 
ovulatory women, the reduction of this ratio may be beneficial for the 
process of follicular maturation. In order to obtain better conditions for 
follicular maturation in PCO-women, it seems justified in selected cases 
to advise ovarian suppression for a period of at least three months 
before an attempt is made to induce ovulation. 
The pretreatment level of estrone in the studied group was compar-
able with the previously found estrone concentration, whereas the mean 
estradiol level was higher than the mean concentration of estradiol 
encountered in these PCO-patients under standardized conditions (see 
Table 3.6). The high serum estradiol levels encountered in two PCO-
patients (no. 108 and 118) were responsible for this difference. Follow-
ing the administration of CPA + EE a gradual reduction of estrone 
levels occurred. After withdrawal of the medication a small rise of the 
estrone concentration was observed, although the pretreatment level 
was not reached. The change of the estrone concentration during and 
after ovarian suppression is probably caused by a direct reduction of 
ovarian estrone production. Because the ovarian androstenedione 
production was also reduced, it is possible that a reduction of the 
peripheral conversion of androstenedione to estrone also accounted for 
the lessened estrone production. 
Estradiol levels decreased progressively during the first period of 
CPA + EE treatment. After withdrawal of this medication, there was an 
increase in the estradiol concentration; however, the pretreatment level 
was not reached. The changing concentration of estradiol provides an 
index of the growth of antral follicles (PETERS and McNATTY, 1980). 
Therefore the fall in estradiol levels during CPA + EE treatment most 
likely represents a reduction of ovarian estradiol production, caused by 
the decrease of FSH secretion and indicating adequate suppression of 
follicular maturation. Although estrone and estradiol levels were still 
elevated at the end of this period of ovarian suppression, the hormonal 
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milieu was less hyperestrogenic and this may benefit appropriate 
gonadotrophin secretion (CHANG et al., 1982a). 
In the PCO-patients a hyperandrogenic state was found at the onset 
of CPA + EE administration. The pretreatment levels of androstenedi-
one and testosterone in the studied group were comparable with those 
previously found. The administration of CPA + EE resulted in a de-
crease of both androstenedione and testosterone. This reduction of 
androgen levels is in agreement with data from several other studies. In 
many of these investigations the effect of a combination preparation on 
the free (unbound) testosterone concentrations and the SHBG levels 
was studied as well. Because of practical reasons it was not possible 
to determine these important parameters during the present study. 
ANDERSEN et al. (1976) reported an increase of SHBG four days 
after the administration of the first tablet of a combination preparation; 
the mean testosterone level was significantly suppressed within nine to 
twelve days and the free testosterone level decreased in every woman 
during the administration of the oral contraceptive. A decrease of 
androgen levels in hyperandrogenic women was also reported by 
GIVENS cs. (GIVENS et al., 1974; 1976b), FERN et al. (1978) and 
TALBERT and SLOAN (1979). Recently BAXENDALE et al. (1982) 
reported a significant reduction of salivary and plasma testosterone 
levels in PCO-patients treated with a combination of cyproterone acetate 
and ethinyl estradiol (reversed sequential regimen). Interestingly the 
treatment resulted in a decrease of salivary testosterone levels in all 
patients studied, whereas the suppression of plasma testosterone was 
not observed in all subjects. Since the measurement of salivary testoster-
one gives a useful indication of levels of biologically available androgen, 
these results demonstrate the effectiveness of this combination of 
preparations in suppressing the hyperandrogenic state encountered in 
PCO-patients. 
After withdrawal of CPA + EE the androstenedione level was slightly 
lower than the pretreatment concentration. This finding is in agreement 
with results reported by GIVENS et al. (1974). At the end of the last 
recovery period the testosterone level was somewhat higher than the 
pretreatment concentration. Data from ANDERSEN et al. (1976) indi-
cated that SHBG levels remained significantly elevated above pretreat-
ment concentrations throughout a posttreatment period of at least 
twelve days. The elevated testosterone concentration encountered in 
our group of PCO-patients after the final withdrawal of medication does 
not necessarily indicate therefore the return of the hyperandrogenic 
state as found before treatment. Possibly the unbound testosterone 
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concentrations remain reduced for some time as a result of the still 
elevated SHBG levels Further research should focus on this aspect. 
From our results one may therefore conclude that during the adminis-
tration of CPA + EE the PCO-patients became less hyperandrogemc 
Since m the present study neither free fractions of androgens nor SHBG 
concentrations were determined it was not possible to demonstrate to 
which degree this depressed androgenic state persisted after withdrawal 
of CPA + EE Several data from the literature however, do suggest that 
a combination preparation not only has its beneficial effects for PCO-
patients during the use of the medication but also until at least twelve 
days after withdrawal of the drug (ANDERSEN et al., 1976) 
The pretreatment Cortisol level was somewhat reduced in comparison 
with the previously found Cortisol concentration in this group of 
patients Probably the simple venipuncture was less stressful! than the 
installation of an intravenous cannula A rapid and significant increase 
of the Cortisol concentration was seen following the onset of CPA + EE 
administration. After the final withdrawal of the combination prepara-
tion, at the end of the third recovery period, the Cortisol concentration 
was still elevated in comparison with the pretreatment levels These 
findings are in agreement with results reported in the literature 
(BULBROOK et al , 1973; DURBER and DALY, 1976) The rise in 
the Cortisol concentration is most likely accounted for by a correspon-
ding rise in the corticosteroid-bindmg-globulm (CBG) concentration 
induced by the administration of an estrogen containing preparation A 
reduced metabolic clearance rate of Cortisol with elevated free Cortisol 
levels results. Consequently a reduction of ACTH release is seen 
(BECK et al , 1972) 
The degree to which adrenal androgen secretion is affected by the use 
of a combination preparation was studied by several investigators It 
was demonstrated that adrenal androgen production is reduced during 
the use of oral contraceptives (BULBROOK et al , 1973, FERN et al , 
1978, MADDEN et al , 1978). Probably this decrease in adrenal andro-
gen production is accomplished by way of a decrease in ACTH (WILD 
et al , 1982). In fact decreased ACTH levels have been reported in oral 
contraceptive users (MEIKLE et al., 1970; MADDEN et al , 1977). 
Although the hyperandrogemsm encountered in PCO-patients is LH 
dependant and suppressing gonadotrophin levels by means of a combina-
tion preparation is a rational therapeutic approach, the effect of these prep-
arations on the adrenals through the decreased stimulation by ACTH 
may to some extend also account for the decrease in androgen levels 
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8. FOLLICULAR MATURATION AFTER OVARIAN 
SUPPRESSION 
8 1 INTRODUCTION 
In the preceding chapter it was hypothesized that, at the end of the 
last recovery period—eight days after withdrawal of the CPA + EE 
combination preparation (Diane®)—the conditions for follicular 
maturation were improved in comparison with the pretreatment situa-
tion The LH/FSH ratio decreased significantly with concomitantly 
reduced serum estrogen levels 
Most PCO-patients wished to become pregnant and therefore the 
process of spontaneous follicular maturation and ovulation could be 
studied further in this particular group of women At regular intervals 
blood samples were obtained for the determination of LH, FSH, 
estrone, estradiol, androstenedione and testosterone Whenever clinical 
data (cervix score, basal body temperature) indicated the presence of an 
ovulatory cycle, blood was collected for the determination of progester-
one In this way 17 women with the PCO-syndrome were investigated 
Twelve patients remained anovulatory during the study period of at least 
24 days, whereas five PCO-patients happened to have an ovulatory cycle 
of whom two conceived In this chapter the hormonal profile of the 
anovulatory and ovulatory women will be analyzed and compared 
A further characterization of the ovulatory group versus the anovula-
tory group was realized by analyzing data obtained in these women 
during the previously performed diagnostic test program (dexametha-
sone suppression test, LH-RH test and ACTH test) 
8 2 MATERIALS AND METHODS 
8 2 1 Subjects 
The process of spontaneous follicular maturation was evaluated in 17 
PCO-women who wished to become pregnant Primary infertility was 
present in 13 patients Three patients reported a spontaneous first 
trimester abortion, in one patient, secondary infertility of one year 
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duration was present with certainty; this woman previously had an 
uncomplicated pregnancy. Although in most women the cycle disturb-
ance was probably the major cause for infertility, in many couples 
(11/17) additional suboptimal andrological factors were present. 
8.2.2 Sampling Procedure 
Since all women started CPA + EE medication on Monday, the last 
tablet of a series of 21 had to be taken on Sunday evening. The first day 
after withdrawal of medication (Monday) was defined as cycle-day one 
(CD 1). The evaluation of the process of spontaneous follicular matura-
tion started one week later, i.e. CD 8. From then on the women visited 
the out-patient department at regular intervals for a varying period of 
time. Blood samples were obtained on Monday, Wednesday and Friday. 
The process of follicular maturation could be evaluated, according to 
this schedule, in all women until CD 24. From CD 26 on several 
patients dropped out for various reasons. 
In one anovulatory patient (no. 114) and three ovulatory patients 
(no. 101, 102, 115), the first blood samples were obtained on either 
CD 7 or CD 9. In these four women, all further blood sampling was per-
formed according to the previously discussed protocol. Therefore, the 
data could be included in the present study by clustering results 
obtained on CD 9 with results obtained on CD 8. 
Determinations of LH, FSH, estrone, estradiol, androstenedione and 
testosterone levels were performed in all blood samples, while proges-
terone was determined only when clinical data indicated the presence of 
an ovulatory cycle. The blood was allowed to clot at room temperature, 
then centrifuged and the supernatant was stored at -20°C until assayed. 
All samples from one patient were determined in the same assay-run. 
Unfortunately a few values of the several parameters are missing becau-
se of an insufficient amount of serum. 
8.2.3 Statistical Analysis 
In this study the statistical analysis was performed on data obtained 
from CD 8 until CD 24. From CD 24 on the number of patients 
dropping out was considered to be too high for adequate statistical 
evaluation. The Wilcoxon one-sample test was used to determine chan-
ges of gonadotrophin and steroid levels during the recovery period. For 
the group of twelve non-ovulating women results are presented by mean 
± SEM for each of the sampling points. Individual courses for the 
hormonal parameters are given for each of the ovulatory women to a 
background hormonal pattern of the non-ovulating group. This kind of 
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presentation will reveal marked differences between both groups. The 
Wilcoxon two-sample test was used for the determination of differences 
between both groups in the dexamethasone suppression test, the LH-RH 
test and the ACTH test. Two-sided ρ values are given for all parameters. 
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FIGURE 8 ι Serum LH and FSH concentrations in a group of 12 anovulatory PCO-
patients during "follicular maturation" following a period of ovarian suppression 
(X ± SEM). 
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8.3 RESULTS 
8.3.1 Introduction 
Hormonal changes in the anovulatory group during the recovery period 
are presented in Figures 8.1-8.5. Hormonal changes in each ovulatory 
woman during the recovery period are presented in Figures 8.6-8.10. 
8.3.2 LH 
A gradual increase of the LH level was found during the recovery phase. 
The LH level in the period from CD 10 until CD 24 was significantly 
elevated in comparison with the LH level measured on CD 8 (p < 0.01). 
The LH concentrations in ovulatory women were not different from 
those found in anovulatory patients (Figures 8.1 and 8.6-8.10). 
8.3.3 FSH 
The FSH concentration did not change significantly during the 
recovery phase. 
Comparison of FSH concentrations of ovulatory women and anovula-
tory women revealed a tendency of differences between both groups 
(Figures 8.1 and 8.6-8.10). 
8.3.4 LHIFSH Ratio 
A gradual increase of LH levels was found during the recovery phase 
whereas FSH levels did not change significantly after the first recovery 
week. The changes of these two parameters defined the pattern of the 
LH/FSH ratio. The LH/FSH ratio in the period from CD 10 until CD 24 
was significantly higher than the LH/FSH ratio determined on CD 8 
(p < 0.01), thus indicating an increase of this ratio. 
Comparison of the LH/FSH ratio in ovulatory women with the ratio 
found in anovulatory women did not give evidence for significant differ-
ences between both groups. 
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8.3.5 Estrone 
A gradual increase of estrone levels was found during the recovery 
phase. The estrone concentration in the period from CD 10 until CD 24 
was significantly elevated in comparison with the estrone level measured 
on CD 8 (p < 0.02). 
Ovulatory women did not have different estrone concentrations but 
the course of their serum estrone levels seems to be different (Figures 
8.2 and 8.6-8.10). 
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FIGURE 8 2 Serum estrone concentrations in a group of 12 anovulatory PCO-
patients during "follicular maturation" following a period of ovarian suppression 
(Χ ± SEM) 
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8.3.6 Estradiol 
A consistent change of estradiol levels during the recovery phase was not 
found. However, the estradiol level on CD 15 and CD 24 was 
slightly elevated in comparison with the estradiol level measured on CD 8. 
During the first 12 days of recovery estradiol concentrations of ovula­
tory women were not different from those found in anovulatory women. 
For all ovulatory women elevated estradiol levels were present from 
CD 17 until CD 24 (Figures 8.3 and 8.6-8.10). 
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FIGURE ял Serum estradiol concentrations in a group of 12 anovulatory PCO-
patients during "follicular maturation" following a period of ovarian suppression 
(X ± SEM). 
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8.3.7 Androstenedione 
A gradual increase of androstenedione levels during the recovery 
phase was seen. 
Ovulatory women tended to have lower androstenedione levels than 
those found in anovulatory women (Figures 8.4 and 8.6-8.10). 
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FIGURE 8 4 Serum androstenedione concentrations m a group of 12 anovulatory 
PCO-gatients during "follicular maturation" following a period of ovarian suppres­
sion (X ± SEM) 
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8.3.8 Testosterone 
No consistent change of the testosterone concentration could be 
demonstrated during the recovery phase. 
Ovulatory women tended to have lower testosterone levels than those 
found in anovulatory women (Figures 8.5 and 8.6-8.10). 
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FIGURE 8 5 Serum testosterone concentrations in a group of 12 anovulatory PCO-
patients during "follicular maturation" following a period of ovarian suppression 
(X ± SEM). 
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8 4 DISCUSSION 
In seventeen PCO-patients follicular maturation was carefully studied 
after discontinuation of CPA + EE (Diane®) Clinical and hormonal 
data indicated the presence of ovulatory cycles in five (29%) of these 
PCO-women Since occasional ovulatory cycles may occur sponta­
neously in women with the PCO-syndrome [incidence 20-30% accor­
ding to GOLDZIEHER and AXELROD (1963) and BAIRD et al 
(1977)], it is not possible to conclude that ovulation in the present study 
was directly related with the preceding period of ovarian suppression 
The suppressive effect of oral contraceptive steroids on the hypotha-
lamic-pituitary-ovanan axis in normal women disappears within a few 
days following discontinuation of the contraceptive preparation. After 
the initial recovery period a completely normal endocrine function was 
found and up to 86% of women ovulated within six weeks (LORAINE 
et al , 1965; RICE-WRAY et al., 1967; KLEIN and MISHELL, 1977, 
LAHTEENMAKIN et al , 1980) By comparing these data from the 
literature with the results of the present study, it can be seen that 
inadequate follicular maturation is characteristic for most PCO-pa-
tients, even after a period of ovarian suppression 
During this study a slight but significant increase of LH levels was 
found No significant differences were revealed when comparing 
ovulatory and anovulatory patients The suppressive effect of CPA + ЕЕ 
on the LH levels disappeared within two weeks after discontinuation of 
medication, and the LH concentration reached a level comparable with, 
or even higher than, pretreatment values A rapid increase of FSH 
levels was seen one week after the discontinuation of CPA + EE It was 
anticipated that this rapid FSH increase and the less pronounced LH 
increase, resulting in a lower LH/FSH ratio, could benefit follicular 
maturation (sec Chapter 7) The FSH level, however, remained relative­
ly low during the succeeding recovery period The ovulatory patients 
had a slightly higher FSH concentration than the anovulatory women 
which indicates a lack of adequate FSH secretion in anovulatory women 
during the first period of follicular maturation In healthy ovulatory 
women the primary role of the early follicular phase rise in FSH levels is 
to recruit the available healthy antral follicles for further development 
(McNATTY, 1981a, 1982) FSH seems to be the critical stimulus tor 
early follicular maturation Most PCO-patients in this study missed an 
adequate quantity of FSH; this relative deficiency of FSH, encountered 
during the early follicular phase, probably determined the destiny of 
follicular maturation in these women After the initial decrease of the 
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LH/FSH ratio, following discontinuation of CFA + ЕЕ, the LH/FSH 
ratio increased during the succeeding recovery period. As could be 
expected ovulatory patients had slightly lower LH/FSH ratios than 
anovulatory women. 
The initial improvement of gonadotrophin secretion encountered in 
the first days after discontinuation of CFA + ЕЕ disappeared during the 
succeeding recovery period; the hormonal characteristics of PCO-
patients as previously discussed (see Chapter 3) returned. Although 
a period of ovarian suppression may benefit the process of follicular 
maturation in these women, most PCO-patients still had a relative 
shortage of FSH during the recovery period. In order to obtain more 
adequate follicular maturation it will be necessary to support follicular 
maturation in these women by administering FSH. In this respect 
two treatment modalities seem to be present: the endogenous FSH 
release is stimulated by the administration of an antiestrogen such as 
clomiphene citrate which should be given immediately after the with­
drawal of the ovarian suppressive agents; the other possibility is to start 
with the administration of purified human pituitary FSH as previously 
discussed (see 1.2.8.3). The suitability of both treatment modalities in 
combination with a preceding period of ovarian suppression should be 
investigated in a prospective study. 
During the first 24 days following the discontinuation of CPA -I- ЕЕ, a 
gradual increase of estrone levels was seen. Ovulatory women tended to 
have lower estrone levels than anovulatory women. The reduced 
estrone levels in the ovulatory women possibly contributed to the 
appropriate secretion of gonadotrophins and, in this way, were bene­
ficial for follicular maturation. However, in anovulatory women the 
increase of the estrone concentration may have been responsible for the 
reestablishment of chronic anovulation due to inappropriate gonado­
trophin secretion. During the first two weeks of recovery, the estradiol 
levels did not differ in either group. As could be expected the estradiol 
level was significantly elevated in the ovulatory women during the 
periovulatory phase. As previously seen for gonadotrophin secretion it 
seems that women who did not ovulate following the period of ovarian 
suppression redeveloped the pattern of estrogen secretion characteristic 
for PCO-patients, namely elevated estrone levels and normal or slightly 
elevated estradiol concentrations. 
After the discontinuation of CPA + ЕЕ a gradual increase of 
androstenedione levels was seen. Ovulatory women tended to have 
lower androstenedione levels than anovulatory women. This may have 
been beneficial for the initiation of adequate follicular maturation. 
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Androstenedione may play an important role in hypothalamic feedback 
mechanisms (BAIRD, 1974). Chronic exposure to elevated concentra­
tions of androstenedione facilitates estrogen-induced LH-release (VAN 
LOOK and BAIRD, 1980). Although the significance of this finding, as 
far as gonadotrophin release is concerned, remains to be elucidated, the 
results of the present study reconfirm that androstenedione may have an 
important role in the initiation of inadequate gonadotrophin release and 
consequently inadequate follicular maturation. 
The testosterone concentration did not change during the recovery 
period. The lower values were seen in the ovulatory group. According 
to LOUVET et al. (1975) elevated androgen levels induce follicular 
atresia and may in this way interfere with follicular maturation. The free 
fraction of testosterone possibly plays an important role in this process. 
It should therefore have been of interest to know the unbound, bio­
logically active, testosterone concentrations in both ovulatory and 
anovulatory women. Unfortunately these parameters could not be 
determined in the present study. It appears that the anovulatory PCO-
patients redeveloped a pattern of increased androgen secretion after 
withdrawal of the suppressive medication with reestablishment of the 
characteristic hyperandrogenic state. 
The ovulatory and anovulatory women also underwent the diagnostic 
test programme. The results obtained with these tests in both groups 
were compared and are presented below. 
Under standardized conditions (t,, LH-RH test, see Chapter 3) 
ovulatory women had significantly lower androstenedione and testoste­
rone concentrations than anovulatory women (p = 0.03 and ρ = 0.05 
respectively). This difference between both groups indicates that 
ovulatory women were less hyperandrogenic than anovulatory patients. 
Dexamethasone administration resulted in significantly lower andro­
stenedione levels in the ovulatory group during the dexamethasone 
suppression test (p = 0.01); although a tendency for lower androstene­
dione and testosterone levels after dexamethasone administration was 
found for the basal values of the ACTH test, a significant difference was 
not demonstrated (p = 0.11 and ρ = 0.11 respectively). The diurnal 
variation of testosterone levels was significantly less pronounced in ovu­
latory women (p = 0.05) and the reduction of testosterone concentra­
tions after dexamethasone administration seemed to be less evident in 
ovulatory women as compared with anovulatory patients (p = 0.08). 
Although dexamethasone suppressible androgen production was pre­
sent in the ovulatory women, these results indicate the presence of a 
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primarily non-adrenal androgen source responsible for androgen over­
production in these patients when compared with data obtained in the 
anovulatory group. The administration of CPA + ЕЕ resulted in 
suppression of ovarian androgen overproduction and this treatment may 
have been beneficial especially for the women with mild hyperandroge-
nism from ovarian origin. 
In patients who responded with an ovulatory cycle a tendency for a 
more pronounced FSH release, following LH-RH administration, was 
found (p = 0.07). This further stresses the importance of adequate FSH 
release in these women and the relative lack of adequate quantities of 
FSH in the anovulatory PCO-group. 
From the above presented results it seems justified to conclude that 
the ovulatory women were less hyperandrogenic than those women who 
did not ovulate. The data discussed also indicate that the adrenal 
component in androgen production was less pronounced in this 
ovulatory group. Finally the ovulatory group responded with a more 
pronounced FSH release after the administration of LH-RH. 
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FiGiJRfc 8 6 Follicular maturation and ovulation 
in PCO-patient no 101 
Following the period of ovarian suppression 
the serum levels of FSH, LH, estradiol, estrone, 
testosterone and androstenedione were deter-
mined In this figure these values are presented 
The mean ± 2 SD of the same parameters in the 
anovulatory group are also indicated 
An adequate release of FSH is seen This FSH 
release resulted in successful follicular maturation 
which is reflected by the rise of the estradiol and 
estrone levels An LH surge can be seen and ovu-
lation followed The progesterone concentrations 
were determined on CD 23, CD 25 and CD 30, 
they were 11 0 ng/ml, 20 0 ng/ml and 32 0 ng/ml 
respectively 
The testosterone level was rather low in com-
parison with the mean testosterone concentration 
of the anovulatory group 
At the onset of this ovulatory cycle the testo-
sterone concentration was fairly normal, whereas 
the androstenedione level was rather high when 
compared with androgen concentrations obtained 
in normal ovulatory women during the early folli-
cular phase (see Table 3 6) 
After 11 years of primary infertility the patient 
became pregnant during this cycle At a men-
strual age of 28 weeks she delivered a son, this 
boy is doing well 
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FIGURC s 7 Follicular maturation and ovulation 
in PCO-patient no 102 
Following the period of ovarian suppression 
the serum levels of FSH, LH, estradiol, estrone, 
testosterone and androstenedione were deter-
mined In this figure these values are presented 
The mean ± 2 SD of the same parameters in the 
anovulatory group are also indicated 
An adequate release of FSH is seen This FSH 
release resulted in successful follicular maturation 
which is reflected by the rise of the estradiol and 
estrone levels The LH surge was missed due to 
the low frequency of sampling However, ovula-
tion took place The progesterone concentrations 
were determined on CD 36, CD 40 and CD 47, 
they were 8 1 ng/ml, 35 0 ng/ml and 30 0 ng/ml 
respectively 
At the onset of this ovulatory cycle both the 
testosterone and the androstenedione levels were 
slightly lower than the mean values found in the 
anovulatory group, however, the concentrations 
of these androgens were slightly elevated when 
compared with values obtained during the early 
follicular phase in normal ovulatory women (see 
Table 3 6) 
After 6 years of primary infertility the patient 
became pregnant during this cycle Near term she 
delivered a healthy son 
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FIGURE к н Follicular maturation and ovulation 
in PCO-patient no 108 
Following the period of ovarian suppression 
the serum levels of FSH, LH, estradiol, estrone, 
testosterone and androstenedione were deter­
mined In this figure these values are presented 
The mean ± 2 SD of the same parameters in the 
anovulatory group are also indicated 
In this patient a rapid rise of FSH levels was 
seen after withdrawal of the suppressive medica­
tion The high FSH levels resulted in a very 
adequate stimulation of follicular maturation 
which is reflected by the rapid increase of both 
estradiol and estrone At the onset of follicular 
maturation the estrogen concentrations were 
comparable with the estradiol and estrone levels 
found in normal ovulatory women during the ear­
ly follicular phase (see Table 3 6) The LH surge 
was missed due to the low frequency of sampling, 
however, ovulation took place The progesterone 
concentrations were determined on CD 29 and 
CD 31, they were 9 1 ng/ml and l l ()ng/ml 
respectively 
At the onset of this ovulatory cycle both the 
testosterone and the androstenedione levels were 
slightly lower than the mean values found in the 
anovulatory group, however, the concentrations 
of these androgens were elevated when compared 
with values obtained during the early follicular 
phase in normal ovulatory women (see Table 
3 6) 
The patient dit not conceive during this cycle, 
menstruation followed on CD 33 
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FIGURE 8 9 Follicular maturation and ovulation 
in PCO-patient no. 115. 
Following the period of ovarian suppression 
the serum levels of FSH, LH, estradiol, estrone, 
testosterone and androstenedione were deter­
mined. In this figure these values are presented. 
The mean ± 2 SD of the same parameters in the 
anovulatory group are also indicated. 
An adequate release of FSH is seen. This FSH 
release resulted in successful follicular maturation 
which is reflected by the rise of the estradiol and 
estrone levels. At the onset of this ovulatory cycle 
the LH levels were rather depressed; a small LH 
surge can be seen and ovulation followed. The 
progesterone concentrations were determined on 
CD 23, CD 26 and CD 28; they were 1.9 ng/ml, 
2 1 ng/ml and 1.7 ng/ml respectively. 
These low progesterone concentrations most 
likely indicate an insufficient luteal phase or 
lutemization of the Graafian follicle. 
The concentrations of both androstenedione 
and testosterone were slightly lower than the 
mean values found in the anovulatory group. At 
the onset of this cycle the testosterone concentra­
tion was sligthly elevated when compared with 
values obtained during the early follicular phase 
in normal ovulatory women (see Table 3.6); the 
androstenedione concentration was comparable 
with the levels found in this normal group. 
The patient did not conceive during this cycle 
and menstruation followed, as could be expected. 
after the insufficient luteal phase. 
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FIGURE к io Follicular maturation and ovulation 
in PCO-patient no. 120. 
Following the period of ovarian suppression 
the serum levels of FSH, LH, estradiol, estrone, 
testosterone and androstencdionc were deter­
mined In this figure these values are presented. 
The mean ± 2 SD of the same parameters in the 
anovulatory group are also indicated. 
This patient had an ovulatory cycle in spite of 
rather low FSH levels. The adequate follicular 
maturation is reflected by the normal increase of 
the estradiol level; the estrone concentration 
also increased but not to an extent as seen in the 
other ovulatory PCO-patients The estrone level 
as determined at the onset of this ovulatory cycle 
was remarkably low. The LH surge was missed in 
this patient due to the low frequency of sampling. 
The progesterone concentrations were deter­
mined on CD 29 and CD 31; they were 6.3 ng/ 
ml and 6 4 ng/ml respectively 
The androgen levels in this patient were com­
parable with the concentrations found in the an­
ovulatory group At the onset of this ovulatory 
cycle the testosterone and androstenedione con­
centrations were elevated when compared with 
androgen levels obtained m normal ovulatory 
women during the earlv tollicular phase (see 
Table 3 6) 
The patient did not conceive during this cycle; 
menstruation followed on CD 38. 
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9. GENERAL DISCUSSION 
In the previous chapters several aspects of the PCO-syndrome have 
been discussed. From an extensive study of the literature it became 
evident that the PCO-syndrome is a disorder of ill-definition and that a 
great clinical and biochemical variability is encountered in this disease. 
However, general agreement does exist concerning some aspects. The 
most characteristic feature of the PCO-syndrome is the presence of 
anovulation. Also most women have clinical signs of androgen excess 
and often obesity is present. Although the name -polycystic ovary 
syndrome- does suggest the presence of cystic changes in the ovaries, 
such a characteristic morphological picture is not always found. 
Inappropriate gonadotrophin secretion and excess androgen production 
are the typical laboratory findings in women with this disease. 
Our PCO-patients either had oligomenorrhea, secondary amenorrhea 
or evidence of chronic anovulation as well as hirsutism and/or obesity. 
The basal endocrinological characteristics of this group of PCO-women 
were comparable with those reported in the literature. Elevated LH 
levels and reduced levels of FSH, resulting in an increase of the LH/FSH 
ratio were found. The serum concentrations of estrone and estradiol 
were also elevated, as were the serum levels of androstenedione and 
testosterone. 
The major cause of inappropriate gonadotrophin release in PCO-syn-
drome patients is found in chronically elevated estrone levels (CHANG 
et al., 1982a). Elevated levels of unbound estradiol, which result from a 
lowered SHBG binding capacity, possibly also play an important role 
(LOBO et al., 1981a). Since the presence of elevated androgen levels 
results in a reduction of SHBG binding capacity, androstenedione and 
testosterone may also play a role in the initiation of inappropriate 
gonadotrophin secretion (LOBO and GOEBELSMANN, 1982). The 
constant acyclical estrogen feedback on the hypothalamic-pituitary 
system as found in PCO-patients is probably of major importance in the 
initiation of inappropriate gonadotrophin secretion. The high levels of 
estrone and estradiol augment pituitary sensitivity to LH-RH with 
favoring the secretion of LH over FSH. In the present study this was 
155 
Proposed mechanism for persistent anovulation in the polycystic ovary syndrome 
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FIGURE 9 1 Sequence of events in the maintenance of chronic anovulation in the 
PCO-syndrome. 
clearly demonstrated by the excessive LH release in the PCO-group 
following the administration of LH-RH. The inappropriate gonadotro-
phin secretion results in inadequate acyclical follicular maturation with 
chronic anovulation. 
The clinical signs and symptoms which characterized our PCO-
patients are related to the hyperandrogenic state found in these women. 
It has been clearly demonstrated that a quantitative relationship exists 
between elevated androgen levels, ovarian dysfunction and infertility 
(STEINBERGER et al., 1981). The glandular source of the excess 
androgen production has been a subject of controversy. In our study an 
effort was made to elucidate the role of the ovaries and the adrenals in 
the androgen overproduction encountered in PCO-patients. 
Results from the circadian rhythm study suggested an excess andro­
gen production by the adrenal glands, whereas data from the dexametha-
sone suppression test suggested the ovaries as a source of androgen 
excess. The hyperandrogenic response following the administration of 
LH-RH indicated androgen overproduction from ovarian origin. On 
the other hand results from the ACTH test demonstrated excess andro­
gen production by the adrenal glands. Considering these different 
findings, a combined adrenal and ovarian source of androgen excess in 
women with the PCO-syndrome seems to be most likely. 
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We would like to postulate the existence of a close inter-relationship 
between ovarian and adrenal steroidogenesis. Due to theca cell hyper-
plasia, resulting from the elevated LH levels, the 17a-OH-progesterone 
production increases in PCO-patients; consequently the peripheral 
concentration of this precursor for adrenal androgen production is 
elevated. Since ACTH secretion in PCO-patients is basically normal 
(CHANG et al., 1982b), the presence of more precursor for adrenal 
androgen production will most likely result in an elevated androgen 
production from adrenal origin. The excess adrenal androgen 
production, in turn, will help to maintain the vicious circle of chronic 
anovulation in women with the PCO-syndrome. 
The proposed mechanism for persistent anovulation in the PCO-
syndrome is presented in Figure 9.1. This schematic representation of 
the sequence of events in the maintenance of chronic anovulation in the 
PCO-syndrome is a modification of the previously published "self-
perpetuating" cycle of YEN et al. (1976b). Inappropriate gonadotro-
phin secretion with a high LH/FSH ratio may be caused by several 
mechanisms of which the most important is the more or less constant 
estrogen feedback on the hypothalamic-pituitary system. Excessive 
LH release results in an increased stimulation of ovarian stromal 
and thecal cells leading to an increased 17a-OH-progesterone and 
androgen production. Since 17a-OH-progesterone serves as a pre-
cursor for adrenal androgen production, the secretion of adrenally 
derived androgens is also elevated. The high androgen production from 
ovarian and adrenal origin provides excessive amounts of substrate for 
conversion of androgen to estrogen by extra-glandular tissues (adipose 
tissue). The high levels of estrogen, in turn, augment pituitary sensitiv-
ity to LH-RH with secretion favoring LH over FSH, resulting in 
inadequate acyclical follicular maturation with chronic anovulation. 
Although the production of SHBG is not included in the above 
presented model, this binding protein is of great importance. Estradiol 
administration causes an increase and androgens cause a fall of SHBG 
levels. According to ANDERSON (1974) free testosterone enhances 
the fall of SHBG, thereby actually further increasing the concentration 
of free testosterone. This concept implies that a small increase in andro-
gen production can be amplified by a fall in SHBG levels. It is clear that 
the rate-limiting factor in the self-perpetuating cycle of increasing 
androgen production in PCO-patients depends on the rate of peripheral 
conversion of estrone to estradiol which will counter-balance the effects 
of the androgens, particularly on the production of SHBG (WHITE and 
GINSBURG, 1981). 
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The presence of a cycle disturbance with evidence of chronic 
anovulation, hirsutism, obesity and sometimes palpable polycystic 
ovaries is associated with a large number of endocrine disorders with 
diverse etiologies. If Cushing's syndrome, congenital adrenal hyperpla-
sia, virilizing ovarian and adrenal tumors and hyper- or hypothyroidism 
have been ruled out, one may consider the patient to have the PCO-
syndrome. Anamnestic data such as postmenarcheal menstrual 
irregularity continuing beyond adolescence, the onset of clinically 
discernible excessive hair growth either before or around the time of 
menarche, as well as the presence of "overweight" prior to menarche 
may add to this diagnosis (YEN et al., 1976b). 
The diagnosis -PCO-syndrome- is confirmed when certain typical la-
boratory findings are present. The most important finding is an ele-
vation of the LH/FSH ratio due to high LH levels and a low or low-
normal concentration of FSH. The high LH concentration results from a 
greater amplitude and increased frequency of pulsatile LH release. 
Since a great day to day variation in the magnitude of LH release is 
present, it is sometimes necessary to collect blood samples over an 
extended period in order to show the elevated LH level typical for the 
PCO-syndrome. Other important laboratory findings are elevated levels 
of estrone and sometimes also of estradiol. Elevated concentrations of 
testosterone and androstenedione will further confirm the diagnosis. 
The quantification of testosterone must be considered in relation to the 
binding to SHBG. Where total testosterone levels in serum show an 
overlap for normal women and those with clinical signs of hyperandro-
genism, serum free testosterone correlates well with the clinical state of 
hirsute women (STRICKLER and WARREN, 1979). It is recommended 
therefore to determine the free, biologically active, androgen levels 
as well as the SHBG concentration. In addition the measurement of 
salivary testosterone gives a useful indication of the available biologi-
cally active androgen (BAXENDALE et al., 1982). 
As mentioned above, serious disorders such as congenital adrenal 
hyperplasia or androgen secreting tumors must be excluded in women 
with hyperandrogenism. Anamnestic data may be helpful in this 
respect. The time course of development of the androgenic signs is of 
great importance. In all women who have virilizing features, plasma 
androgens and their precursors ( 17a-OH-progesterone and 11 -desoxycor-
tisol) should be determined. Although in this study a short dexametha-
sone suppression test was performed, prolonged adrenal suppression of 
at least two weeks duration seems more appropriate (ABRAHAM et 
al., 1976; MAROULIS, 1981). According to these authors this long 
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dexamethasone suppression test does give optimal information concer-
ning the source of androgen overproduction However, according to 
many other investigators, neither the dexamethasone suppression test 
nor the hCG stimulation test are of value in determining the primary 
source of androgen overproduction (WHITE and GINSBURG, 1981) 
Whatever one's interpretation of dexamethasone suppressibihty, both 
the short and long dexamethasone suppression test identify glucocorti-
coid-suppressible hyperandrogenism and are useful in determining 
proper endocrine therapy (ABRAHAM et al , 1981, STEINBERGER 
et al , 1982) Therefore these tests do have a place in the diagnostic 
work-up of women with the PCO-syndrome 
The therapeutic management of the PCO-syndrome is either directed 
to establishment of ovulatory cycles and consequently improvement of 
fertility, or the reversal of obesity and hirsutism, acne and other clinical 
signs of androgen excess If pregnancy is not the goal, the therapeutic 
approach should be suppression of the hypothalamic-pituitary-ovanan 
axis by the use of an estrogen-progestogen (anti-androgen) preparation 
This, amongst others, results in regulation of cyclicity of uterine bleed-
ing and is associated with a reduction of circulating androgen levels 
Although suppression of ovarian steroidogenesis by means of an oral 
contraceptive does not correct the underlying pathophysiology of the 
PCO-syndrome, this approach may also benefit patients who wish to 
become pregnant Further progression of the disorder is not possible 
during the use of an estrogen-progestogen combination preparation 
and, as was demonstrated in our study, after withdrawal of the suppres-
sive medication the hormonal milieu is more adequate for the initiation 
of follicular maturation This therapeutic approach may be called 
non-surgical, medical, wedge resection 
In order to obtain better conditions for follicular maturation m PCO-
women, it seems justifiable in selected cases to advice ovarian suppress-
ion for a period of three months at least before an attempt is made to 
induce ovulation It is tempting to speculate that the induction of follicu-
lar maturation by means of clomiphene citrate, often in combination 
with dexamethasone, following this non-surgical, medical, wedge 
resection will be more successful than the previously used therapeutic 
approaches 
Most PCO-patients have a relative shortage of FSH Therefore the 
induction of ovulation should also be directed towards this aspect 
Recently SEIBEL et al (1982) and KAMRAVA et al (1982) demon-
strated the reversal of persistent anovulation in polycystic ovarian 
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disease by the administration of chronic low-dose FSH. All endocrine 
parameters improved after the initiation of this treatment and preg-
nancies were reported. Unfortunately however, at present only limited 
quantities of "pure" FSH are available for clinical use. One may hope 
that in the near future gonadotrophin preparations with low or absent 
LH content will be at our disposal in order to provide an additional safe 
and effective, non-surgical treatment modality for patients who are 
anovulatory due to the PCO-syndrome. 
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SUMMARY 
There is no general agreement concerning the exact definition of the 
polycystic ovary syndrome (PCO-syndrome) Most investigators 
diagnose their patients according to several clinical and hormonal 
characteristics The pathophysiology of the PCO-syndrome is as yet not 
known; however, evidence for both ovarian and adrenal disorders is 
present 
In an attempt to elucidate some pathophysiological, diagnosticai and 
therapeutical aspects of this disease it was decided to study women with 
primarily clinical features of the syndrome The functional characteris-
tics of the hypothalamic-pituitary-ovanan axis and the hypothalamic-
pituitary-adrenal axis were studied by means of several suppression 
and stimulation tests In addition the process of spontaneous folli-
cular maturation was carefully evaluated after a period of ovarian 
suppression 
In Chapter 1 the literature concerning the PCO-syndrome is reviewed 
Preceding this survey of the literature several aspects of the normal 
menstrual cycle, including follicular development and maturation, are 
described 
In Chapter 2 the selection criteria of the PCO-group and the control 
group are presented The following criteria were used for qualifying the 
PCO-patients for this study they had oligomenorrhea, secondary 
amenorrhea or otherwise evidence of chronic anovulation, as well as 
hirsutism and/or obesity The control women had regular menstrual 
cycles and a normal body weight Twenty-two women fulfilled the PCO-
cntena and agreed to participate in the study The control group 
consisted of 31 women All women gave their informed consent prior to 
the study 
Also in this chapter the test schedule of the investigations was 
presented together with the applied radioimmunoassay procedures 
In Chapter 3 several clinical and endocrinological characteristics of 
the PCO-group are compared with findings in the control group Since 
androgen and estrogen production m women depends on the stage of 
follicular development, an effort was made to obtain the basal endo-
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crinological data under standardized conditions The PCO-patients had 
significantly higher LH levels and significantly lower FSH levels as 
compared to the control women Consequently the LH/FSH ratio was 
significantly elevated in the PCO-patients Serum estrone and estradiol 
concentrations were also significantly elevated in the PCO-patients, as 
were the serum levels ot androstenedione and testosterone Despite 
these differences a marked degree of overlap existed in the PCO-
patients and control women for gonadotrophin, estrogen and androgen 
levels. It was concluded that although the presence of polycystic ovaries 
in the investigated PCO-group of women was not confirmed by 
laparoscopy, laparotomy or histological examination of ovarian tissue, 
these women had basal endocrinological characteristics comparable 
with those found in well-proven PCO-patients reported in the literature. 
In Chapter 4 the results of the dexamethasonc suppression test are 
presented Preceding the administration ot dexamethasonc the 
circadian rhythms of several steroids from ovarian and adrenal origin 
were determined A normal Cortisol rhythm could be demonstrated m 
both study groups In the PCO-group a diurnal androstenedione and 
testosterone rhythm was found, whereas in the control group such a 
rhythm was absent These findings suggest an excess androgen produc-
tion ot adrenal origin in the PCO-group The PCO-patients had very 
low levels of Cortisol after the administration of dexamethasonc, 
indicating that these women were not suffering from early developing 
hypercortisolism In the PCO-patients and the control women the an-
drostenedione and testosterone levels were significantly reduced after 
the administration of dexamethasonc. However, m the PCO-patients 
the circulating levels of androstenedione and testosterone still remained 
higher than in the control women, indicating the ovaries to be a possible 
source of hypcrandrogemsm It is concluded that a combined adrenal 
and ovarian source of androgen excess in women with the PCO-syn-
drome seems to be the most likely explanation for these findings 
In Chapter 5 the results of the LH-RH test are presented The 
gonadotrophin release and the changes in ovarian and adrenal steroid 
levels after the administration of a low dose of LH-RH were assessed. 
A significant increase in LH and FSH levels and a decrease in Cortisol 
concentrations were demonstrated in both study groups after the 
administration of LH-RH The LH response was significantly exagger-
ated in the PCO-group when compared with the control women The 
estrone and estradiol levels did not change in either group The andro-
stenedione and testosterone concentrations did not change or decreased 
in the control group, whereas an increase of these hormones was seen in 
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the PCO-group In the PCO-group a positive correlation between the 
LH response and the androstenedione response was noticed These 
findings indicate that the hyperandrogenic state encountered m PCO-
patients is at least in part of ovarian origin 
In Chapter 6 the results of the ACTH test are presented This test was 
performed in order to evaluate more directly the adrenal part in the 
hyperandrogenic state found in PCO-patients Under standardized and 
basal conditions the PCO-patients had elevated levels of 17a-OH-
progesterone, androstenedione and testosterone After the administra-
tion of ACTH a significant increase of Cortisol, progesterone, 17a-OH-
progesterone, androstenedione and testosterone was demonstrated in 
both groups The Cortisol and androstenedione responses in the PCO-
group were significantly exaggerated in comparison with the control 
group, whereas no differences in the progesterone, 17a-OH-
progesterone, testosterone, estrone and estradiol responses were seen 
From these findings it was postulated that the exaggerated adrenal 
androstenedione and Cortisol production in PCO-patients following the 
administration of ACTH, was due to the presence of an increased 
amount of 17a-OH-progesterone from ovarian origin The following 
hypothesis was put forward adrenal function in PCO-patients is basi-
cally normal, however, as a consequence of an increased quantity of 
precursor (17a-OH-progesterone) from ovarian origin, adrenal 
androgen production is elevated 
In Chapter 7 the results of a study concerning the dynamics of gona-
dotrophin and steroid changes in PCO-patients, using an estrogen-
progestogen combination preparation, arc presented The PCO-
patients used the combination preparation, which contained cyprote-
rone acetate and ethinyl estradiol (Diane®), for a period of 12 weeks 
The LH and FSH levels decreased during the treatment period Due to 
the prompt decline of FSH the inappropriate gonadotrophin secretion, 
characteristic of women with the PCO-syndrome, persisted After with-
drawal of the medication a rapid increase of FSH levels was seen, 
whereas the LH concentration remained relatively low Consequently 
the LH/FSH ratio tended to normalize during the recovery period A 
decrease of the estrogen and androgen levels was seen during the use of 
the combination preparation After withdrawal of this medication the 
estrogen concentrations remained relatively low, whereas the androgen 
concentrations returned to levels comparable with the pretreatment 
concentrations From these findings it was concluded that, due to the 
decreased LH/FSH ratio with the concomitantly reduced serum 
estrogen levels, found at the end of the last recovery period, the 
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conditions for follicular maturation were improved when compared with 
the pretreatment situation. In order to obtain better conditions for 
follicular maturation in PCO-women, ovarian suppression for a period 
of approximately 12 weeks seems justified before an attempt is made to 
induce ovulation. 
In Chapter 8 the results of a study concerning the process of follicular 
maturation following a period of ovarian suppression are presented. In 
17 PCO-patients follicular maturation was carefully studied; 5 women of 
this group had ovulatory cycles. The LH levels in the PCO-patients with 
ovulatory cycles were comparable with those found in the anovulatory 
women. The ovulatory women tended to have higher FSH levels and 
lower estrone, androstenedione and testosterone concentrations when 
compared with the non-ovulating PCO-patients. From these findings it 
was concluded that most women still had a non-optimal hormonal state 
for adequate follicular maturation although in some instances ovulatory 
cycles were seen. It is suggested that in order to obtain proper follicular 
development and maturation in PCO-patients the relative shortage of 
FSH should be corrected. Induction of ovulation with anti-estrogens 
(e.g. clomiphene citrate) can probably be achieved best if this medica-
tion is given immediately after the withdrawal of the ovarian suppressive 
agents, or the administration of a "pure" FSH preparation will prove to 
be the best treatment modality. 
In Chapter 9 the most important findings and conclusions of the 
preceding chapters are discussed. An updated model demonstrating the 
sequence of events in the maintenance of chronic anovulation in the 
PCO-syndrome is presented. 
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HET POLYCYSTEUS OVARIUM SYNDROOM 
ENIGE PATHOPHYSIOLOGISCHE DIAGNOSTISCHE EN THERAPEUTISCHE ASPECTEN 
SAMENVATTING 
Er bestaat geen eenheid van opvatting over de juiste definiëring van 
het polycysteus ovarium syndroom (PCO-syndroom) De meeste onder-
zoekers diagnosticeren patiënten op grond van klinische en hormonale 
kenmerken Hoewel de pathophysiologie van het PCO-syndroom tot 
dusver onbegrepen is, zijn er aanwijzingen dat zowel ovanele als adre-
nale stoornissen een rol kunnen spelen 
Teneinde meer inzicht te krijgen in de pathophysiologic, de diagnos-
tiek en de therapie van het PCO-syndroom werd besloten om nader on-
derzoek te verrichten bij vrouwen met klinische kenmerken van dit 
ziektebeeld. Door middel van verschillende suppressie- en stimulatie-
testen werden de functionele kenmerken van de hypothalamus-
hypophyse-ovanum-as en de hypothalamus-hypophyse-bijnier-as on-
derzocht Tevens werd het proces van follikelrijping na een voorafgaan-
de periode van ovanele suppressie nauwkeurig bestudeerd 
In Hoofdstuk 1 wordt de literatuur die betrekking heeft op het PCO-
syndroom besproken In dit hoofdstuk is ook een korte beschrijving van 
de hormonale veranderingen tijdens de normale menstruele cyclus en 
het daaraan ten grondslag liggende proces van follikelgroei en follikel-
rijping opgenomen 
In Hoofdstuk 2 wordt aangegeven aan welke selectie-cnteria de PCO-
patienten en de controlevrouwen moesten voldoen om te kunnen deel-
nemen aan het onderzoek Voor PCO-patienten werden de volgende 
criteria gehanteerd er diende bij hen sprake te zijn van Oligomenorrhoe, 
secundaire amenorrhoe of anderszins tekenen van chronische ano-
vulatie, en tevens dienden ZIJ zich te kenmerken door de aanwezigheid 
van hirsutisme en/of adipositas Bij controlevrouwcn moesten er een re-
gelmatige menstruele cyclus en een normaal lichaamsgewicht bestaan 
Volgens de gestelde criteria werden 22 vrouwen voor de PCO-groep en 
31 vrouwen voor de controlegroep geselecteerd Alle deelnemende 
vrouwen werden voorafgaand aan het onderzoek geïnformeerd over de 
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aard van de studie en zij stemden toe in het ondergaan van de verschil-
lende testen 
In dit hoofdstuk wordt eveneens een overzicht gepresenteerd van de 
verschillende testen, die tijdens het onderzoek werden uitgevoerd Ook 
worden de toegepaste laboratoriummethoden besproken. 
In Hoofdstuk 3 worden enige klinische en endocnnologische kenmer-
ken van de PCO-groep en de controlegroep vergeleken Daar de pro-
ductie van androgenen en oestrogenen bij vrouwen bepaald wordt door 
het stadium van follikelnjping, werd er naar gestreefd om de basale en-
docnnologische gegevens onder gestandaardiseerde omstandigheden te 
verzamelen De PCO-patienten hadden in vergelijking met de controle-
vrouwen significant hogere serum-LH-spiegels en significant lagere 
serum-FSH-spiegels Als gevolg hiervan was de LH/FSH-ratio signi-
ficant verhoogd bij de PCO-patienten De serumspiegels van oestron, 
oestradiol, androsteendion en testosteron waren ook significant hoger in 
de PCO-groep In weerwil van deze verschillen tussen de beide groepen 
werd vastgesteld dat de individuele waarnemingen, gedaan bij de PCO-
patienten en de controlevrouwen, elkaar voor een belangrijk deel over-
lapten De vergelijking van de in de beide groepen verzamelde hormo-
nale parameters leerde dat de basale endocnnologische kenmerken van 
de PCO-groep goed overeenkwamen met de in de literatuur beschreven 
hormonale karaktenstica van vrouwen met bewezen polycysteuze 
ovaría 
In Hoofdstuk 4 worden de resultaten van de dexamethason suppres-
sietest gepresenteerd Voorafgaand aan de toediening van dexame-
thason werd het dagritme van verschillende Steroiden vastgelegd Een 
normaal cortisolntme werd in beide groepen vrouwen gevonden. In de 
PCO-groep kon een dagritme voor androsteendion en voor testosteron 
worden aangetoond, terwijl in de controlegroep een dergelijk verschil 
tussen de ochtend- en middagserumconcentraties met aanwezig was. 
Deze waarnemingen suggereren een overmaat aan androgenenproduc-
tie van adrenale origine in de PCO-groep 
De PCO-patienten hadden zeer lage serumcortisolspiegels na de toe-
diening van dexamethason, deze bevinding geeft aan dat er bij deze 
groep vrouwen geen sprake was van een vroege vorm van hypercortiso-
lisme. Na toediening van dexamethason werden bij zowel de PCO-pa-
tienten als bij de controlevrouwen significant lagere androsteendion- en 
testosteronspiegels gevonden In de PCO-groep bleven de serumwaar-
den van androsteendion en testosteron hoger dan in de controlegroep. 
Deze waarneming suggereert een overmaat aan androgenenproductie 
van ovanele origine. 
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De uiteenlopende resultaten die bij het bepalen van de dagritmen der 
verschillende Steroiden en bij de dexamethason-suppressietest werden 
gevonden, leidden tot de conclusie dat bij vrouwen met het PCO-
syndroom de hyperandrogene status hoogst waarschijnlijk zowel van 
ovanele als van adrenale origine is 
In Hoofdstuk 5 worden de resultaten van de LH-RH-test gepresen-
teerd In beide onderzoeksgroepen werd na de toediening van LH-RH 
een significante toename van de serumspiegels van LH en FSH en een 
significante daling van de serumcortisol-concentraties gevonden De 
LH-respons was significant meer uitgesproken m de PCO-groep De se-
rumconcentraties van oestron en oestradiol veranderden in geen van 
beide groepen De serumspiegels van androsteendion en testosteron 
veranderden niet of daalden in de controlegroep, terwijl in de PCO-
groep een toename van de concentraties van deze Steroiden werd vast-
gesteld In de PCO-groep werd een positieve correlatie tussen de LH-
respons en de androsteendionrespons aangetoond 
Deze bevindingen bevestigen het vermoeden dat de hyperandrogene 
status die bij vrouwen met het PCO-syndroom wordt gevonden tenmin-
ste ten dele van ovanele origine is 
In Hoofdstuk 6 worden de resultaten van de ACTH-tcst gepresen-
teerd Deze test werd uitgevoerd om op meer directe wijze het aandeel 
van de bijnieren in de hyperandrogene status der PCO-patienten te ana-
lyseren Onder gestandaardiseerde en basale omstandigheden hadden 
de PCO-patienten, bij het begin van deze test, significant hogere serum-
spiegels van 17a-OH-progesteron, androsteendion en testosteron dan 
de vrouwen m de controlegroep Na toediening van ACTH werd in bei-
de groepen een significante toename van de serumconcentratics van cor-
liso!, progesteron, 17a-OH progesteron, androsteendion en testosteron 
waargenomen De cortisolrespons en de androsteendionrespons waren 
significant meer uitgesproken in de PCO-groep, terwijl voor de andere 
parameters (progesteron, 17a-OH-progesteron, testosteron, oestron en 
oestradiol) geen verschillen tussen beide groepen konden worden aan-
getoond 
Deze bevindingen leidden tot de gedachte dat de extra adrenale produc 
tie van androsteendion en Cortisol, volgend op de stimulatie met ACTH, 
toegeschreven kon worden aan de hoge basale concentratie 17a-OH-pro-
gesteron van ovanele origine De volgende hypothese werd geformuleerd 
de bijnieren van PCO-patienten functioneren normaal, echter, als gevolg 
van de aanwezigheid van een meer dan normale hoeveelheid door de 
ovana geproduceerde precursor (17a-OH-progesteron) zullen de bij-
nieren een meer dan normale hoeveelheid androgenen produceren 
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In Hoofdstuk 7 worden de resultaten gepresenteerd van het bij de 
PCO-patienten uitgevoerde onderzoek naar de veranderingen der 
serumconcentraties van gonadotrofinen en verschillende Steroiden tij-
dens een periode van ovanele suppressie De patiënten gebruikten het 
combinatiepreparaat Diane® (2 mg cyproteronacetaat en 0,05 mg ethiny-
loestradiol), volgens het bijsluitervoorschnft, gedurende 12 weken De 
serumspiegels van LH en FSH daalden tijdens de periodes van „pilge-
bruik" Door de snelle daling van de FSH-concentratie en de wat trage 
daling van de LH-spiegel bleef de, voor PCO-patienten kenmerkende, 
verhoogde LH/FSH-ratio tijdens het „pilgebruik" bestaan Na het staken 
van de medicatie werd een zeer snelle toename van de serumspiegels van 
FSH gezien, terwijl de serum-LH-concentraties nog relatief verlaagd ble-
ven Deze veranderingen van de gonadotrofinen na het staken van het 
combinatiepreparaat leidden tot een tijdelijke verbetering van de LH/ 
FSH-ratio 
Een daling van de serumconcentraties van de oestrogenen en van de 
androgenen werd tijdens het gebruik van de „pil" gezien Na het staken 
van deze ovanele suppressie bleven de serumspiegels van de oestrogenen 
relatief laag, terwijl een terugkeer naar de uitgangswaarden voor de se-
rumconcentraties der androgenen werd vastgesteld 
Deze bevindingen leidden tot de conclusie dat, als gevolg van de ge-
daalde LH/FSH-ratio en de gedaalde oestrogenenconcentratie, de om-
standigheden voor adequate follikelnjping aan het einde van de periode 
van ovanele suppressie beter waren dan voorheen Gesteld werd dat 
vrouwen met het PCO-syndroom er voordeel van kunnen hebben gedu-
rende enige tijd een combinatiepreparaat, bestaande uit een oestrogeen 
en een progestageen, te gebruiken Aldus zouden de voorwaarden voor 
folhkelgroei en follikelnjping gunstig veranderen 
In Hoofdstuk 8 worden de resultaten gepresenteerd van het onderzoek 
naar het verloop van het folhkelnjpingsproces bij PCO-patienten na een 
voorafgaande periode van ovanele suppressie Bij 17 PCO-patienten 
werd de follikelnjping nauwkeurig bestudeerd, 5 vrouwen van deze 
groep bleken een ovulatoire cyclus te hebben De serum-LH-concentra-
ties van de ovulatoire vrouwen waren vergelijkbaar met de spiegels ge-
meten bij de anovulatoire vrouwen De ovulatoire vrouwen 
onderscheidden zich van de anovulatoire vrouwen door wat hogere 
serumconcentraties van FSH en wat lagere oestron-, androsteendion- en 
testosteronspiegels 
Geconcludeerd werd dat, hoewel enkele vrouwen mogelijk voordeel 
hadden van de voorafgaande periode van ovanele suppressie, bij de 
meerderheid der PCO-patienten in dit onderzoek de omstandigheden 
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nog niet optimaal bleken te zijn voor adequate follikelrijping. Het lijkt 
derhalve dat, teneinde deze niet optimale situatie te verbeteren, het 
relatieve tekort aan FSH, dat bij PCO-patiënten bestaat, dient te worden 
aangevuld. De toediening van een anti-oestrogeen zoals clomipheen-ci-
traat, dat kort na de periode van de ovariële suppressie gegeven moet 
worden, of de toediening van gezuiverd FSH, zouden dan de optimale 
behandelingsmethoden kunnen blijken te zijn. 
In Hoofdstuk 9 worden de belangrijkste bevindingen en conclusies van 
het totale onderzoek met elkaar in verband gebracht en verder bespro-
ken. Het bestaande model van de pathophysiologie van het PCO-syn-
droom werd gemodificeerd naar de thans ontwikkelde inzichten. Dit mo-
del wordt gepresenteerd. 
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APPENDIX 
Appendix to figure 3.2 
Age, height, weight and Ouetelet-index of women in the PCO-group 
, 
ibject 
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103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
D 
edian 
Age 
(years) 
36 
31 
29 
24 
28 
23 
20 
27 
33 
28 
22 
21 
23 
31 
32 
19 
27 
31 
27 
33 
28 
24 
27 1 
4.7 
27 
Height 
(cm) 
158 
164 
159 
163 
164 
164 
180 
161 
163 
175 
175 
155 
166 
174 
169 
160 
159 
163 
171 
165 
165 
155 
165 
7 
164 
Weight 
(kg) 
88.8 
77.5 
54 0 
92.2 
83 6 
80 5 
74 4 
83 5 
103 7 
84 5 
111.5 
55 7 
79 7 
87 0 
89.3 
67.0 
101 5 
72 4 
99 3 
81.6 
108 5 
84 1 
85 
15 
84 
Ouetelet-
index 
356 
288 
214 
347 
311 
299 
230 
322 
390 
276 
364 
232 
289 
287 
313 
262 
402 
273 
340 
300 
399 
350 
193 
Appendix to figure 3.2 
Age, height, weight and Quetelet-index of women in the control group 
luject 
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008 
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014 
015 
016 
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018 
019 
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Age 
(years) 
29 
21 
39 
32 
32 
28 
27 
33 
30 
37 
36 
38 
28 
39 
27 
33 
35 
32 
36 
33 
34 
24 
32 
29 
24 
33 
38 
30 
31 
33 
36 
31 9 
45 
32 
Height 
(cm) 
173 
170 
168 
156 
175 
153 
170 
165 
164 
159 
164 
168 
169 
170 
174 
168 
165 
168 
179 
172 
165 
164 
169 
169 
163 
180 
162 
173 
157 
162 
170 
167 
6 
168 
Weight 
(kg) 
58 0 
48 5 
65 0 
67 0 
660 
47 8 
640 
56 0 
50 0 
56 0 
55 0 
75 0 
58 3 
600 
68 0 
58 0 
600 
80 0 
71 0 
62 5 
63 0 
55 4 
66 0 
49 0 
54 0 
70 0 
53 0 
63 0 
49 0 
54 0 
65 0 
60 
8 
60 
Quetelet-
index 
194 
168 
230 
275 
216 
204 
222 
206 
186 
222 
205 
266 
204 
208 
225 
206 
220 
283 
222 
211 
231 
206 
231 
172 
203 
216 
202 
211 
199 
206 
225 
194 
Appendix to figure 4.1 
Serum Cortisol concentrations (μπιοΐ/ΐ) in the PCO-group during the dexamethasone 
suppression test 
Subject Sampling time 
9 00a m 4 00p m 9 00a m 
101 0 42 0 31 0 01 
102 0 45 0 16 0 01 
103 0 65 0 25 0 02 
104 0 56 0 13 0 01 
106 0 58 0 39 0 03 
107 0 85 0 55 0 01 
108 0 48 0 18 0 01 
109 0 30 0 01 0 01 
110 0 54 0 15 0 01 
111 0 54 0 54 0 01 
112 0 41 0 31 0 01 
113 0 48 0 15 0 01 
114 0 42 0 48 0 02 
115 0 61 0 52 0 01 
116 0 21 0 19 0 01 
117 0 46 0 26 0 01 
118 0 53 0 53 0 02 
119 0 42 0 23 0 04 
120 0 41 0 51 0 02 
121 0 76 0 50 0 02 
122 0 29 0 13 0 01 
X 
SD 
SEM 
0 49 
0 15 
0 03 
0 31 
0 17 
004 
0 02 
0 01 
000 
Serum Cortisol concentrations (μπιοΐ/ΐ) in the control group during the dexamethasone 
suppression test 
Subject Sampling time 
9 00a m 4 00p m 9 00a m 
021 0 29 0 21 0 02 
022 0 40 0 21 0 01 
023 0 30 0 14 0 01 
024 0 30 0 46 — 
025 0 69 0 63 0 06 
026 0 55 0 22 0 01 
027 0 55 0 43 0 03 
028 0 48 0 58 0 02 
029 0 68 0 50 0 01 
030 0 55 0 23 0 02 
031 0 25 0 28 0 01 
X 0 46 0 35 0 02 
SD 0 16 0 17 0 02 
SEM 0 05 0 05 0 01 
Appendix to figure 4.2 
Serum estrone concentrations (pg/ml) in the PCO-group during the dexamethasone 
suppression test 
Subject 
9 00 a m 
Sampling time 
4 OOp m 900a m 
101 
102 
103 
104 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
240 
47 
69 
110 
130 
120 
51 
100 
73 
120 
75 
140 
93 
240 
90 
60 
56 
76 
160 
100 
170 
57 
70 
120 
110 
170 
64 
110 
61 
140 
94 
170 
170 
350 
95 
60 
110 
140 
110 
330 
45 
78 
130 
170 
100 
62 
120 
52 
68 
150 
92 
240 
110 
86 
89 
65 
82 
110 
98 
X 
SD 
SEM 
108 
55 
12 
125 
67 
15 
114 
68 
15 
Serum estrone concentrations (pg/ml) in the control group during the dexamethasone 
suppression test 
Subject 
9 00a m 
Sampling time 
400p m 9 00a m 
021 
022 
023 
024 
025 
026 
027 
028 
029 
030 
031 
60 
42 
36 
58 
56 
69 
44 
64 
53 
27 
72 
60 
45 
54 
66 
57 
47 
57 
66 
69 
29 
49 
73 
38 
45 
60 
48 
55 
91 
57 
19 
X 
SD 
SEM 
51 
13 
4 
57 
13 
4 
54 
19 
6 
196 
Appendix to figure 4.3 
Serum estradiol concentrations (pg/ml) in 
suppression test 
Subject 
101 
102 
103 
104 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
D 
EM 
900a m 
130 
33 
77 
50 
120 
130 
81 
74 
89 
52 
100 
82 
380 
280 
220 
110 
63 
63 
86 
68 
140 
116 
83 
18 
Serum estradiol concentrations (pg/ml) in 
suppression test 
Subject 
021 
022 
023 
024 
025 
026 
027 
028 
029 
030 
031 
900a m 
37 
110 
35 
97 
73 
55 
48 
82 
55 
61 
64 
PCO-group during the dexamethasone 
Sampling time 
4 00p.m 
150 
20 
62 
66 
77 
110 
77 
57 
58 
91 
120 
71 
340 
280 
130 
85 
55 
57 
79 
57 
83 
101 
76 
17 
9.00 a.m 
190 
20 
68 
55 
86 
57 
81 
77 
55 
45 
120 
87 
550 
260 
87 
110 
71 
72 
70 
69 
60 
109 
114 
25 
control group during the dexamethasone 
Sampling time 
4 00p m 
83 
110 
42 
84 
72 
67 
59 
48 
82 
52 
27 
9 00a m 
64 
110 
56 
74 
110 
73 
80 
140 
46 
33 
X 65 66 79 
SD 24 23 33 
SEM 7 7 10 
Appendix to figure 4.4 
Serum androstenedione concentrations (ng/dl) in the PCO-group during the 
dexamethasone suppression test 
Subject 
900a m 
Sampling time 
400p m 9 00a m 
101 
102 
103 
104 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
275 
433 
890 
680 
403 
447 
110 
463 
360 
471 
454 
376 
340 
379 
316 
365 
437 
334 
372 
478 
238 
258 
360 
696 
612 
301 
352 
99 
350 
294 
455 
509 
383 
357 
319 
305 
334 
436 
345 
411 
394 
140 
217 
135 
498 
338 
380 
99 
81 
339 
240 
311 
390 
256 
393 
159 
205 
211 
283 
281 
268 
350 
140 
X 
SD 
SEM 
411 
156 
34 
367 
134 
29 
265 
108 
24 
Serum androstenedione concentrations 
dexamethasone suppression test 
Subject 
900a m 
(ng/dl) in the control group during the 
Sampling time 
400p m 900a m 
021 
022 
023 
024 
025 
026 
027 
028 
029 
030 
031 
89 
185 
121 
115 
306 
101 
114 
158 
199 
155 
120 
117 
168 
98 
144 
293 
76 
143 
175 
172 
157 
137 
101 
147 
78 
115 
67 
62 
101 
127 
122 
110 
X 
SD 
SEM 
151 
62 
19 
153 
56 
17 
103 
27 
9 
198 
Appendix to figure 4.5 
Serum testosterone concentrations (ng/dl) m the PCO-group during the dexamethasone 
suppression test 
Subject Sampling time 
900a m 400p m 900a m 
101 71 68 73 
102 60 53 40 
103 139 123 93 
104 87 69 73 
106 140 105 137 
107 77 74 25 
108 30 27 21 
109 140 123 109 
110 78 51 55 
111 65 65 54 
112 97 114 97 
113 83 68 55 
114 121 122 115 
115 63 56 53 
116 71 55 54 
117 116 103 115 
118 55 50 44 
119 65 51 50 
120 90 94 86 
121 119 74 76 
122 39 31 24 
X 
SD 
SEM 
86 
32 
7 
75 
30 
7 
69 
33 
7 
Serum testosterone concentrations (ng/dl) in the control group during the dexamethasone 
suppression test 
Subject Sampling time 
900a m 4 0 0 p m 900a m 
021 14 20 15 
022 40 39 39 
023 20 15 10 
024 28 33 — 
025 48 35 25 
026 22 14 9 
027 27 27 18 
028 18 26 18 
029 16 15 14 
030 31 19 21 
031 16 22 9 
X 
SD 
SEM 
25 
11 
3 
24 
9 
3 
18 
9 
3 
199 
Appendix to figure 5 1 
Serum LH concentrations (IU/1) in the PCO group during the LH-RH test 
Subject 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
- 3 0 
13 0 
19 0 
21 0 
120 
22 0 
10 0 
16 0 
23 0 
33 0 
25 0 
23 0 
20 0 
16 0 
15 0 
22 0 
27 0 
35 0 
30 0 
27 0 
10 0 
21 0 
7 2 
1 6 
- 1 5 
130 
15 0 
23 0 
12 0 
22 0 
9 4 
14 0 
18 0 
30 0 
23 0 
15 0 
17 0 
12 0 
150 
21 0 
30 0 
21 0 
26 0 
22 0 
8 4 
18 3 
6 3 
1 4 
0 
12 0 
15 0 
23 0 
7 8 
21 0 
10 0 
11 0 
17 0 
28 0 
23 0 
14 0 
17 0 
17 0 
14 0 
16 0 
26 0 
23 0 
24 0 
17 0 
10 0 
17 3 
5 8 
1 3 
Sampli 
10 
21 0 
23 0 
46 0 
17 0 
38 0 
4 4 0 
25 0 
27 0 
75 0 
39 0 
45 0 
34 0 
28 0 
23 0 
28 0 
59 0 
86 0 
53 0 
46 0 
16 0 
38 7 
18 8 
4 2 
ing time 
20 
22 0 
39 0 
52 0 
23 0 
61 0 
63 0 
24 0 
35 0 
100 0 
45 0 
74 0 
30 0 
23 0 
29 0 
42 0 
71 0 
94 0 
70 0 
66 0 
18 0 
49 1 
24 7 
5 5 
(min) 
30 
19 0 
36 0 
56 0 
21 0 
72 0 
57 0 
24 0 
36 0 
8 4 0 
49 0 
62 0 
28 0 
23 0 
25 0 
35 0 
68 0 
75 0 
75 0 
65 0 
18 0 
46 4 
22 2 
5 0 
45 
20 0 
37 0 
48 0 
140 
61 0 
44 0 
20 0 
29 0 
72 0 
45 0 
51 0 
25 0 
21 0 
23 0 
37 0 
65 0 
71 0 
61 0 
41 0 
180 
40 2 
18 8 
4 2 
60 
14 0 
31 0 
47 0 
16 0 
600 
38 0 
19 0 
26 0 
61 0 
39 0 
43 0 
27 0 
13 0 
27 0 
28 0 
53 0 
57 0 
61 0 
49 0 
160 
36 3 
168 
3 8 
90 
18 0 
28 0 
33 0 
13 0 
45 0 
27 0 
180 
21 0 
59 0 
43 0 
30 0 
17 0 
13 0 
19 0 
23 0 
50 0 
55 0 
39 0 
37 0 
14 0 
30 1 
14 4 
3 2 
Scrum LH concentrations (IU/1) in the control group during the LH RH test 
Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
X 
SD 
SEM 
- 3 0 
20 0 
13 0 
7 6 
12 0 
6 5 
130 
15 0 
13 0 
19 0 
14 0 
13 3 
4 2 
1 3 
15 
23 0 
13 0 
7 1 
150 
7 6 
20 0 
9 4 
16 0 
21 0 
14 0 
146 
5 6 
1 8 
0 
21 0 
16 0 
6 6 
16 0 
11 0 
20 0 
13 0 
100 
13 0 
14 0 
14 1 
4 4 
1 4 
Sampling time 
10 
32 0 
17 0 
14 0 
25 0 
16 0 
180 
23 0 
25 0 
17 0 
21 0 
20 8 
5 5 
I 7 
20 
42 0 
23 0 
17 0 
26 0 
28 0 
26 0 
32 0 
28 0 
30 0 
26 0 
27 8 
6 4 
2 0 
(mm) 
30 
34 0 
27 0 
18 0 
26 0 
26 0 
23 0 
34 0 
27 0 
34 0 
22 0 
27 1 
5 5 
1 7 
45 
36 0 
21 0 
19 0 
22 0 
24 0 
21 0 
28 0 
20 0 
31 0 
21 0 
24 3 
5 6 
1 8 
60 
28 0 
18 0 
15 0 
16 0 
19 0 
18 0 
23 0 
18 0 
32 0 
18 0 
20 5 
5 5 
1 7 
90 
30 0 
17 0 
14 0 
13 0 
19 0 
15 0 
23 0 
17 0 
36 0 
20 0 
20 4 
7 4 
2 3 
200 
Appendix to figure 5 2 
Serum FSH concentrations (IU/1) in the PCO-group during the LH-RH test 
Subject 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
- 3 0 
4 4 
5 0 
4 7 
3 7 
4 7 
3 4 
7 9 
5 5 
6 4 
3 2 
4 2 
4 3 
7 1 
5 0 
6 1 
4 2 
3 9 
4 5 
7 1 
3 0 
4 9 
1 4 
0 3 
- 1 5 
4 7 
4 1 
5 3 
2 7 
4 8 
3 1 
6 5 
5 4 
5 7 
3 9 
4 4 
3 9 
5 8 
3 9 
5 6 
3 3 
2 8 
3 4 
7 0 
2 4 
4 4 
1 3 
0 3 
0 
3 9 
4 7 
4 1 
3 2 
4 9 
4 0 
6 3 
5 5 
5 8 
4 5 
4 1 
3 5 
5 8 
3 8 
5 1 
4 3 
3 5 
3 4 
6 2 
2 6 
4 5 
1 1 
0 2 
Sampling time 
10 
5 1 
5 3 
4 2 
3 4 
5 9 
6 3 
7 6 
7 0 
7 0 
5 4 
4 6 
4 4 
10 0 
4 8 
6 3 
4 8 
5 2 
4 4 
6 7 
3 0 
5 6 
I 6 
0 4 
20 
7 1 
6 0 
4 7 
3 5 
6 8 
8 4 
9 7 
8 3 
8 0 
5 5 
6 3 
4 6 
11 0 
5 5 
7 7 
4 4 
5 6 
4 5 
8 1 
3 4 
6 5 
2 1 
0 5 
(min) 
30 
6 1 
6 4 
5 2 
4 0 
7 2 
7 8 
12 0 
8 0 
8 9 
6 5 
6 9 
4 1 
11 0 
5 8 
7 0 
5 1 
5 0 
5 3 
9 4 
3 9 
6 8 
2 2 
0 5 
45 
7 1 
5 5 
6 0 
3 8 
6 9 
8 0 
9 0 
7 2 
8 0 
7 1 
6 3 
4 3 
9 6 
5 9 
7 4 
5 3 
4 9 
4 8 
8 0 
4 0 
6 5 
1 7 
0 4 
60 
6 3 
5 4 
5 5 
3 7 
6 3 
6 7 
10 0 
6 5 
7 3 
5 5 
5 6 
3 9 
10 0 
6 0 
6 9 
6 1 
5 0 
5 8 
9 5 
3 7 
6 3 
1 8 
0 4 
90 
6 5 
5 4 
5 2 
4 1 
6 6 
6 2 
9 1 
6 9 
7 9 
4 9 
5 1 
3 6 
8 8 
5 2 
6 8 
5 3 
4 2 
4 8 
9 7 
4 3 
6 0 
1 8 
0 4 
Serum FSH concentrations (Ш/І) in the control group during the LH-RH test 
Subject 
001 
002 
003 
004 
005 
006 
(Ю7 
008 
009 
010 
- 3 0 
6 6 
7 1 
6 1 
5 8 
4 3 
6 5 
6 8 
6 0 
5 5 
5 6 
- 1 5 
5 9 
6 8 
6 0 
5 0 
4 4 
6 3 
6 4 
5 8 
7 3 
5 8 
0 
8 1 
8 2 
6 5 
4 6 
3 6 
5 8 
6 9 
6 8 
6 2 
5 1 
Sampl 
10 
8 6 
6 8 
7 1 
6 4 
4 2 
5 8 
6 7 
6 4 
7 2 
6 1 
ing time 
20 
13 0 
7 8 
8 5 
7 9 
5 7 
8 2 
7 6 
6 9 
7 2 
7 2 
(mm) 
30 
10 0 
8 1 
7 4 
8 0 
5 7 
7 7 
9 1 
6 7 
9 5 
7 9 
45 
15 0 
9 1 
8 1 
8 0 
5 2 
6 7 
8 8 
7 0 
11 0 
7 8 
60 
10 0 
8 2 
7 0 
7 4 
5 9 
6 9 
8 3 
6 8 
10 0 
6 5 
90 
13 0 
7 8 
8 2 
6 7 
5 6 
7 5 
8 8 
6 9 
6 1 
7 8 
X 60 60 62 65 8 0 80 87 77 78 
SD 08 0 8 15 11 19 13 27 14 21 
SEM 03 03 05 04 0 6 04 09 05 07 
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Appendix to figure 5.4 
Seram estrone concentrations (pg/ml) in the PCO-group during the LH-RH test 
Sampling time (mm) Subject v 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
0 
EM 
-30 
240 
64 
75 
150 
85 
150 
65 
110 
67 
100 
110 
84 
80 
53 
90 
70 
77 
110 
180 
110 
104 
46 
10 
-15 
240 
57 
66 
130 
83 
140 
63 
130 
67 
78 
110 
66 
62 
38 
73 
54 
72 
90 
160 
99 
94 
47 
11 
0 
320 
64 
73 
120 
77 
140 
49 
100 
74 
88 
110 
64 
62 
34 
69 
57 
71 
89 
140 
96 
95 
60 
13 
10 
260 
54 
62 
130 
64 
180 
58 
100 
72 
100 
120 
44 
50 
36 
72 
65 
71 
95 
140 
110 
94 
53 
12 
20 
210 
51 
74 
130 
69 
180 
67 
67 
66 
76 
130 
60 
57 
29 
75 
100 
70 
94 
130 
120 
94 
45 
10 
30 
240 
50 
64 
110 
65 
120 
61 
63 
61 
98 
100 
57 
56 
46 
84 
80 
83 
110 
140 
99 
89 
44 
10 
45 
200 
48 
69 
120 
69 
130 
51 
87 
69 
79 
130 
58 
49 
48 
66 
85 
75 
100 
130 
100 
88 
38 
9 
60 
230 
55 
68 
130 
67 
130 
60 
88 
66 
90 
120 
72 
47 
52 
34 
81 
86 
97 
160 
98 
92 
45 
10 
90 
250 
53 
80 
120 
73 
— 
43 
70 
71 
100 
160 
53 
46 
53 
54 
100 
87 
120 
140 
110 
94 
50 
12 
Serum estrone concentrations (pg/ml) in the control group during the LH-RH test 
Sampling time (mm) Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
-30 
52 
33 
69 
82 
54 
70 
48 
73 
49 
76 
-15 
52 
32 
77 
74 
52 
63 
46 
78 
43 
78 
0 
48 
34 
74 
73 
57 
53 
40 
65 
62 
38 
10 
52 
38 
78 
72 
50 
51 
48 
65 
41 
— 
20 
39 
31 
77 
80 
44 
51 
47 
55 
51 
53 
30 
42 
32 
70 
68 
52 
33 
50 
67 
40 
58 
45 
49 
34 
69 
65 
47 
72 
47 
64 
42 
68 
60 
40 
24 
76 
67 
57 
42 
37 
79 
45 
55 
90 
55 
34 
69 
58 
47 
57 
44 
70 
53 
54 
X 61 60 54 55 53 51 56 52 54 
SD 16 17 14 14 15 14 13 18 11 
SEM 5 5 5 5 5 5 4 6 3 
Appendix to figure 5 5 
Serum estradiol concentrations (pg/ml) in the PCO-group during the L H - R H test 
Sampling time (mm) 
Subject 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
3 
ΞΜ 
-30 
70 
78 
51 
84 
45 
92 
63 
60 
82 
97 
65 
64 
65 
79 
62 
75 
63 
71 
89 
71 
14 
3 
-15 
50 
43 
64 
42 
75 
39 
67 
69 
71 
77 
88 
63 
52 
60 
76 
54 
70 
69 
66 
87 
64 
14 
3 
0 
46 
52 
72 
51 
100 
39 
68 
65 
61 
57 
98 
71 
65 
65 
69 
64 
69 
67 
71 
87 
67 
15 
3 
10 
44 
41 
65 
46 
80 
40 
66 
59 
77 
76 
130 
65 
56 
74 
89 
60 
72 
74 
71 
88 
69 
20 
5 
20 
46 
55 
62 
45 
75 
39 
72 
65 
73 
72 
100 
57 
52 
70 
71 
55 
83 
73 
83 
87 
67 
15 
3 
30 
54 
35 
75 
42 
77 
29 
69 
55 
62 
80 
110 
44 
61 
73 
67 
60 
73 
74 
85 
76 
65 
19 
4 
45 
51 
58 
39 
90 
42 
68 
61 
70 
81 
120 
45 
57 
76 
73 
55 
69 
67 
100 
68 
68 
20 
5 
60 
60 
47 
59 
48 
67 
51 
66 
53 
85 
61 
110 
54 
49 
84 
77 
52 
74 
78 
56 
79 
66 
16 
4 
90 
52 
66 
55 
71 
50 
56 
55 
99 
77 
110 
55 
76 
80 
75 
59 
70 
78 
71 
71 
70 
16 
4 
Serum estradiol concentrations (pg/ml) in the control group during the LH-RH test 
Sampling time (mm) 
Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
D 
EM 
-30 
33 
43 
36 
90 
47 
79 
57 
58 
45 
68 
56 
19 
6 
-15 
38 
27 
40 
81 
45 
85 
57 
45 
48 
67 
53 
19 
6 
0 
33 
60 
42 
80 
37 
80 
50 
53 
38 
60 
53 
17 
5 
10 
43 
60 
34 
96 
42 
70 
54 
45 
38 
67 
55 
19 
6 
20 
43 
61 
36 
97 
41 
67 
49 
44 
39 
86 
56 
21 
7 
30 
35 
65 
45 
75 
36 
54 
52 
47 
44 
89 
54 
17 
5 
45 
42 
62 
53 
94 
48 
65 
47 
45 
49 
91 
60 
19 
6 
60 
37 
65 
39 
87 
59 
77 
51 
51 
33 
76 
58 
19 
6 
90 
36 
64 
60 
71 
66 
72 
54 
52 
40 
83 
60 
15 
5 
204 
Appendix to figure 5.6 
Serum androstenedione concentrations (ng/dl) in the PCO-group during the LH-RH test 
Sampling time (mm) 
Subject 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
D 
EM 
-30 
176 
500 
754 
515 
381 
554 
211 
566 
361 
349 
339 
370 
310 
244 
340 
422 
685 
371 
560 
315 
416 
152 
34 
-15 
188 
449 
673 
470 
364 
337 
140 
569 
331 
384 
436 
363 
250 
231 
302 
411 
544 
356 
532 
380 
386 
132 
30 
0 
141 
352 
733 
506 
265 
245 
112 
441 
306 
330 
384 
309 
249 
177 
299 
399 
448 
330 
476 
374 
344 
140 
31 
10 
148 
345 
704 
452 
296 
561 
105 
424 
322 
339 
466 
332 
197 
205 
321 
445 
444 
449 
490 
383 
371 
143 
32 
20 
135 
359 
778 
523 
284 
312 
154 
485 
356 
344 
422 
313 
180 
186 
321 
412 
456 
404 
469 
331 
361 
148 
33 
30 
140 
387 
704 
535 
322 
476 
146 
406 
341 
379 
460 
350 
198 
205 
296 
425 
435 
391 
504 
322 
371 
137 
31 
45 
136 
440 
637 
504 
319 
417 
103 
400 
347 
334 
412 
344 
217 
249 
284 
439 
408 
419 
528 
290 
361 
129 
29 
60 
162 
357 
595 
567 
323 
409 
109 
402 
360 
327 
363 
339 
252 
270 
293 
460 
460 
432 
452 
321 
363 
118 
26 
90 
143 
330 
549 
500 
302 
544 
151 
410 
335 
336 
380 
319 
261 
236 
331 
475 
482 
366 
462 
280 
360 
117 
26 
Serum androstenedione concentrations (ng/dl) in the control group during the LH-RH 
test 
Sampling time (mm) 
Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
-30 
124 
343 
110 
200 
114 
166 
199 
269 
126 
129 
-15 
133 
293 
110 
192 
103 
170 
184 
214 
132 
116 
0 
136 
288 
106 
123 
104 
137 
139 
244 
129 
112 
10 
139 
255 
99 
120 
96 
116 
149 
211 
104 
119 
20 
127 
225 
102 
117 
120 
83 
155 
229 
115 
118 
30 
105 
218 
89 
108 
102 
85 
122 
242 
114 
122 
45 
113 
277 
85 
94 
102 
75 
153 
197 
86 
153 
60 
113 
279 
83 
116 
96 
53 
169 
227 
84 
187 
90 
142 
298 
106 
110 
105 
32 
167 
229 
74 
137 
X 178 165 152 141 139 131 134 141 140 
SD 77 59 62 52 50 54 64 72 77 
SEM 24 19 20 17 16 17 20 23 24 
Appendix to figure 5.7 
Serum testosterone concentrations (ng/dl) in the PCO-group during the LH-RH test 
Sampling time (mm) 
Subject 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
D 
EM 
-30 
34 
70 
154 
121 
51 
52 
30 
90 
105 
71 
90 
55 
45 
43 
69 
54 
91 
82 
132 
62 
75 
33 
7 
-15 
24 
57 
117 
124 
45 
37 
22 
88 
71 
52 
75 
54 
36 
23 
55 
44 
87 
80 
104 
51 
62 
30 
7 
0 
19 
53 
118 
100 
40 
32 
18 
101 
89 
45 
72 
55 
34 
15 
63 
49 
66 
69 
103 
60 
60 
30 
7 
10 
18 
57 
113 
119 
46 
44 
17 
95 
88 
33 
65 
52 
38 
10 
67 
46 
64 
73 
102 
56 
60 
31 
7 
20 
21 
58 
123 
118 
43 
36 
21 
87 
86 
51 
74 
62 
37 
15 
57 
41 
65 
85 
107 
61 
62 
31 
7 
30 
19 
55 
122 
116 
39 
43 
21 
90 
82 
41 
78 
58 
35 
24 
64 
40 
73 
89 
120 
49 
63 
32 
7 
45 
23 
58 
101 
134 
48 
49 
17 
91 
84 
45 
84 
55 
35 
24 
65 
46 
73 
75 
116 
59 
64 
31 
7 
60 
22 
72 
113 
130 
46 
60 
19 
98 
76 
36 
103 
67 
39 
26 
70 
53 
75 
89 
111 
54 
68 
32 
7 
90 
23 
68 
119 
126 
44 
67 
23 
105 
93 
51 
115 
65 
40 
25 
91 
48 
64 
85 
130 
54 
72 
35 
8 
Serum testosterone concentrations (ng/dl) in the control group during the LH-RH test 
Sampling time (mm) Subject 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
D 
EM 
-30 
27 
65 
30 
23 
22 
34 
22 
58 
24 
31 
34 
15 
5 
-15 
25 
61 
28 
21 
20 
27 
19 
51 
18 
23 
29 
15 
5 
0 
22 
52 
21 
19 
20 
26 
13 
49 
20 
21 
26 
13 
4 
10 
23 
52 
22 
17 
18 
22 
18 
46 
16 
19 
25 
13 
4 
20 
24 
55 
24 
17 
21 
21 
16 
43 
20 
22 
26 
13 
4 
30 
19 
48 
19 
17 
16 
18 
15 
47 
20 
25 
24 
12 
4 
45 
24 
49 
19 
18 
18 
18 
19 
42 
16 
29 
25 
11 
4 
60 
19 
51 
21 
15 
20 
10 
20 
49 
20 
26 
25 
14 
4 
90 
22 
56 
24 
15 
24 
7 
20 
51 
12 
30 
26 
16 
5 
206 
Additional appendix to chapter 5 
Serum | 
Subject 
progesterone 
- 3 0 
concentrations 
- 1 5 0 
(ng/ml) in the PCO-group 
Sampling time 
10 20 
(mm) 
30 
during 
45 
the LH-
60 
-RH test 
90 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
112 
113 
115 
116 
117 
118 
119 
120 
121 
122 
0 1 
0 1 
0 1 
0 1 
0 5 
0 1 
0 1 
0 1 
0 1 
0 6 
0 0 
0 5 
1 1 
0 8 
0 5 
0 7 
1 7 
0 8 
0 7 
0 3 
04 
02 
1 1 
04 
03 
05 
03 
05 
03 
00 
07 
05 
07 
1 0 
04 
05 
06 
08 
04 
05 
X 
SD 
SEM 
0 5 
0 4 
0 1 
0 5 
0 3 
0 1 
Serum 
Subjeci 
progesterone 
r 
- 3 0 
concentrations 
- 1 5 0 
(ng/ml) in the control group during 
Sampling time 
10 20 
(mm) 
30 45 
the LH-
60 
-RH test 
90 
001 
002 
003 
004 
005 
006 
007 
008 
009 
010 
X 
SD 
SEM 
0 7 
1 4 
0 7 
0 9 
0 4 
0 1 
0 6 
0 4 
0 6 
0 6 
0 6 
0 3 
0 1 
05 
09 
05 
04 
05 
01 
07 
03 
05 
08 
05 
02 
0 1 
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Appendix to figure 6 2 
Serum progesterone concentrations (ng/ml) in the PCO-group during the ACTH test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
in 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
- 3 0 
0 1 
0 1 
0 1 
0 1 
0 1 
0 1 
0 I 
0 3 
0 2 
0 3 
0 5 
0 4 
0 4 
0 2 
0 4 
0 4 
0 5 
0 5 
0 3 
0 3 
0 3 
0 2 
0 0 
0 
0 1 
0 3 
0 1 
0 1 
0 1 
0 1 
0 1 
0 2 
0 3 
0 3 
0 4 
0 4 
0 2 
0 2 
0 4 
0 4 
0 5 
0 4 
0 2 
0 2 
0 3 
0 1 
0 0 
Sampling time 
30 
0 1 
0 8 
0 5 
0 1 
0 1 
0 5 
0 1 
0 6 
0 9 
0 9 
1 1 
1 I 
1 1 
1 2 
1 2 
1 3 
1 7 
1 9 
0 9 
1 7 
0 9 
0 6 
0 1 
60 
0 4 
0 9 
0 9 
0 5 
0 4 
0 6 
0 1 
0 6 
1 1 
0 9 
1 3 
1 1 
1 4 
1 1 
1 3 
1 6 
2 3 
2 5 
1 1 
1 8 
1 1 
0 6 
0 1 
90 
0 4 
1 0 
0 8 
0 5 
0 3 
0 5 
0 1 
0 5 
1 4 
0 9 
1 3 
1 0 
1 6 
1 3 
1 5 
1 7 
2 2 
2 1 
1 1 
2 2 
1 1 
0 6 
0 1 
Serum progesterone concentrations (ng/ml) in the control group during the ACTH test 
Subject 
011 
012 
013 
014 
015 
016 
017 
018 
019 
X 
SD 
SEM 
- 3 0 
0 3 
0 3 
0 1 
0 4 
1 0 
0 7 
0 4 
0 5 
0 3 
0 4 
0 3 
0 1 
0 
0 2 
0 2 
0 1 
0 5 
1 1 
0 6 
0 3 
0 5 
0 3 
0 4 
0 3 
0 1 
Sampling time 
30 
0 9 
0 9 
1 2 
1 2 
1 7 
1 4 
1 1 
1 7 
1 1 
1 2 
0 3 
0 1 
60 
1 1 
1 0 
1 5 
1 4 
1 9 
2 0 
1 3 
1 5 
1 3 
1 4 
0 3 
0 1 
90 
1 5 
1 2 
I 3 
1 4 
2 2 
1 4 
1 4 
1 8 
1 4 
1 5 
0 3 
0 1 
209 
Appendix to figure 6.3 
Serum 17a-OH-progesterone concentrations (ng/dl) in the PCO-group during the ACTH 
test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
-30 
47 
135 
147 
58 
75 
66 
23 
92 
70 
77 
108 
74 
68 
50 
57 
67 
103 
81 
83 
60 
77 
29 
7 
0 
45 
133 
162 
— 
64 
50 
26 
82 
63 
65 
100 
71 
59 
26 
42 
46 
75 
85 
64 
50 
69 
34 
8 
Sampling time (mm) 
30 
193 
228 
280 
119 
84 
147 
64 
146 
158 
100 
148 
112 
181 
110 
86 
111 
184 
140 
131 
112 
142 
52 
12 
60 
222 
284 
314 
182 
97 
194 
76 
155 
199 
106 
166 
129 
231 
117 
118 
112 
307 
206 
145 
141 
175 
70 
16 
90 
233 
240 
293 
187 
123 
156 
71 
190 
200 
88 
157 
108 
265 
119 
131 
182 
340 
189 
178 
162 
181 
68 
15 
Serum 17a-OH-progesterone concentrations (ng/dl) in the control group during the 
ACTH test 
Subject 
011 
012 
013 
014 
015 
016 
017 
018 
019 
X 
SD 
SEM 
-30 
37 
39 
36 
29 
79 
28 
11 
37 
14 
34 
20 
7 
0 
19 
39 
22 
24 
70 
17 
9 
35 
К) 
27 
19 
6 
Sampling time (mm) 
30 
67 
92 
105 
74 
140 
98 
43 
245 
136 
111 
59 
20 
60 
90 
115 
104 
96 
146 
138 
44 
268 
168 
130 
63 
21 
90 
127 
149 
101 
121 
157 
115 
53 
237 
185 
138 
52 
17 
210 
Appendix to figure 6 4 
Serum androstenedione concentrations (ng/dl) in the PCO group during the ACTH test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
-30 
154 
481 
378 
269 
313 
350 
83 
334 
189 
221 
242 
253 
196 
149 
203 
204 
308 
215 
209 
203 
248 
91 
20 
0 
130 
431 
381 
— 
319 
226 
72 
307 
172 
211 
252 
225 
189 
115 
141 
145 
310 
241 
228 
150 
223 
94 
22 
Sampling time (mm) 
30 
269 
483 
561 
308 
306 
422 
138 
403 
293 
232 
322 
262 
328 
255 
251 
208 
473 
290 
248 
169 
311 
108 
24 
60 
317 
544 
540 
383 
348 
491 
163 
414 
311 
240 
341 
269 
377 
316 
272 
201 
619 
386 
323 
231 
354 
120 
27 
90 
334 
526 
557 
452 
399 
449 
154 
474 
362 
220 
317 
286 
503 
249 
298 
295 
768 
327 
364 
226 
378 
143 
32 
Serum androstenedione concentrations (ng/dl) in the control group during the ACTH test 
Subject Sampling time (mm) 
-30 0 30 60 90 
011 89 66 146 166 246 
012 88 70 124 181 194 
013 37 32 67 66 67 
014 40 52 80 99 103 
015 197 160 288 315 379 
016 22 18 40 53 47 
017 14 11 30 29 31 
018 49 46 75 86 77 
019 16 23 40 50 58 
X 
SD 
SEM 
61 
58 
19 
53 
45 
15 
99 
81 
27 
116 
91 
30 
134 
117 
39 
211 
Appendix to figure 6.5 
Serum cestosterone concentrations (ng/ml) in the PCO-group during the ACTH test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
-30 
40 
77 
85 
57 
88 
62 
21 
103 
58 
44 
60 
46 
69 
33 
47 
41 
65 
66 
56 
50 
58 
20 
4 
0 
39 
71 
92 
— 
80 
41 
19 
113 
48 
42 
49 
44 
56 
23 
48 
29 
65 
55 
45 
42 
53 
23 
5 
Sampling time 
30 
36 
75 
91 
60 
88 
58 
21 
115 
51 
46 
55 
48 
79 
31 
50 
33 
60 
55 
47 
34 
57 
23 
5 
60 
40 
88 
109 
54 
81 
58 
25 
107 
55 
43 
52 
41 
72 
47 
57 
25 
82 
69 
56 
57 
61 
23 
5 
90 
43 
83 
100 
75 
93 
60 
23 
104 
60 
39 
49 
50 
91 
37 
50 
36 
82 
62 
62 
41 
62 
24 
5 
Serum testosterone concentrations (ng/dl) in the control group during the ACTH test 
Subject 
011 
012 
013 
014 
015 
016 
017 
018 
019 
X 
SD 
SEM 
-30 
23 
26 
12 
16 
52 
14 
8 
28 
7 
21 
14 
5 
0 
20 
20 
11 
12 
37 
11 
6 
26 
6 
17 
10 
3 
Sampling time 
30 
22 
25 
14 
24 
43 
12 
9 
31 
8 
21 
11 
4 
60 
26 
29 
15 
23 
46 
19 
10 
32 
12 
24 
11 
4 
90 
33 
32 
15 
22 
52 
17 
12 
34 
15 
26 
13 
4 
212 
Appendix to figure 6.6 
Serum estradiol concentrations (pg/ml) in the PCO-group during the ACTH test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
- 3 0 
47 
71 
65 
91 
66 
66 
170 
69 
87 
67 
120 
87 
66 
83 
50 
45 
68 
54 
60 
92 
76 
28 
6 
0 
52 
65 
по 
ПО 
69 
45 
180 
67 
86 
88 
ПО 
79 
57 
65 
49 
46 
72 
67 
78 
92 
79 
31 
7 
Sampling time 
30 
52 
63 
100 
120 
74 
59 
180 
72 
79 
77 
140 
82 
67 
67 
48 
54 
68 
66 
70 
82 
81 
32 
7 
60 
51 
73 
97 
250 
69 
44 
170 
80 
ПО 
91 
120 
84 
55 
79 
59 
62 
70 
73 
64 
91 
90 
47 
11 
90 
49 
61 
74 
100 
63 
53 
170 
63 
ПО 
81 
120 
76 
74 
60 
61 
47 
75 
66 
72 
93 
78 
29 
6 
Serum estradiol 
Subject 
concentrations 
- 3 0 
(pg/ml) 
0 
in the control group 
Sampling time (mm) 
30 
during 
60 
the ACTH test 
90 
011 
012 
013 
014 
015 
016 
017 
018 
019 
76 
86 
64 
70 
82 
59 
100 
78 
90 
63 
83 
56 
44 
86 
60 
100 
67 
76 
70 
91 
47 
67 
100 
64 
100 
67 
83 
60 
77 
78 
52 
130 
54 
90 
75 
76 
58 
79 
67 
38 
120 
89 
78 
63 
X 78 71 77 77 74 
SD 13 17 18 24 24 
SEM 4 6 6 8 9 
Appendix to figure 6.7 
Serum estrone concentrations (pg/ml) in the PCO-group during the ACTH test 
Subject 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
117 
118 
119 
120 
121 
122 
X 
SD 
SEM 
-30 
38 
91 
100 
93 
72 
140 
120 
89 
55 
80 
140 
91 
58 
47 
62 
77 
95 
81 
110 
97 
87 
28 
6 
0 
38 
92 
ПО 
70 
61 
100 
98 
100 
50 
73 
88 
91 
63 
48 
66 
58 
64 
74 
81 
ПО 
77 
21 
5 
Sampling time 
30 
48 
100 
по 
— 
100 
90 
100 
120 
53 
87 
110 
99 
75 
52 
76 
56 
120 
74 
140 
91 
90 
26 
6 
60 
52 
95 
ПО 
87 
90 
150 
96 
97 
57 
75 
120 
100 
73 
63 
57 
89 
92 
83 
100 
130 
91 
25 
6 
90 
52 
88 
100 
90 
78 
ПО 
89 
120 
62 
93 
140 
ПО 
80 
57 
83 
73 
100 
100 
90 
ПО 
91 
22 
5 
Serum estrone concentrations (pg/ml) in the control group during the ACTH test 
Subject Sampling time 
-30 0 30 60 90 
011 81 94 65 57 82 
012 48 43 49 53 73 
013 33 16 16 25 46 
014 70 78 95 62 70 
015 77 45 60 64 74 
X 
SD 
SEM 
62 
21 
9 
55 
31 
14 
57 
29 
13 
52 
16 
7 
69 
14 
6 
214 
Appendix to figure 7.1 
Serum LH concentrations (IU/1) in the PCO-group during ovarian suppression 
Subject 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
118 
119 
120 
121 
122 
X 
SD 
SEM 
0 
89 
15 0 
21 0 
13 0 
17 0 
29 0 
18 0 
14 0 
180 
43 0 
22 0 
23 0 
180 
20 0 
20 0 
38 0 
28 0 
23 0 
16 0 
11 0 
20 8 
85 
1 9 
05 
22 0 
14 0 
17 0 
120 
— 
36 0 
86 
12 0 
26 0 
57 0 
37 0 
26 0 
23 0 
41 0 
37 0 
25 0 
39 0 
50 0 
23 0 
17 0 
27 5 
13 5 
3 1 
1 
11 0 
15 0 
14 0 
11 0 
26 0 
36 0 
72 
14 0 
29 0 
39 0 
29 0 
20 0 
29 0 
29 0 
34 0 
18 0 
26 0 
24 0 
20 0 
12 0 
22 2 
92 
2 I 
Sampling time (weeks) 
1 5 
130 
13 0 
13 0 
12 0 
— 
18 0 
13 0 
14 0 
24 0 
33 0 
21 0 
14 0 
14 0 
26 0 
28 0 
24 0 
17 0 
22 0 
20 0 
16 0 
18 7 
6 1 
1 4 
2 
9 1 
10 0 
14 0 
13 0 
26 0 
97 
28 0 
12 0 
17 0 
38 0 
14 0 
12 0 
— 
34 0 
23 0 
12 0 
19 0 
— 
— 
83 
17 6 
9 1 
22 
4 
110 
28 0 
17 0 
33 0 
29 0 
19 0 
14 0 
20 0 
20 0 
23 0 
20 0 
17 0 
— 
23 0 
— 
20 0 
21 0 
18 0 
10 0 
72 
19 5 
66 
1 6 
6 
62 
14 0 
12 0 
16 0 
54 0 
12 0 
40 
15 0 
15 0 
19 0 
— 
65 
— 
21 0 
24 0 
12 0 
21 0 
16 0 
21 0 
63 
16 4 
11 0 
26 
8 
19 0 
93 
10 0 
15 0 
14 0 
99 
92 
120 
19 0 
180 
18 0 
98 
— 
29 0 
15 0 
18 0 
23 0 
22 0 
14 0 
12 0 
15 6 
54 
1 2 
10 
17 0 
12 0 
19 0 
99 
15 0 
84 
96 
10 0 
13 0 
30 0 
15 0 
69 
— 
13 0 
23 0 
10 0 
16 0 
13 0 
11 0 
18 0 
14 2 
56 
1 3 
12 
18 0 
16 0 
14 0 
14 0 
— 
14 0 
— 
13 0 
24 0 
28 0 
25 0 
11 0 
10 0 
30 0 
150 
16 0 
22 0 
17 0 
15 0 
12 0 
17 4 
5 9 
1 4 
215 
Appendix to figure 7 1 
Serum FSH concentrations (IU/1) in the PCO-group during ovarian suppression 
Sampling time (weeks) Subject 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
118 
119 
120 
0 
79 
50 
47 
36 
66 
47 
48 
44 
49 
60 
46 
40 
35 
5 5 
68 
26 
38 
47 
05 
46 
5 1 
40 
3 3 
— 
47 
2 1 
29 
24 
69 
38 
32 
5 0 
7 1 
59 
28 
34 
5 1 
1 
43 
28 
42 
28 
7 1 
45 
08 
3 1 
37 
60 
29 
27 
46 
46 
57 
1 5 
4 1 
29 
1 5 
3 1 
33 
44 
35 
— 
34 
08 
1 3 
55 
50 
30 
3 1 
34 
4 1 
45 
1 1 
30 
30 
2 
34 
23 
46 
35 
54 
1 4 
08 
1 0 
6 1 
5 1 
29 
23 
— 
40 
44 
1 2 
25 
— 
4 
40 
4 1 
43 
34 
38 
45 
25 
63 
47 
7 9 
52 
47 
— 
62 
— 
36 
35 
55 
6 
2 1 
29 
16 
36 
52 
19 
1 2 
20 
46 
55 
— 
1 4 
— 
40 
4 1 
1 8 
20 
22 
8 
4 1 
44 
22 
47 
5 3 
59 
28 
75 
60 
66 
36 
32 
— 
64 
57 
34 
43 
47 
10 
35 
33 
3 1 
29 
57 
1 7 
06 
3 1 
4 1 
67 
29 
1 4 
— 
32 
36 
1 5 
24 
1 6 
12 
60 
57 
4 1 
43 
— 
6 1 
25 
8 5 
68 
69 
55 
40 
33 
72 
55 
42 
44 
4 1 
121 36 45 40 36 — 39 38 40 23 51 
122 
X 
SD 
SEM 
38 
48 
1 3 
03 
43 
43 
1 4 
03 
33 
38 
1 5 
03 
54 
34 
1 3 
03 
1 6 
3 1 
1 7 
04 
43 
46 
1 3 
03 
32 
30 
13 
03 
35 
47 
1 4 
03 
1 6 
29 
1 5 
03 
34 
5 1 
1 5 
04 
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Appendix to figure 7.3 
Serum estradiol concentrations (pg/ml) in the PCO-group during ovarian suppression 
Sampling time (weeks) 
Subject . K B v ' 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
118 
119 
120 
121 
122 
Э 
ΞΜ 
0 
50 
70 
71 
85 
38 
88 
64 
160 
89 
83 
80 
82 
84 
60 
75 
240 
74 
80 
75 
69 
86 
43 
10 
05 
59 
74 
142 
83 
— 
33 
38 
78 
61 
76 
93 
91 
56 
23 
57 
50 
61 
54 
57 
78 
67 
26 
6 
1 
45 
63 
52 
81 
110 
53 
49 
27 
71 
64 
88 
59 
69 
52 
79 
200 
69 
52 
58 
70 
71 
35 
8 
1 5 
37 
61 
95 
56 
— 
37 
27 
29 
52 
58 
36 
25 
23 
46 
33 
200 
33 
24 
42 
32 
50 
40 
9 
2 
80 
63 
71 
63 
59 
40 
28 
31 
28 
69 
38 
33 
— 
39 
43 
140 
20 
— 
— 
39 
52 
29 
7 
4 
68 
76 
98 
110 
100 
50 
50 
49 
63 
82 
57 
84 
— 
50 
— 
63 
50 
72 
66 
76 
70 
19 
4 
6 
43 
20 
330 
54 
80 
24 
23 
22 
45 
44 
— 
38 
— 
37 
25 
47 
48 
20 
33 
45 
54 
70 
17 
8 
69 
54 
200 
73 
77 
96 
20 
20 
60 
68 
23 
41 
— 
80 
44 
64 
55 
60 
62 
97 
66 
39 
9 
10 
49 
20 
70 
55 
61 
29 
48 
20 
20 
33 
48 
30 
— 
49 
26 
42 
53 
60 
32 
270 
53 
55 
13 
12 
85 
60 
98 
110 
— 
43 
91 
20 
55 
110 
41 
63 
66 
80 
80 
47 
57 
84 
71 
69 
70 
24 
5 
218 
Appendix to figure 7.4 
Serum androstenedione concentrations (ng/dl) in the PCO-group during ovarian sup­
pression 
Sampling time (weeks) 
Subject ^ ^ _ _ 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
118 
119 
120 
121 
122 
D 
ΞΜ 
0 
280 
312 
— 
427 
322 
657 
549 
124 
371 
349 
352 
331 
326 
340 
331 
405 
628 
285 
576 
279 
381 
134 
31 
0.5 
379 
255 
624 
413 
— 
319 
362 
100 
354 
271 
328 
299 
344 
310 
264 
354 
377 
284 
466 
294 
337 
103 
24 
1 
359 
265 
450 
308 
425 
301 
315 
69 
269 
240 
282 
281 
333 
296 
197 
358 
490 
284 
378 
227 
306 
93 
21 
1.5 
279 
261 
424 
293 
— 
297 
342 
95 
235 
234 
390 
205 
223 
279 
174 
329 
316 
276 
336 
173 
272 
79 
18 
2 
185 
197 
450 
310 
524 
273 
320 
109 
133 
219 
326 
274 
— 
308 
194 
314 
309 
.— 
— 
148 
270 
109 
26 
4 
263 
230 
610 
612 
427 
392 
255 
124 
321 
327 
325 
316 
— 
398 
— 
361 
521 
315 
383 
223 
356 
128 
30 
6 
162 
234 
510 
403 
519 
209 
324 
130 
211 
228 
— 
237 
— 
222 
173 
294 
355 
283 
294 
184 
276 
111 
26 
8 
267 
301 
392 
409 
368 
298 
243 
119 
307 
290 
331 
190 
— 
384 
147 
397 
350 
386 
522 
257 
314 
98 
22 
10 
216 
130 
275 
270 
178 
248 
302 
190 
148 
240 
260 
262 
— 
159 
139 
253 
323 
346 
302 
145 
231 
67 
15 
12 
511 
281 
560 
454 
— 
352 
219 
222 
260 
292 
306 
244 
228 
403 
171 
344 
630 
325 
379 
261 
339 
125 
29 
219 
Appendix to figure 7.5 
Serum testosterone concentrations (ng/dl) in the PCO-group during ovarian suppression 
Sampling time (weeks) 
Subject 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
116 
118 
119 
120 
121 
122 
} 
ΞΜ 
0 
61 
62 
— 
92 
54 
73 
69 
34 
156 
72 
56 
71 
56 
64 
51 
45 
87 
74 
85 
47 
69 
26 
6 
0 5 
99 
60 
95 
99 
— 
61 
53 
27 
146 
63 
60 
70 
74 
67 
49 
44 
64 
68 
108 
78 
73 
27 
6 
1 
99 
57 
77 
71 
67 
63 
57 
30 
133 
67 
78 
60 
69 
67 
45 
52 
73 
92 
102 
80 
72 
22 
5 
1.5 
63 
49 
72 
71 
— 
68 
60 
32 
74 
53 
75 
47 
54 
54 
43 
41 
62 
71 
87 
49 
59 
14 
3 
2 
50 
41 
83 
65 
73 
67 
72 
41 
54 
56 
75 
61 
— 
71 
41 
48 
62 
— 
— 
46 
59 
13 
3 
4 
46 
49 
96 
107 
67 
85 
50 
40 
109 
79 
61 
76 
— 
91 
— 
54 
75 
100 
81 
55 
73 
22 
5 
6 
40 
43 
81 
104 
76 
57 
61 
50 
73 
53 
61 
— 
72 
34 
46 
71 
81 
72 
37 
62 
19 
4 
8 
61 
59 
73 
110 
67 
90 
47 
46 
94 
77 
81 
59 
— 
90 
39 
60 
76 
98 
101 
35 
72 
22 
5 
10 
42 
38 
59 
80 
46 
60 
62 
58 
61 
51 
51 
62 
— 
41 
30 
39 
61 
92 
68 
49 
55 
15 
3 
12 
45 
53 
88 
116 
— 
97 
46 
64 
86 
83 
75 
65 
54 
109 
40 
54 
85 
104 
91 
66 
75 
23 
5 
220 
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Appendix to figure 8.1 
Serum LH concentrations (lU/l) in 12 anovulatory PCO-patients during "follicular 
maturation" following a period of ovarian suppression 
Subject 
10 
Sampling time (days) 
12 15 17 19 22 24 26 29 31 33 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
14.0 
14 0 
14.0 
28.0 
15.0 
10.0 
30.0 
16 0 
22 0 
15.0 
12.0 
15 0 
14.0 
23.0 
21 0 
33 0 
18 0 
10 0 
28 0 
20 0 
41.0 
16 0 
10.0 
23 0 
24.0 
21.0 
23 0 
32.0 
16 0 
11.0 
32 0 
16 0 
18 0 
17 0 
13.0 
17.0 
20.0 
19.0 
33.0 
28.0 
18.0 
30.0 
33.0 
35.0 
19.0 
14.0 
13.0 
22.0 
20.0 
28.0 
31.0 
34.0 
19.0 
16.0 
33 0 
30.0 
18.0 
18 0 
11.0 
15.0 
13.0 
22.0 
29 0 
26.0 
19.0 
28.0 
32.0 
23.0 
25 0 
22 0 
14.0 
15.0 
14.0 
24.0 
24 0 
32.0 
18.0 
130 
34.0 
22.0 
160 
11.0 
17.0 
12.0 
21.0 
22 0 
27 0 
21 0 
14 0 
31.0 
26.0 
23.0 30 0 27 0 — 
35.0 
19 0 
30.0 
35.0 
30.0 
36 0 
24.0 
16 0 
32 0 
38 0 
17 0 
19 0 
38 0 
97 
15.0 
99 
15.0 
12 0 
16 0 15.0 
35 0 
21 0 
24 0 
29 0 
21.0 
X 
SD 
SEM 
17.3 
6.5 
2.0 
20.8 
9 3 
2 7 
20 5 
6 7 
1 9 
23 3 
8.0 
2.3 
23.3 
7 5 
2 2 
22.3 
6 1 
1 8 
20 3 
7 7 
2 3 
19.6 
6 7 
2.0 
24.6 
9.4 
3.3 
23.7 
9 3 
3.5 
25 7 
10 4 
4.2 
26.0 
6.0 
2.7 
Appendix to figure 8.1 
Serum FSH concentrations (IU/1) in 12 anovulatory PCO-palients during "follicular 
maturation" following a period of ovarian suppression 
Subject 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
X 
SD 
SEM 
8 
4.1 
4.3 
— 
6.1 
6 9 
4 1 
3 3 
7.2 
4.2 
4.4 
5.1 
3.4 
4.8 
1 3 
0.4 
10 
5.5 
3.0 
4.6 
5.6 
5 8 
4.3 
5 2 
7 4 
3.7 
4 8 
5 4 
6 4 
5 1 
1.2 
0 3 
12 
6.3 
3.2 
5.6 
6.1 
5.3 
4 6 
3.3 
5.7 
4.2 
4.6 
5.1 
5 4 
4.9 
1 0 
0 3 
15 
6.9 
4 5 
8.2 
5 9 
5 2 
5.0 
4 1 
5.0 
4 9 
3 5 
4.9 
3 1 
5 1 
1 4 
0.4 
Sampling 
17 
4 3 
5.1 
6 4 
6 1 
7 7 
4.6 
4.1 
6.4 
4.4 
4.1 
4.6 
3.3 
5 1 
1.3 
0.4 
19 
5.1 
4.5 
5.5 
6.3 
4.8 
4.3 
4 6 
4.7 
4.4 
4.0 
3.9 
4.3 
4 7 
0 7 
0 2 
time (days) 
22 
6.4 
3 3 
4.5 
5.1 
4 7 
3.3 
4.9 
5.0 
3.1 
— 
5 1 
3.8 
4 5 
1.0 
0 3 
24 
4 7 
6 7 
5.4 
4.3 
5 8 
3.6 
4.5 
6 0 
3 5 
3 1 
3 2 
2 8 
4.5 
1 3 
0.4 
26 
3 2 
5.8 
— 
5 9 
3 5 
5 3 
5 8 
4 5 
— 
3 9 
3 5 
4.6 
1 1 
0 4 
29 
— 
10.0 
— 
6.0 
3.3 
5.6 
5 6 
— 
— 
4 4 
3 1 
5.4 
2 3 
0 9 
31 
— 
4.2 
— 
5.2 
2 3 
4.3 
5 5 
— 
— 
3.8 
3.7 
4.1 
1.1 
0.4 
33 
— 
— 
— 
7 3 
3 5 
4.1 
5 3 
— 
— 
5.5 
— 
5.1 
1 5 
0 7 
222 
Appendix to figure 8.2 
Serum estrone concentrations (pg/ml) in 12 anovulatory PCO-patients during "follicular 
maturation" following a period of ovarian suppression 
Sampling time (days) Subject 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
D 
EM 
8 
48 
100 
— 
48 
80 
110 
53 
85 
56 
180 
140 
85 
90 
42 
13 
10 
81 
120 
94 
85 
84 
130 
51 
57 
84 
86 
130 
130 
94 
27 
8 
12 
100 
130 
100 
92 
86 
140 
60 
92 
78 
96 
170 
120 
105 
30 
9 
15 
78 
110 
130 
110 
65 
140 
57 
84 
69 
79 
140 
no 
99 
31 
9 
17 
95 
130 
130 
61 
72 
130 
44 
84 
84 
130 
160 
120 
103 
35 
10 
19 
HO 
280 
no 96 
44 
120 
59 
120 
81 
86 
100 
99 
109 
59 
17 
22 
120 
120 
100 
98 
70 
200 
44 
100 
62 
74 
130 
150 
106 
43 
12 
24 
92 
120 
— 
140 
89 
150 
63 
82 
— 
51 
120 
160 
107 
37 
12 
26 
— 
no 
— 
67 
100 
45 
90 
98 
— 
120 
130 
95 
28 
10 
29 
— 
95 
— 
73 
100 
48 
130 
— 
— 
120 
150 
102 
35 
13 
31 
.— 
97 
— 
76 
160 
45 
110 
— 
— 
170 
150 
115 
47 
18 
33 
— 
— 
— 
75 
160 
38 
88 
— 
— 
120 
— 
96 
46 
21 
Appendix to figure 8.3 
Serum estradiol concentrations (pg/ml) in 12 anovulatory PCO-patients during "follicular 
maturation" following a period of ovarian suppression 
Sampling time (days) 
Subject . . 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
8 
98 
110 
— 
43 
110 
60 
66 
80 
47 
57 
71 
69 
10 
79 
86 
87 
69 
62 
52 
60 
57 
46 
71 
60 
72 
12 
100 
97 
110 
69 
85 
46 
62 
94 
53 
55 
38 
58 
15 
130 
89 
89 
84 
76 
62 
180 
110 
60 
64 
44 
82 
17 
59 
87 
83 
68 
76 
56 
61 
71 
89 
64 
64 
74 
19 
92 
71 
100 
94 
41 
57 
56 
65 
61 
88 
83 
52 
22 
80 
89 
95 
150 
45 
84 
63 
62 
61 
57 
64 
95 
24 
80 
68 
81 
290 
76 
41 
57 
61 
— 
73 
85 
100 
26 
69 
65 
— 
60 
67 
41 
55 
88 
— 
85 
110 
29 
— 
71 
— 
55 
61 
46 
57 
— 
— 
80 
86 
31 
— 
75 
— 
38 
47 
40 
44 
— 
— 
81 
75 
33 
— 
— 
— 
52 
81 
37 
46 
— 
58 
— 
X 74 67 72 89 71 72 79 92 71 65 57 55 
SD 23 13 24 37 11 19 28 67 20 14 19 17 
SEM 7 4 7 1 1 3 6 8 2 0 7 5 7 7 
Appendix to figure 8.4 
Serum androstenedione concentrations (ng/dl) in 12 anovulatory PCO-patients during 
"follicular maturation" following a period of ovarian suppression 
Subject Sampling time (days) 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
8 
560 
454 
— 
352 
292 
276 
228 
403 
344 
630 
379 
261 
10 
427 
422 
538 
291 
265 
259 
217 
408 
304 
612 
376 
188 
12 
537 
643 
804 
346 
302 
232 
415 
485 
347 
464 
672 
285 
15 
661 
500 
583 
339 
333 
377 
290 
494 
348 
628 
393 
— 
17 
632 
939 
505 
323 
292 
442 
284 
471 
364 
616 
— 
326 
19 
638 
494 
448 
328 
321 
301 
283 
461 
446 
585 
— 
377 
22 
697 
518 
— 
363 
367 
— 
322 
572 
379 
459 
526 
320 
24 
713 
558 
712 
341 
277 
306 
328 
519 
560 
464 
635 
309 
26 
701 
454 
— 
316 
431 
211 
402 
678 
— 
539 
339 
29 
— 
420 
— 
357 
340 
307 
448 
— 
— 
580 
439 
31 
— 
— 
— 
— 
329 
507 
381 
466 
— 
— 
615 
360 
33 
— 
— 
— 
244 
371 
407 
475 
— 
— 
581 
— 
X 
SD 
SEM 
380 
126 
38 
359 
129 
37 
461 
175 
51 
450 
130 
39 
472 
197 
59 
426 
117 
35 
452 
124 
39 
477 
162 
47 
452 
163 
54 
413 
91 
34 
443 
108 
44 
416 
125 
56 
Appendix to figure 8.5 
Serum testosterone concentrations (ng/dl) in 12 anovulatory PCO-patients during 
"follicular maturation" following a period of ovarian suppression 
Subject 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
X 
SD 
SEM 
8 
88 
116 
— 
97 
83 
64 
54 
109 
54 
85 
91 
66 
82 
21 
6 
10 
102 
123 
82 
143 
71 
69 
51 
91 
49 
96 
84 
63 
85 
28 
8 
12 
90 
127 
79 
96 
92 
72 
46 
102 
52 
81 
93 
63 
83 
22 
6 
15 
ПО 
107 
65 
115 
89 
71 
66 
108 
57 
95 
75 
— 
87 
21 
6 
Sampl 
17 
118 
78 
63 
96 
76 
54 
48 
93 
53 
85 
— 
74 
76 
21 
6 
ing time (days) 
19 
123 
102 
63 
95 
63 
58 
52 
90 
56 
69 
— 
79 
77 
23 
7 
22 
118 
103 
— 
102 
78 
— 
52 
94 
44 
41 
79 
78 
79 
26 
8 
24 
122 
115 
83 
87 
59 
62 
55 
87 
56 
49 
76 
79 
78 
23 
7 
26 
120 
60 
— 
65 
55 
51 
70 
67 
— 
64 
100 
72 
23 
8 
29 
— 
63 
— 
71 
57 
49 
81 
— 
— 
66 
101 
70 
17 
6 
31 
— 
— 
— 
60 
63 
49 
95 
— 
— 
77 
85 
72 
17 
7 
33 
— 
— 
— 
55 
53 
52 
77 
— 
— 
69 
— 
61 
11 
5 
224 
Additional appendix to chapter 8 
The LH/FSH ratio in 12 anovulatory PCO-patients during "follicular maturation" 
following a period of ovarian suppression 
Subject 
103 
104 
105 
106 
110 
111 
113 
114 
118 
119 
121 
122 
X 
SD 
8 
3 41 
3 26 
— 
2 30 
4 06 
3 66 
3 03 
4 17 
3 81 
5.00 
2 94 
3 53 
3 56 
0 72 
10 
2 73 
4 67 
5.00 
3 75 
5 69 
4 19 
1 92 
3 78 
5 41 
8 54 
2 96 
1 56 
4 18 
1 90 
12 
3 65 
7 50 
3 75 
3 77 
604 
3 48 
3 33 
5 61 
3 81 
3 91 
3 33 
2 41 
4 22 
1 43 
15 
2 46 
4 44 
2 32 
5 59 
5.38 
360 
7 32 
6 60 
7 14 
5 43 
2 86 
4 19 
4 78 
1 75 
Sampling time (days) 
17 
5 12 
3 92 
4 38 
5 08 
4 42 
4 13 
3 90 
5 16 
6 82 
4 39 
3 91 
3 33 
4 55 
0 91 
19 
2 94 
2 89 
4.00 
460 
5 42 
4 42 
609 
6 81 
5 23 
6.25 
5.64 
3 26 
4 80 
1 33 
22 
2 34 
4 24 
5 33 
4 71 
6 81 
5 45 
2 65 
6 80 
7 10 
— 
3 14 
2 89 
4 68 
1 77 
24 
3 62 
1 79 
3 89 
5 12 
4.66 
5 83 
3 11 
5 17 
7 43 
— 
3 03 
5 36 
4 46 
1 57 
26 
— 
3 97 
— 
5.93 
5 43 
566 
6 03 
6 67 
— 
2 54 
4 29 
5 06 
1 36 
29 
— 
300 
— 
600 
7 27 
2 86 
5 71 
— 
— 
2 73 
5 16 
4 68 
1 81 
31 
— 
6 43 
— 
7.31 
7 39 
4 42 
6 91 
— 
— 
— 
4 05 
6 08 
1 48 
33 
— 
— 
— 
4 79 
600 
5 85 
5 47 
— 
— 
3 82 
— 
5 19 
0 90 
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STELLINGEN 
BEHOREND BIJ HET PROEFSCHRIFT 
THE POLYCYSTIC OVARY SYNDROME 
M.J. HEINEMAN 

STELLINGEN 
1 
Het verdient aanbeveling nader onderzoek te verrichten naar de vermoede 
interrelatie tussen de ovanele en adrenale synthese van Steroiden 
(Dit proefschrift) 
II 
Medicijngebruik kan ongewenste infertiliteli tot gevolg hebben 
(M J Heineman et al . Eur J Obstet Gynecol Reprod Biol , 12, 1981, 
297-303 ) 
III 
De opvatting dat kinderen met een gespleten lip en/of gehemelte minder 
intelligent zouden zijn dan „normale" kinderen berust op verouderde 
onderzoeksgegevens en vooroordelen 
(J A Heineman-de Boer, 1982, persoonlijke mededeling) 
IV 
Het zou toe te juichen zijn als de farmaceutische industrieën, werkzaam op 
het gebied van extractie van gonadotrofinen uit urine, zich zouden toe-
leggen op verdere zuivering van humaan menopausaal gonadotrofine tot 
een FSH-njke en een LH-njke fractie 
(R Rolland, Inaugurele Rede, 19 september 1980) 
V 
In een universitair centrum voor reproduktieve endocrinologie en infertili-
teit dient aan echtparen een compleet programma van onderzoek en 
behandeling te worden aangeboden 
Daartoe behoort ook kunstmatige hcterologe inseminatie 
VI 
Uit het toenemend aantal verzoeken tot refertihsatie mag met worden 
geconcludeerd dat de keuze voor definitieve anticonceptie weinig wel-
overwogen werd gemaakt 
VII 
Het aantal aan een proefschrift toegevoegde stellingen blijkt niet bepalend 
te zijn voor de verdere carrière van de jonge doctor 
(J L H Evers, in 25 jaar Instituut voor Obstetric en Gynaecologie, Sint 
Radboudziekenhuis, Nijmegen, 1981) 



